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Abstract 
Elevated intraocular pressure (IOP) is a major risk factor for open angle 
glaucoma (OAG) and medical IOP reduction is the standard treatment, yet no 
randomised placebo-controlled study of medical IOP reduction has been 
undertaken previously. In the present thesis, the methodology, baseline 
characteristics and results from the United Kingdom Glaucoma Treatment 
Study (UKGTS), the first randomised, double-masked, placebo-controlled, 
multicentre treatment trial for OAG, are presented. Survival analysis shows a 
statistically significant difference in the time from baseline to the event of 
confirmed visual field progression in the medical treatment (latanoprost) 
group, as compared to placebo, over 24 months. The role of average IOP 
during follow-up, as a risk factor for progression, is evaluated. Median IOP, as 
measured by Goldmann Applanation Tonometry (GAT), Dynamic Contour 
Tonometry and the Ocular Response Analyzer, is significantly, but weakly, 
correlated with visual field progression. Corneal compensated IOP (IOPcc) is 
the best predictor of progression across all the UKGTS sites.  While the addition 
of central corneal thickness (CCT) slightly improves the GAT IOP prediction 
model, CCT on its own is not a significant predictor of progression in the 
UKGTS. 
The role of mitochondrial dysfunction and oxidative stress as risk factors for 
glaucoma progression is investigated within an exploratory study. Experiments 
conducted on the lymphocytes of healthy subjects and patients, contrast 
individuals at the extremes of IOP susceptibility: rapidly progressing patients 
with Normal Tension Glaucoma (NTG) and non-progressing patients with 
Ocular Hypertension (OHT). The experimental data presented show, for the 
first time, that OHT patients may have more efficient mitochondria at a 
  
5 
 
systemic level, when compared to age-similar NTG subjects and non-
glaucomatous controls. Overall, OHT lymphocytes produce higher levels of ATP 
(Complex I and Complexes II/III), have higher mitochondrial membrane 
potential, enhanced capacity to deal with exogenous oxidative stress insults, 
higher serum levels of urate, a potent antioxidant, and are more capable of 
taking up and buffering cytosolic calcium, as compared to NTG and control 
lymphocytes. Lymphocytes from NTG patients, when compared to the OHT 
and control groups, show lower ATP synthesis from Complex IV, lower 
aconitase activity, lower serum levels of vitamin C, and enhanced antioxidant 
defence (SOD2). In conclusion, this study implicates the role of a) systemic 
oxidative damage and complex IV-linked mitochondrial defects in the 
pathogenesis of NTG and b) efficient systemic mitochondria in resistance to 
glaucomatous optic neuropathy development and progression, particularly in 
the context of OHT. 
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with 5µM instant rotenone, 5µM rotenone for 2hrs, 0.5µM rotenone for 24hrs 
and 100µM paraquat for 24hrs (n=7). 
Fig 4.12: Graph showing the change in the aconitase enzymatic activity of 
volunteers’ lymphocytes and Raji cells with and without treatment with 100µM 
paraquat over 24hrs (n=5). 
Fig 4.13: Schematic representation of the experimental design used for the 
patients’ and controls’ PBMC. 
Fig 4.14: The rate of ATP synthesis by complex I in the lymphocytes of NTG, 
OHT patients and controls. 
Fig 4.15: The rate of ATP synthesis by complexes II/III in the lymphocytes of 
NTG, OHT patients and controls. 
Fig 4.16: The rate of ATP synthesis by complex IV in the lymphocytes of NTG, 
OHT patients and controls. 
Fig 4.17: The rate of ATP synthesis by complex IV, after correction for porin, in 
the lymphocytes of NTG, OHT patients and controls. 
Fig 4.18: This graph presents the TMRM staining in the lymphocytes of controls 
and NTG and OHT patients. 
Fig 4.19: The TMRM staining in the lymphocytes of controls and NTG and OHT 
patients, upon rotenone treatment (0.5µM 24hrs). 
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Fig 4.20: Graph showing the change in fluo3 fluorescence upon ionomycin 
treatment divided by the baseline fluo3 fluorescence (fluo3 ΔF/Fo) in the 
control, NTG and OHT lymphocytes. 
Fig 4.21: Graph showing the fluo3 ΔF/Fo for the control, NTG and OHT 
lymphocytes, in non-smokers. 
Fig 4.22: Graph showing the change in rhod2 fluorescence upon ionomycin 
treatment divided by the baseline rhod2 fluorescence (rhod2 ΔF/Fo) in the 
control, NTG and OHT lymphocytes. 
Fig 4.23: Graph showing the rhod2 ΔF/Fo for the control, NTG and OHT 
lymphocytes, in non–smokers. 
Fig 4.24: Graph showing the rate of increase in the rhod2 fluorescence during 
the chronic phase divided by the rate of increase in the fluo3 fluorescence 
during the same phase (Δrhod2 chr/ Δfluo3 chr) in the control, NTG and OHT 
lymphocytes. 
Fig 4.25: Graph showing the Δrhod2 chr/ Δfluo3 chr for the control, NTG and 
OHT lymphocytes, in non–smokers.   
Fig 4.26: The mTOR activity, expressed as the ratio between phosphorylated 
(active) mTOR and total mTOR, in the control, NTG and OHT lymphocytes. 
Fig 4.27: The mTOR activity in the control, NTG and OHT lymphocytes, in 
subjects without history of vasospasm-Raynaud’s. 
Fig 4.28: Graph showing the protein levels of TOM20 in the control, NTG and 
OHT lymphocytes. 
Fig 4.29: Representative western blot bands for TOM20, porin and SOD2, as 
well as for the loading control (b-actin). 
Fig 4.30: Graph showing the protein levels of porin in the control, NTG and OHT 
lymphocytes. 
Fig 4.31: Graph showing the citrate synthase (CS) activity in the control, NTG 
and OHT lymphocytes. 
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Fig 4.32: Graph showing the percentage change in the rate of DHE oxidation in 
the lymphocytes from control, NTG and OHT subjects at baseline (before 
treatment with 0.5µM rotenone for 24hrs). 
Fig 4.33: Graph showing the percentage increase in the rate of DHE oxidation in 
the lymphocytes from control, NTG and OHT subjects after treatment with 
0.5µM rotenone for 24hrs. 
Fig 4.34: Graph showing the aconitase enzymatic activity in the control, NTG 
and OHT lymphocytes. 
Fig 4.35: Graph showing the aconitase enzymatic activity in the control, NTG 
and OHT lymphocytes, after treatment with paraquat (PQ) 100µM for 24hrs. 
Fig 4.36: Graph showing the level of SOD2 in the control, NTG and OHT 
lymphocytes. 
Fig 4.37: Graph showing the level of SOD2 in the control, NTG and OHT 
lymphocytes, after correction for mitochondrial content. 
Fig 4.38: Graph showing the level of urinary 8OHdG in the control, NTG and 
OHT subjects. 
Fig 4.39: Graph showing the level of urinary 8OHdG in a subgroup of control, 
NTG and OHT subjects, with no history of DM or active cancer. 
Fig 4.40: Graph showing the levels of urate in the serum of control, NTG and 
OHT subjects. 
Fig 4.41: Graph showing the levels of vitamin A in the serum of control, NTG 
and OHT subjects. 
Fig 4.42: Graph showing the levels of vitamin C in the serum of control, NTG 
and OHT subjects. 
Fig 4.43: Graph showing the levels of vitamin B6 in the plasma of control, NTG 
and OHT subjects. 
Fig 4.44: Graph showing the levels of vitamin B12 in the serum of control, NTG 
and OHT subjects. 
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Fig 4.45: Graph showing the levels of serum folate in control, NTG and OHT 
subjects. 
Fig 4.46: Graph showing the levels of red blood cell folate in control, NTG and 
OHT subjects. 
Fig 4.47: Graph showing the levels of plasma homocysteine in control, NTG and 
OHT subjects. 
Fig 4.48: Graph showing the systolic perfusion pressure (SPP) during the day 
for the control, NTG and OHT subjects. 
Fig 4.49: Graph showing the diastolic perfusion pressure (DPP) during the day 
for the control, NTG and OHT subjects. 
Fig 4.50: Graph showing the mean ocular perfusion pressure (MOPP) during 
the day for the control, NTG and OHT subjects. 
Fig 4.51: Graph showing the SPP at night for the control, NTG and OHT 
subjects. 
Fig 4.52: Graph showing the diastolic perfusion pressure (DPP) at night for the 
control, NTG and OHT subjects. 
Fig 4.53: Graph showing the mean ocular perfusion pressure (MOPP) at night 
for the control, NTG and OHT subjects. 
 
 
 
 
 
 
  
27 
 
Abbreviations 
Adenosine diphosphate                            ADP 
Adenosine triphosphate                                                                                                        ATP 
Advanced Glaucoma Intervention Study                  AGIS 
Ambulatory blood pressure                                 ABP 
α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate                                  AMPA 
Anterior chamber depth                   ACD 
Apoptosis-inducing factor                                                                                                                 AIF 
Apoptosome activating factor-1                                                                                               APAF-1 
Association for Research in Vision and Ophthalmology                                                          ARVO   
Autosomal dominant optic atrophy                                                                                            ADOA  
Axial length                         AL 
Barbados Incidence Study of Eye Diseases                             BISED 
Basic-fibroblast growth factor                                                                                           b-FGF 
Bicinchoninic acid                      BCA 
4E-binding protein 1                               4EBP1 
Blood pressure                                     BP 
Bovine serum albumin                                                                                                            BSA 
Body mass index                                  BMI 
Brain-derived neurotrophic factor                                                                                           BDNF 
Calcium                                                                                                                                                Ca2+ 
Carbon Dioxide                                                                                                                                   CO2 
carbonyl cyanide 4-trifluoromethoxyphenyl hydrazone                FCCP 
Caspase-3                                                                                                                                          Cas-3 
Catalase                                    CAT 
Central corneal thickness                                 CCT 
Central retinal artery                                  CRA 
Central retinal vein                       CRV 
Citrate synthase                        CS 
Collaborative Normal Tension Glaucoma Study             CNTGS 
Collaborative Initial Glaucoma Treatment Study                            CIGTS 
Confidence interval                          CI 
Corneal-compensated IOP                   IOPcc 
Corneal hysteresis                        CH 
Corneal resistance factor         CRF 
Cyclic guanosine monophosphate                                                                                           cGMP 
Cyclic nucleotide gated                                CNG 
Cytochrome c oxidase                                                                                                                       COX 
Decibel                         dB 
8-OH-deoxy-guanosine                8OHdG 
Deoxyribonucleic acid                                                                                                                      DNA 
Diastolic blood pressure                    DBP 
Diastolic perfusion pressure                     DPP 
Diet restriction                        DR 
2', 7'-dihydroethidium                                                                                                                      DHE  
  
28 
 
Dimethyl sulfoxide                                                                                                                     DMSO 
Dioptres                           D 
5, 5'-dithiobis-2-nitrobenzoic acid                              DTNB 
Dynamic Contour Tonometry                     DCT 
Early Manifest Glaucoma Trial                             EMGT 
Edinger-Westphal nucleus                                                                                                                 EW 
Electron transport chain                                 ETC 
Endoplasmic reticulum                       ER 
Enzyme linked immunosorbent assay                            ELISA 
Ethylenediamine tetra-acetic acid                              EDTA 
Foetal bovine serum                                                                                                                          FBS 
Foetal calf serum                                                                                                                                 FCS 
Gamma-amino-butyric acid                                                                                                        GABA 
Ganglion cell layer                                                                                                                         GCL 
Glaucoma progression analysis                   GPA 
Glial fibrillary acidic acid                                                                                                        GFAP 
Glutamine synthase                         GS 
Glutathione peroxidase                     GPO 
Glutathione-S-transferase                     GST 
Goldmann Applanation Tonometry                   GAT 
Guanosine monophosphate                                                                                                           GMP 
Guanosine triphosphate                                                                                                                   GTP 
Guanylate cyclase                                                                                                                                 GC 
Guanylate-cyclase-activating protein                                                                                          GCAP 
Hank's Balanced Salt Solution                   HBSS 
Hazard ratio                         HR 
Heat shock protein                                                                                                                  HSP 
Heidelberg Retina Tomography                     HRT 
High Performance Liquid Chromatography                              HPLC 
High tension glaucoma                    HTG 
Homocysteine                                    Hcy 
Horseradish peroxidase                    HRP 
Hydrogen                                                                                                                                                H+ 
Hydrogen peroxide                                                                                                                           H2O2  
Hydroxyl radical                                 HO• 
Hypoxia inducible factor 1α                             HIF1α 
Immunoelectroblotting                                                                                                                      IEB 
Immunoreactive                                      IR 
Inner limiting membrane                                                                                                           ILM 
Inner nuclear layer                                                                                                                          INL 
Inner plexiform layer                                                                                                                           IPL 
Interquartile range                      IQR 
Intraocular lens                                    IOL 
Intraocular pressure                                                                                                                          IOP 
Iron                                                                                                                                                       Fe+2 
Kainate                          KA 
Koniocellular                                                                                                                                            K 
  
29 
 
Lamina cribrosa                         LC 
Lateral Geniculate Nucleus                                                                                                              LGN 
Leber's Hereditary Optic Neuropathy                                                                                         LHON  
Lens Opacities Classification System                   LOCS 
L-Glutamate/L-aspartate transporter                                                                                       GLAST          
Los Angeles Latino Eye Study                              LALES 
Low-Pressure Glaucoma Treatment Study                            LoGTS 
Magnesium                                                                                                                                        Mg+2 
Magnocellular                                                                                                                                        M 
Mammalian target of rapamycin                             mTOR 
Manganese                                                                                                                                           Mn 
Mean deviation                       MD 
Mean arterial pressure                   MAP 
Mean ocular perfusion pressure                MOPP 
Micrometres                                    µm 
Millimetres                       mm 
Minimal Essential Medium                                                                                                            MEM 
Mitochondrial calcium uniport                  MCU 
Mitochondrial calcium uptake 1                           MICU1 
Mitochondrial DNA                                                                                                                      mtDNA  
Mitochondrial membrane potential                   ΔΨm 
Mitochondrial permeability transition pore                                                                               mPTP 
Mitochondrial superoxide dismutase                                                                                      MnSOD  
Molecular weight                     MW 
Nanometres                                                                                                                                          nm 
National Institute of Clinical Excellence                               NICE 
Nerve fibre layer                                                                                                                         NFL 
Nicotinamide adenine dinucleotide phosphate (reduced)           NADPH 
Nitric oxide                                                                                                                                 NO 
Nitric oxide synthase                                                                                                                 NOS 
N-methyl-D-aspartate                                                                                                       NMDA 
Normal tension glaucoma                                NTG 
Ocular hypertension                     OHT 
Ocular Response Analyzer                                ORA 
Open angle glaucoma                                 OAG 
Optic nerve                                    ON 
Optic nerve head                                                                                                                        ONH 
Optical Coherence Tomography                   OCT 
Outer limiting membrane                                                                                                          OLM 
Outer nuclear layer                                                                                                                        ONL 
Outer plexiform layer                                                                                                                        OPL 
Oxidative phosphorylation             OXPHOS 
Oxygen                                                                                                                                           O2 
Paraquat                         PQ 
Parvocellular                                                                                                                                            P 
Peroxisome-proliferator-activated receptor coactivator 1α            PGC1α 
Peripheral blood mononuclear cell                             PBMC 
  
30 
 
Phosphatase and tensin homologue deleted on chromosome ten                           PTEN 
Phosphate buffered saline                                                                                                            PBS 
Phosphodiesterase                       PDE 
Phosphoinositide 3                       PI3 
Photoreceptor(s)                                                                                                                              PR(s) 
Pituitary adenylate cyclase activating polypeptide                                                                 PACAP 
Polyacrylamide gel electrophoresis                                                                                              PAGE 
Polymerase gamma gene                   POLG 
Polyphosphates                               PolyPs 
Polyvinylidene difluoride                   PVDF 
Posterior ciliary artery                                  PCA 
Potassium                                                                                                                                                K
+
 
Prelaminar region                                    PLR 
Primary angle closure glaucoma                  PACG 
Primary open angle glaucoma                POAG 
Protein kinase B                       PKB 
Protein kinase C                                                                                                                         PKC 
Pseudoexfoliation                                                                                                                               PXF 
Pseudoexfoliation glaucoma                                      PXG 
Reactive oxygen species                                                                                                           ROS 
Research and Development                    R&D 
Retina                             R 
Retinal artery                                     RA 
Retinal ganglion cell(s)                                                                                                       RGC(s) 
Retinal nerve fibre layer                   RNFL 
Retinal pigment epithelium                                                                                                            RPE 
Retinohypothalamic tract                                                                                                                 RHT  
p70 ribosomal S6 protein kinase               p70S6K 
Roswell Park Memorial Institute                  RPMI 
Rotenone                                    Rot 
Rotterdam Eye Study                       RES 
Serum separator tube                       SST 
Sodium                                                                                                                                                  Na+ 
Sodium dodecyl sulphate                                                                                                            SDS 
Spherical equivalent                                     SE 
Standard deviation                        SD 
Standard error of the mean                                                                                                             SEM  
Subarachnoid space                                   SAS 
Sulfur                             S 
Superoxide dismutase                    SOD 
Suprachiasmatic nucleus                                                                                                                  SCN  
Systolic blood pressure                     SBP 
Systolic perfusion pressure                     SPP 
3, 3’, 5, 5’-tetramethylbenzidine                    TMB 
N, N, N′, N′-tetramethyl-p-phenylenediamine              TMPD 
Tetramethylrhodamine methyl ester               TMRM 
  
31 
 
Total antioxidant status                     TAS 
Total reactive antioxidant potential                               TRAP 
Trabecular meshwork                                   TM 
Translocase of the Outer Membrane 20              TOM20 
Triethylamine                                    TEA 
Tumour necrosis factor-alpha                                                                                           TNF-α 
Tyrosine kinase receptor                      TKR 
Ultraviolet                                                                                                                                             UV 
United Kingdom Glaucoma Treatment Study             UKGTS 
Vascular endothelial growth factor                              VEGF 
Visual field                         VF 
Visual Impairment Project                      VIP 
Voltage-dependent anion-selective channel protein 1           VDAC1 
Zinc                                                                                                                                                          Zn 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
32 
 
 
 
 
 
 
Chapter 1 
 
 
 
 
General Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
33 
 
Chapter 1: General Introduction 
1.1 Anatomy of the eye and physiology of the retina 
1.1.1 Gross anatomy of the eye 
 
Fig 1.1: Sagittal section of the adult human eye (Netter's Anatomy Charts, 
Anatomy of the Eye, Third Edition, Saunders, 2003). 
 
The human eye is an asymmetric sphere with a sagittal diameter of 
approximately 23-25 mm and a transverse diameter of 24 mm. A cross-
sectional view of the eye (Fig 1.1) shows three layers:                                                                                        
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 The external layer, formed by the sclera and cornea  
 The intermediate layer, divided into two parts: anterior (iris and ciliary 
body) and posterior (choroid)  
 The internal layer, or the sensory part of the eye, the retina  
Moreover, three chambers of fluid can be identified:  
 Anterior chamber (between cornea and iris) 
 Posterior chamber (between iris, zonule fibres and lens)  
 The vitreous chamber (between the lens and the retina) 
The first two chambers are filled with aqueous humour, whereas the vitreous 
chamber is filled with a more viscous fluid, the vitreous humour.  
The sagittal section of the eye also reveals the lens, which is a transparent 
body located behind the iris. The lens is suspended by ligaments, the zonule 
fibers, attached to the anterior portion of the ciliary body. The tension or 
relaxation of these ligaments, as a consequence of ciliary muscle actions, 
changes the shape of the lens, a process called accommodation that allows the 
formation of a sharp image on the retina. 
The arterial input to the eye is provided by several branches from the 
ophthalmic artery, which is derived from the internal carotid artery (Fig 1.2). 
These branches include the central retinal artery, the short and long posterior 
ciliary arteries, and the anterior ciliary arteries. Venous outflow from the eye is 
primarily via the vortex veins and the central retinal vein, which merge with 
the superior and inferior ophthalmic veins that drain into the cavernous sinus, 
the pterygoid venous plexus and the facial vein (Fig 1.2). 
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Fig 1.2: Arterial (left) and venous (right) connections to the systemic circulation 
(Anatomy of the Human Body, Gray H, 2th Edition, Lea & Febiger, Philadelphia, 
1954). 
 
1.1.2 Anatomy of the retina and optic nerve  
All vertebrate retinas are composed of three layers of nerve cell bodies and 
two layers of synapses (Fig 1.3). The outer nuclear layer (ONL) contains the cell 
bodies of the photoreceptors (PRs), the inner nuclear layer (INL) contains the 
cell bodies of the bipolar, horizontal and amacrine cells and the ganglion cell 
layer (GCL) contains the cell bodies of the retinal ganglion cells (RGCs) and 
displaced amacrine cells (Anderson et al 1992). These nerve cell layers are 
divided by two neuropils, where synaptic contacts occur. The first area of 
neuropil is the outer plexiform layer (OPL) where connections between the 
rods and cones, as well as between the vertically running bipolar cells and 
horizontally oriented horizontal cells, occur. The second neuropil of the retina 
is the inner plexiform layer (IPL), which functions as a relay station for the 
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vertical-information-carrying bipolar cells to connect to RGCs. In addition, 
different varieties of horizontally- and vertically-directed amacrine cells 
interact in further networks to influence and integrate the ganglion cell signals. 
In other words, a direct three-neuron chain – from photoreceptor to bipolar 
and then to RGC – is the major route of information flow from the light source 
to the optic nerve, while the horizontal and amacrine cells are primarily 
responsible for lateral interactions. It is at the culmination of all this neural 
processing in the IPL that the message concerning the visual image is 
transmitted to the brain along the optic nerve (Kolb 1991). 
 
Fig 1.3: Schematic diagram of a vertical section through the human retina 
(Anatomy of the Human Body, Gray H, 2th Edition, Lea & Febiger, Philadelphia, 
1954). 
The retina is supplied by the central retinal artery and the short posterior 
ciliary arteries (PCAs). The central retinal artery travels in or beside the optic 
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nerve as it pierces the sclera then branches to supply the layers of the inner 
retina, while the photoreceptors and the greater portion of the OPL are 
nourished indirectly from the choriocapillaris, a richly anastomotic vascular 
layer that corresponds to the pia-arachnoid vessels in the rest of the brain. The 
main retinal vessels form two capillary plexuses: the superficial capillary 
network lying in the nerve fibre layer (NFL), and the deep capillary network 
lying in the boundary plane between the INL and the OPL. These two layers 
anastomose, but the main retinal arteries are end-arteries without inter-
anastomoses; hence, occlusion of a retinal artery affects its entire distribution, 
causing complete inner retinal ischaemia (Osborne et al 2004). There are 
marked species differences in the inner retinal vascularisation, with primates 
having a complex 4-zone arrangement and an avascular zone at the fovea, 
lagomorphs having a rather simple narrow band of superficial vessels, rodents 
having a wagon-wheel spoke-like arrangement and guinea pigs having no inner 
retinal vessels (Fig 1.4). Retinal venules and veins coalesce into the central 
retinal vein, which exits the eye with the optic nerve parallel and counter-
current to the central retinal artery. 
 
Fig 1.4: Fundus photographs of the human (left), rabbit (middle) and rat (right) 
retina (The Ocular Circulation, Kiel JW, San Rafael (CA), Morgan & Claypool Life 
Sciences, 2010). 
The RGC axon fibres travel within the NFL to converge on the optic disc while 
obeying strict retinotopic organisation. The adult optic nerve head (ONH) is 
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typically elliptical in shape, having a slightly greater mean vertical (1.9 mm) 
than mean horizontal (1.7–1.8 mm) diameter (Levin 2003). The retinal axons 
leave the retinal plane to enter the optic nerve head at an angle of about 90° 
taking up position in a specific order: central RCG axons are located in the 
inner part of the optic nerve rim whilst peripheral RCG axons are found in the 
outer layers of the optic disc rim, while some studies have shown that RGC 
axons from most points in the retina are scattered throughout the thickness of 
the RNFL (Fitzgibbon et al 1996). All RGC axons pass through the optic nerve 
head, which consists of three parts: the prelaminar portion (between the 
lamina cribrosa and the vitreous), the lamina cribrosa (the connective tissue 
extension of the sclera through which the optic nerve axons and the central 
retinal artery and vein pass), and the postlaminar portion. The RGC axons are 
surrounded by astrocytes in the prelaminar portion and then stream through 
the foramina of the lamina cribrosa to enter the postlaminar portion where 
oligodendrocytes and connective tissue become part of the glial structure. 
Here, the axon fibers become myelinated and the optic nerve ensheathed by 
the meninges. After passing through the optic disc, the RGC axons travel in the 
intraorbital (about 30 mm), the intracanalicular (5–12 mm), and the 
intracranial portions of the optic nerve (8–19 mm). At the optic chiasma, the 
nasal fibres decussate to join the temporal fibres of the contralateral optic 
nerve to form the optic tract, which projects to the lateral geniculate nucleus, 
the pretectal nuclei, the superior colliculus, the hypothalamus and possibly 
other brain structures (Levin 2003, Kanski 1999). 
It is interesting to note that an excess number of RGCs is produced early during 
prenatal development. Up to 70% of axons in the human fetal optic nerve die 
between 16 weeks (3.7 million) and 29 weeks of gestation (1.1 million) (Taylor 
2005). This excess production is thought to be required to achieve the 
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subsequent selection of axons that make correct contact with the above brain 
targets. After this rapid elimination of more than 2 million RGCs early in human 
embryonic development, axonal cell decline is gradual by an estimated 5,000 
axons per year of life (Levin 2003). 
The vascular supply of the optic nerve is complex (Fig 1.5). The optic nerve has 
three zones referenced to the lamina cribosa: the prelaminar optic nerve 
supplied by collaterals from the choroidal and retinal circulations, the laminar 
zone supplied by branches from the short posterior ciliary and pial arteries, 
and the post laminar zone supplied by the pial arteries. Venous drainage is via 
the central retinal vein and pial veins. 
 
Fig 1.5: Vascular supply of the optic nerve. The following structures are shown: 
PCA, posterior ciliary artery; NFL, nerve fibre layer; LC, lamina cribrosa; ON, 
optic nerve; CRA, central retinal artery; CRV, central retinal vein; OD, optic disc; 
R, retina; C, choroid; S, sclera; P, pia; A, arachnoid; D, dura; PLR, prelaminar 
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region; RA, retinal artery; Col. Br., collateral branches; SAS, subarachnoid space 
(The Ocular Circulation, Kiel JW, San Rafael (CA), Morgan & Claypool Life 
Sciences, 2010) 
It is, however, important to note that the central retinal artery circulation 
makes significant contributions only to the superficial optic nerve fibres (not 
the remaining prelaminar portion of the ONH) and the posterior portion of the 
ONH. Thus, the PCA circulation supplies both the outer retina via the 
choriocapillaris and most of the ONH. Also, PCAs and their branches in the 
choroid and ONH behave as end arteries in vivo, which helps to explain the 
localised nature of choroidal and ONH lesions (Hayreh 2004). Unlike the 
fenestrated capillaries of the choriocapillaris, the capillaries of the ONH are 
non-fenestrated with tight junctions. In addition, the ONH vessels are capable 
of autoregulation, unlike the choriocapillaris. Thus, even though the ONH 
circulation is derived from the posterior ciliary circulation, its blood-retina 
barrier function and capability to autoregulate resemble more the retinal than 
the choroidal circulation (Hayreh 1995). For the optic nerve vessels, the 
laminar zone marks the transition from exposure to the intraocular pressure 
(IOP) to exposure to the cerebral fluid pressure within the optic nerve sheath.  
 
1.1.3 Anatomy and physiology of the retinal ganglion cells 
There are approximately 1.2 to 1.5 million RGCs in the human retina. They 
consist of cell bodies, multiple dendrites and large diameter axons capable of 
passing the electrical signal to the retinal recipient areas of the brain many 
centimeters distant from the retina. Based on their projections and functions, 
there are at least five main classes of RGCs: 
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o Parvocellular (P)  
o Magnocellular (M)  
o Koniocellular (K)  
o Photosensitive ganglion cells  
o Other ganglion cells projecting to the lateral geniculate nucleus 
(LGN) for control of the pupillary light reflex  
Parvocellular (P) retinal ganglion cells project to the parvocellular layers of the 
LGN. These cells are also known as midget RGCs, based on the small sizes of 
their dendritic trees and cell bodies. About 80% of RGCs are parvocellular cells. 
They receive inputs from relatively few PRs (rods and cones). They have slow 
conduction velocity and respond to changes in colour, but respond only weakly 
to changes in contrast unless the change is great (Kandel et al 2000). They have 
simple ON/OFF centre-surround receptive fields. 
Magnocellular (M) retinal ganglion cells project to the magnocellular layers of 
the LGN. These cells are also known as parasol RGCs, based on the large sizes 
of their dendritic trees and cell bodies. About 10% of RGCs are magnocellular 
cells. They receive inputs from relatively many rods and cones. They have fast 
conduction velocity and can respond to low-contrast stimuli, but are not very 
sensitive to changes in colour. They have much larger receptive fields, which 
are nonetheless also centre-surround (Shapley et al 1986). 
Koniocellular (K) retinal ganglion cells project to the koniocellular layers of the 
LGN. The name koniocellular comes from the Greek word “konis” which means 
“dust” and therefore koniocellular means “cells as small as dust”. The 
koniocellular retinal ganglion cells have been identified only relatively recently, 
as their small size makes them hard to find (Yucel et al 2003). About 10% of 
RGCs are koniocellular cells. They receive inputs from intermediate numbers of 
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rods and cones. They have moderate spatial resolution, moderate conduction 
velocity, can respond to moderate-contrast stimuli and may be involved in 
colour vision. They have very large receptive fields that only have centres (no 
surrounds) and are always ON to the blue cone and OFF to both the red and 
green cones. 
Photosensitive ganglion cells contain their own photopigment, melanopsin, 
which makes them respond directly to light even in the absence of rods and 
cones. They project to the suprachiasmatic nucleus (SCN) via the 
retinohypothalamic tract (RHT) (Newman et al 2003, Hannibal et al 2004).  In 
humans, melanopsin is expressed only in the eye and its expression is 
restricted to cells within the ganglion and amacrine cell layers of the primate 
and murine retinas. Notably, expression is not observed in retinal PR cells. The 
unique inner retinal localisation of melanopsin suggests that it is not involved 
in image formation, but rather may mediate nonvisual photoreceptive tasks, 
such as the regulation of circadian rhythms and the acute suppression of pineal 
melatonin (Provencio et al 2000). Typically, RGCs communicate information to 
central visual structures by receiving input from retinal PRs via bipolar and 
amacrine cells. As melanopsin ganglion cells do not require synaptic input to 
generate light-induced signals, these cells need not receive synapses from 
other neurones in the retina. Instead, the melanopsin ganglion cells are 
intrinsically sensitive to light, perhaps responding via a melanopsin-based 
signaling pathway (Peirson et al 2006). However, Belenky et al (2003) have 
shown that melanopsin-immunoreactive (IR) dendrites in the inner region of 
the IPL do receive bipolar and amacrine terminals, suggesting that PR signals 
may be capable of modifying the intrinsic light response in melanopsin-
expressing RGCs.  
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Other retinal ganglion cells projecting to the LGN include cells making 
connections with the Edinger-Westphal nucleus (EW) for the control of the 
pupillary light reflex and giant retinal ganglion cells. 
Of particular relevance to this thesis is the fact that RGC axons within the globe 
are laden with mitochondria (Fig 1.6). Wang et al (2003) have demonstrated 
that unmyelinated intraretinal ganglion cell axons in the primate eye (human 
and nonhuman) contain numerous bulb-shaped varicosities at all retinal 
eccentricities. Moreover, the fact that the unmyelinated part of the ganglion 
cell stains for cytochrome c oxidase (COX), whereas the myelinated part does 
not, supports the morphological studies regarding the distribution of 
mitochondria along the ganglion cell axon (Barron 2004). The varicosities 
associated with ganglion cell axons within the globe have been observed in 
human specimens ranging from 1 to 85 years old. The diameters of the 
varicosities are approximately four times larger, on average, than the interbulb 
regions of the axons. These bulb regions have no vesicle-containing chemical 
synaptic structures, but are rich in mitochondria, suggesting a possible zone of 
metabolic demand (Wang 2003). Previous studies have also described bulb-
shaped structures on intraretinal ganglion cell axons in other mammalian 
species, such as rats (Hildebrand 1985, Black 1984), rabbits (Reichenbach 1988) 
and cats (Hollander 1991). 
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Fig 1.6: Diagrammatic view of pattern for staining of COX in the RGC system. 
On the left side is a sagittal view of the human eye. The boxed part is enlarged 
and schematically illustrated with emphasis on the RGC cellular system. 
Mitochondrial distribution is shown from the RGC somata through the 
unmyelinated (COX+) portion of the axon in the NFL and penetrating the 
lamina cribrosa at the optic nerve head. Mitochondrial accumulations are 
represented in the varicosities within the NFL and in the prelaminar region. 
There is a drastic decrease in mitochondrial numbers within the retrolaminar 
portion (COX−). Mitochondria in this part of the RGC axon are mostly located 
under the unmyelinated nodes of Ranvier. On the right side, a histological 
sagittal section of a normal human eye is illustrated showing a parallel 
transition from the retina to the optic nerve head, the lamina cribrosa and a 
portion of the myelinated retrolaminar optic nerve. The ocular tissue was 
stained by a method using immunoperoxidase for myelin basic protein (Carelli 
V et al 2004). 
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1.1.4 Other retinal neurones  
In addition to RGCs, the retina has five other basic types of retinal neurones: 
PRs, horizontal, bipolar, inter-plexiform and amacrine cells (Masland 2012). 
The cell bodies of the PRs form the ONL, while horizontal cells lie along the 
outer margin of the INL and bipolar cell perikarya are located mainly in the 
middle of the INL. Amacrine and inter-plexiform cell perikarya are arranged 
along the proximal border of the INL (Fig 1.3). 
The two types of photoreceptors are the rods and the cones. There are 120 to 
130 million rods in each eye, while there are only 6.5 to 7 million cones. The 
outer segments of rods (Fig 1.7) contain the visual pigment rhodopsin within 
disks (up to 1000 per cell) enclosed by a single plasma membrane (Hargrave et 
al 1992). The disks are produced at the base of the outer segment and 
gradually travel to the distal end of the outer segment, where they are 
phagocytosed by the retinal pigment epithelium (RPE). Cones are typically 
shorter than rods and the photopigment is not stored in membranous disks, 
but rather invaginations of the cytoplasmic membrane. The cell bodies of rods 
and cones are connected by an inner fibre to specialised synaptic terminals, 
known as spherules and pedicles, respectively. The outer segments are 
separated by an extracellular ground substance containing inter-photoreceptor 
binding protein within a sialic acid and proteoglycan-binding matrix. The myoid 
represents the inner part of the inner segment and contains numerous 
organelles, including Golgi apparatus, smooth endoplasmic reticulum, 
microtubules and glycogen, indicating a metabolically and synthetically active 
cell. The ellipsoid represents the outer part of the inner segment and is 
connected to the outer segment by a modified cilium. The ellipsoid itself is rich 
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in mitochondria indicative of the high-energy requirements of these cells 
(Curcio et al 1991).  
 
Fig 1.7: Schematic diagram of a photoreceptor (Hargrave PA, McDowell JH. 
Rhodopsin and phototransduction: a model system for G protein-linked 
receptors. FASEB J 1992; 6: 2323-31). 
The rods and cones are unevenly distributed. The density of the rods exceeds 
that of the cones, except in the fovea, the central point for image focus in the 
human retina, where the cone density is the highest. The central region of the 
fovea (foveola) is rod-free. The rods and cones differ in the degree of 
convergence onto RGCs. The rods are more sensitive, slower in response, and 
have maximum sensitivity at wavelengths of light around 498 nm (green-blue). 
The cones are less sensitive, faster in response, and come in three different 
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varieties, with greatest sensitivity at three different wavelengths: short (S), 
medium (M), and long (L) wavelengths. Each of the 3 types of cone pigment is 
most sensitive to a certain wavelength of light: short (430-440 nm), medium 
(535-540 nm) and long (560-565 nm). Cones mediate colour vision, because 
they allow for different portions of the electromagnetic spectrum to be 
differentiated. Moreover, while inputs from many rods converge to a single 
ganglion cell, the latter receive inputs from a single cone or from very few. 
Convergence makes the rod system a better light detector, but reduces its 
spatial resolution. It is, therefore, the one-to-one mapping within the cone 
system that maximises the discrimination of fine detail, namely visual acuity. In 
the fovea a maximally focused image initiates resolution of the finest detail 
and direct transmission of that detail to the brain is needed for perception 
(Rodieck 1973). Light must travel through the thickness of the retina before 
striking and activating the rods and cones. Subsequently the absorption of 
photons by the visual pigment of the photoreceptors is translated into a 
biochemical message and then an electrical message that can stimulate all the 
succeeding neurones of the retina (Polyak 1941). The name of this biochemical 
process that takes place in the photoreceptors is phototransduction (Fig 1.8) 
and constitutes an essential component of light perception (Fain et al 2001).  
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Fig 1.8: The phototransduction cascade. Light causes photoisomerisation of 
rhodopsin, activating the heterotrimeric G-protein transducin. The GTP-bound 
a-subunit activates phosphodiesterase (PDE), which degrades cGMP to GMP. 
The decrease in cGMP concentration leads to closure of cyclic-nucleotide-
gated (CNG) channels, resulting in two effects, a decrease in Ca
2+
 influx and 
hyperpolarisation of the membrane potential. The resulting decrease in 
intracellular Ca
2+
 concentration is important for adaptation. Lowered 
intracellular Ca
2+
 concentration disinhibits guanylate-cyclase-activating protein 
(GCAP), leading to activation of guanylate cyclase (GC) and resynthesis of 
cGMP (Kramer et al 2001). 
 
Horizontal cells derive their name from the extensive horizontal extensions of 
their cell processes. These processes extend widely in the OPL and mediate 
lateral interactions in this first synaptic zone (Thoreson 2012). There are two 
subtypes of horizontal cell: type A is an axonless cell with dendrites that 
synapse only with cones; type B has dendrites that make contact with cones, in 
addition to which it has an axon that synapses with multiple rod spherules. The 
horizontal cells have an integrative role in retinal processing and release 
inhibitory neurotransmitters, mainly gamma-amino-butyric acid (GABA).  
The bipolar cells can be divided into ON and OFF bipolar cells, which respond 
differently to the PR signal, because they express different receptors 
(metabotropic and ionotropic glutamate receptors, respectively). The bipolar 
cells are the output neurones that carry visual information from outer to inner 
plexiform layers, while the inter-plexiform cells carry information from the 
inner to the outer plexiform layers. Inter-plexiform cells are either GABAergic 
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or dopaminergic and send their processes to both outer and inner plexiform 
layers.  
The amacrine cells, while predominantly located in the proximal aspect of the 
INL, are also found in the IPL where they are known as interstitial cells and 
their main function is to mediate interactions within this layer. Amacrine cells 
display great morphologic diversity and contain a broad range of 
neurotransmitters (Kolb et al 1992). 
 
1.1.5 Non-neuronal retinal cells 
Three basic types of glial cell are found in the human retina: Müller cells, 
astroglia and microglia. 
The predominant glial cell type in the retina is the Müller cell. These cells 
extend vertically through the retina, from the distal margin of the ONL to the 
inner margin of the retina. The distal border of Müller cells is marked by the 
OLM, which consists of junctional complexes made between the processes of 
different Müller cells or between the processes of Müller cells and 
photoreceptors. Müller cells extend beyond the OLM into the subretinal space, 
forming microvilli. The proximal border is marked by the ILM, consisting of an 
expansion of the cell membrane of the Müller cell, called the endfoot, and a 
basement membrane. The nuclei of the Müller cells are typically located in the 
middle of the INL. The Müller cells contain glycogen, mitochondria and 
intermediate filaments and have a range of functions all of which are vital to 
the health of the retinal neurons (Reichenbach et al 1995). They protect 
neurons from exposure to excess neurotransmitters, such as glutamate, using 
well developed uptake mechanisms to recycle this transmitter. They also 
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protect neurons from deleterious changes in their ionic environment by taking 
up extracellular K
+
 and redistributing it. Moreover, they are thought to 
synthesise retinoic acid from retinol, which is known to be important in the 
development of the eye and the nervous system (Edwards et al 1994). Finally, 
Müller cells may be involved in phagocytosis of neuronal debris. 
Astrocytes are sparsely distributed in the GCL and IPL. However, they are the 
major glial cell type in the ONH and are vital for RGC survival (Schnitzer 1988). 
Astrocytes not only provide mechanical support to nearby neurons (Stone et al 
1987), but also aid in maintaining the extracellular levels of glutamate through 
the Na
+
 dependent L-glutamate transporters (GLAST and GLT-1) and regulate 
the extracellular levels of K
+
 and H
+
 ions (Trivino et al 1996). 
Microglial cells are present in three separate retinal layers: GCL, including the 
NFL, IPL and OPL. They may be of two types. One form is thought to enter the 
retina at earlier stages of development from the optic nerve mesenchyme and 
lie dormant in the retinal layers for much of the life of the retina. The other 
form of microglia appears to be blood borne cells, possibly originating from 
vessel pericytes (Boycott et al 1981). Both types can be stimulated into a 
macrophagic function on trauma to the retina and may engage in phagocytosis 
of degenerating retinal neurons (Gallego et al 1986). 
 
1.2 Glaucoma: an overview 
1.2.1 Introduction 
Glaucoma is an irreversible progressive optic neuropathy in which RGC axons 
are damaged and degenerate, giving rise to a characteristic appearance of the 
ONH and pattern of visual field (VF) loss (Fig 1.9). The definition, relevant to 
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epidemiological studies, suggested by an international consensus panel in 2002 
specifies that glaucoma is present when three or more locations of the field 
test, in a particular pattern, are notably outside the limits of normal between-
subject variability and when, in the same eye, the cup-to-disc ratio is greater 
than that seen in 97.5% of the general population (Foster et al 2002). These 
criteria assure that the structural finding is unlikely to be simply a typical 
variation in healthy individuals and that both structural and functional injury 
has occurred. 
 
 
Fig 1.9: Histological basis for loss of ganglion cells in glaucoma. Loss of RGCs 
and their axons may occur preferentially, with upper and lower axons and their 
RGCs being more affected than nasal and temporal axons, which is evident as 
an hour-glass shaped pattern in the optic nerve just behind the eye (A). 
Atrophic areas are lighter in colour than non-atrophic areas (B). The 
preferential polar axon loss may be related to the lower density of connective 
tissue in the upper and lower quadrants of the optic nerve head (B). The visual 
field result shows the corresponding upper and lower mid-peripheral loss of 
function from polar area axons at a moderate stage of glaucoma (C). V=vein; 
A=artery; SUP=superior; TEM=temporal; INF=inferior; NAS=nasal (Quigley 
2011). 
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1.2.2 Epidemiology 
Worldwide, glaucoma is responsible for more blindness than any other eye 
condition, except cataract. Data from population-based surveys indicate that 1 
in 40 adults older than 40 years has glaucoma with loss of visual function, 
which equates to 60 million people worldwide being affected; 8.4 million are 
bilaterally blind from glaucoma (Quigley 2011). In the United Kingdom, 
glaucoma remains the second leading cause of blind registrations (Bunce et al 
2010). While glaucoma affects more than 2% of those older than 49 years of 
age, its prevalence rises to at least 4% in white and 13% in some black 
populations by the age of 80. Glaucoma can occur in all age groups, including 
in infants, but it is most common in elderly people. Although there are several 
conditions with the same end result of VF loss and ONH damage that are 
included under the umbrella term ‘glaucoma’, the most common types of 
glaucoma are primary open-angle glaucoma (POAG) and primary angle-closure 
glaucoma (PACG). Asia accounts for a disproportionate number of PACG cases, 
whereas the prevalence of POAG is more evenly distributed throughout the 
world (Quigley 1996). Clinical research reports still commonly refer to patients 
with open-angle glaucoma and untreated IOP of less than 21 mmHg as having 
normal tension glaucoma (NTG); however, there is little evidence that such 
dichotomous subdivision has a scientific basis, and investigators are now urged 
to treat IOP as a continuous variable in studies of open-angle glaucoma (OAG). 
For the purpose of this thesis, we shall focus mainly on OAG, as the most 
common form of glaucoma. 
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1.2.3 Clinical manifestations of glaucoma 
In open angle glaucoma, RGC death may be accompanied by pathological ONH 
cupping (Fig 1.10 A-B), glaucomatous optic atrophy (Shields 1997), changes in 
the structure of the retinal nerve fibre layer (RNFL) (Read et al 1974) and a 
characteristic VF loss (Quigley 2011). This optic nerve excavation consists of 
both loss of RGC axons and deformation of connective tissues supporting the 
optic disc (Fig 1.10 C-F). 
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Fig 1.10: Typical features of the eye in healthy individuals and in patients with 
glaucoma. The optic disc of individuals without glaucoma has a central pale 
area (cup) that occupies about half or less of the optic disc with a surrounding 
orange rim of nerve tissue (A). With glaucomatous damage the cup occupies an 
increasing proportion of the disc, the rim disappears, and the cup becomes 
excavated with a deep floor and a rim that may be undermined (B). The typical 
histological appearance of the optic nerve head (C) changes in glaucoma with 
tissue loss from the rim and deepening of the cup (D). The connective tissues 
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of the optic nerve head in healthy individuals, when seen after digestion of 
neural tissue, are like a thin meshwork across the ONH, perforated by pores for 
nerve bundles (E). The cup in glaucoma deepens and widens with fixed 
deformation of the connective tissue, leading to the characteristic excavation 
seen clinically (F) (Modified from Quigley 2011). 
This excavation or abnormal structural deepening of the optic disc connective 
tissue is one of the main clinical features that separates glaucoma from 
ischaemic optic neuropathy or chiasmal tumour-induced neuropathy (Danesh-
Meyer et al 2010). OAG is also distinguished from other optic neuropathies by 
slow progression over months to years (Heijl et al 2009). It is usually bilateral, 
but asymmetric (Broman et al 2008). Glaucoma is sometimes referred to as the 
“silent blinder”, because many people are unaware of having the disease 
(Tielsch et al 1991). It remains undiagnosed in nine out of ten affected people 
worldwide and in about 50% of those in developed countries, thus improved 
case detection is needed. Importantly, the loss of peripheral vision, depth 
perception and contrast sensitivity associated with glaucoma can have a major 
effect on an individual’s life. Injuries caused by car crashes and falls are 
associated with the types of visual impairment that arise in glaucoma and such 
injuries can occur even if a person has excellent central acuity (Glynn et al 
1991, Owsley et al 1998). 
 
1.2.4 Risk factors (overview) and relevance to the optic nerve head 
The pattern and progression of VF loss due to ganglion cell death varies among 
glaucoma patients suggesting that there is some variability in the magnitude of 
the insult responsible for the cell loss. Data derived from clinical observations 
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and from animal experiments suggest that the axons of the optic nerve and the 
RGC somata do not die at the same time but that death can vary between 
months and many years (Osborne et al 1999). It seems therefore reasonable to 
assume that when a patient is diagnosed initially as having glaucoma, only 
some ganglion cells are dead, whereas others may range from being slightly 
affected to completely normal (Neufeld 1998).  
IOP is a major, and currently the only modifiable, risk factor for VF loss in 
glaucoma, whether raised (high tension glaucoma) or within the normal range 
(normal tension glaucoma), which accounts for one third to one half of all 
cases (Klein et al 1992a, Tielsch et al 1991). This would suggest that, although 
glaucoma may be associated with increased IOP, its diagnosis does not rely on 
a specific level of IOP (Coleman 2000) and patients are known to progress at 
varying rates at all levels of IOP. While there has been success in slowing 
progression by lowering IOP in both high tension and normal tension glaucoma 
(Heijl et al 2002, CNTGS AJO 1998) and at both the early and late stages of the 
disease (Weinreb and Khaw 2006), additional factors (Douglas 1998) must be 
sought to explain why IOP lowering does not always prevent deterioration. 
Several possible mechanisms have been proposed for glaucomatous RGC 
damage (section 1.3 below), which is thought to occur at the ONH (Fig 1.10). 
The lamina cribrosa of the ONH is likely to be at risk because of the transition 
between an efficient (myelinated axons) and a not so efficient (unmyelinated 
axons) energy system of action potential transmission (Osborne et al 1999), 
and a variable reduction of ATP is likely to exist in the RGCs over time with the 
greatest effect being in the ONH region. This may cause a reduced normal 
resting membrane potential with homeostasis of the RGCs now maintained at 
a lower status, so making them more susceptible to further insults. There is 
also strong support for a vascular mechanism in which impairment of blood 
  
flow at the ONH is due either to raised 
al 1998, Kerr et al 1998) or to intrinsic vascular factors (Osborne et al 2001, 
Spaeth 1977, Hayreh 1985, Flammer et al 1998, Flammer et al 1999, Chung et 
al 1999, Yamamoto et al 1998)
Fig 1.11: Possible causes of ganglion cell death in glaucoma. It is suggested that 
activation of sufficient risk factors causes the quality of blood supply in the 
ONH to be affected. As a result, the nutritional supply to the 
compromised (oligaemia/hy
and RGC axons. Such insults eventually lead to the death of 
also envisage other modes of stimulating ganglion cell death in glaucoma 
(lighter green boxes) where the vascular system does not 
Some of these possibilities may also be linked to certain risk factors, such as 
black race, ageing, history of steroid use and sleep
but these are not indicated (Osborne
57 
IOP (Yamazaki et al 1996, Grunwald et 
 (Fig 1.11).  
ONH
poxia) particularly affecting astrocytes, microglia 
RGCs
have a direct role. 
-related breathing disorder
 et al 2001). 
 is slowly 
. One may 
s, 
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1.2.5 Management 
The goal in the treatment of OAG is to prevent further loss of functional vision 
during the remainder of a patient’s life and to avoid an adverse impact on the 
patient’s quality of life (EGS 1998, AAO 1996). The prevention of loss of vision 
is mainly achieved by lowering the IOP to a threshold that is deemed to be safe 
for the RGCs given the current amount of damage in the ONH (target IOP) 
(Jampel 1997). Once this has been achieved, the patient should be monitored 
every 4–12 months, although more frequent monitoring might be required for 
patients who are monocular or have advanced bilateral VF loss. Preferred 
practice patterns from professional organisations suggest monitoring 
structural glaucoma damage by clinical observation of the optic disc and by 
photography or digital imaging of the optic disc and nerve fibre layer. 
Automated visual field testing with threshold strategies is repeated regularly to 
establish the rate of progressive worsening as a means to judge the success of 
treatments that lower IOP (Chauhan et al 2008, Heijl et al 2008). A consensus 
panel in the UK, the National Institute of Clinical Excellence (NICE), based its 
recommendations for whether to treat patients with IOP greater than 21 
mmHg on assessment of risk factors, including age and central corneal 
thickness (NICE 2009).  Lowering of IOP is accomplished by daily eye drops, 
laser treatment to the trabecular meshwork or ciliary body, or surgery. The 
effectiveness of these approaches has been compared pair-wise in randomised 
controlled trials, with the main differences being the rate and type of side 
effects (GLT 1995, Ederer et al 2004, Lichter et al 2001). Because patients with 
OAG can continue to lose vision despite reductions of IOP, the role of 
neuroprotection in the management of OAG warrants consideration (Caprioli 
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1997, Levin 2003). In the not so distant future, sustained delivery of treatment 
may prove beneficial, either through depot placement of sustained-release 
treatment or by placement of cells engineered to produce IOP-lowering and/or 
neuroprotective substances (Tao et al 2002). 
 
1.3 Pathways involved in retinal ganglion cell loss in glaucoma  
 
1.3.1 The role of mitochondria 
RGCs, because of their high energy requirement, are heavily dependent on 
mitochondria for survival and function (Raichle et al 2002, Yu et al 2001).   
Mitochondria play a pivotal role in the maintenance of cellular homeostasis 
regulating death signalling pathways (Kroemer et al 2000, Naoi et al 2009) and 
various metabolic functions that include oxidative energy metabolism, 
intracellular pH maintenance, calcium signalling (Pozzan et al 2000) and 
neuronal excitability (Chan 2006, Schapira 2006). Mitochondria are also 
involved in the control of synaptic transmission and the production of reactive 
oxygen species (ROS) that promote and regulate apoptosis (Halliwell et al 
1999).  
Oxidative phosphorylation (oxphos) is a major metabolic pathway in the 
mitochondria, that uses an electrochemical or chemiosmotic gradient of 
protons (H
+
) across the inner mitochondrial membrane to generate the energy-
rich molecule ATP from ADP (Knowles 1980). Functionally, the mitochondrial 
oxphos system comprises around 85 different gene products assembled into 
five multimeric protein-lipid enzyme complexes (Hatefi 1985): i) At complex I 
(NADH dehydrogenase) NADH is oxidised to NAD
+
, a process that releases 
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electrons and reduces Q (ubiquinone) to QH2 (ubiquinol), while at the same 
time four protons are pumped from the mitochondrial matrix to the 
intermembrane space (Fig 1.12). ii) At complex II (succinate dehydrogenase) 
succinate is oxidised to fumarate, a process that releases electrons and 
reduces FAD to FADH2, which carries the original electrons to reduce Q to QH2. 
Again protons are pumped into the intermembrane space. iii) At complex III 
(ubiquinone cytochrome c oxidoreductase) Q-cycle transfers electrons from 
QH2 to cytochrome c (cyt c), while protons are again pumped into the 
intermembrane space. iv) At complex IV (cytochrome c oxidase) cyt c transfers 
electrons to oxygen with the release of water. Again protons are pumped into 
the intermembrane space. v) At complex V (ATP synthase) protons pumped 
into the intermembrane space now return to the matrix, while this rotary 
complex combines ADP and inorganic phosphate into ATP. Complex I is the 
largest complex of the electron transport system and is composed of 46 
subunits that are encoded by both mitochondrial DNA and nuclear genes, and 
defects in this complex are the most frequent cause of oxphos impairment 
underlying mitochondrial disease (Smeitink et al 2001). All the other complexes 
are also derived from both nuclear and mitochondrial DNA, with the exception 
of complex II which is entirely nuclear-gene derived.   
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Fig 1.12: The oxidative phosphorylation pathway. The concentration gradient 
of hydrogen ions across the inner mitochondrial membrane is formed by 
complexes I to IV. This concentration gradient provides the driving force for 
ATP production through complex V. Leakage of electrons at complexes I and III 
are major sites of reactive oxygen species formation (Kong et al 2009). NAD: 
nicotinamide adenine dinucleotide; FAD: flavin adenine dinucleotide, CoQ: 
coenzyme Q; O2: oxygen; H
+
: proton; e
-
: electron; H2O: water; CytC: 
cytochrome C; ADP: adenosine diphosphate; ATP: adenosine triphosphate. 
Significantly, and as mentioned previously (1.1.3), RGC axons are unmyelinated 
within the ocular globe and have mitochondria-enriched axon varicosities 
(Barron et al 2004, Wang et al 2003), which are interpreted as functional sites 
with local high-energy demand, critical for maintaining the transmission of 
action potentials along the pre-laminar axons within the globe (Andrews et al 
1999, Bristow et al 2002, Carelli et al 2004) and for axoplasmic flow (Hollander 
et al 1995, Minckler et al 1977). The high concentration of mitochondria at the 
optic nerve head also implies dependency on some aspect of mitochondrial 
function (Barron et al 2004). It is therefore clear that alteration in the 
functional status of these RGC axon mitochondria may influence ganglion cell 
survival in a disease like glaucoma (Osborne 2008). RGCs are thought to die by 
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apoptosis at varying rates depending on, for example, the ganglion cells' 
receptor profile (Osborne et al 1999) and other factors, such as the number 
and spatial distribution of the RGC mitochondria (Yu-Wai-Man et al 2005) and 
their axonal length and position within the globe (Osborne 2010). This may 
explain why the preferential loss of RGCs in glaucoma is also a key pathological 
feature found in the two most common inherited mitochondrial optic 
neuropathies, Leber hereditary optic neuropathy (LHON; MIM#535000), 
mostly caused by a defect in oxidative phosphorylation (OXPHOS) complex-I 
(Mackey et al 1996), and autosomal dominant optic atrophy (ADOA; 
MIM#165500) (Yu-Wai-Man et al 2009), caused by mutations in the nuclear 
genes encoding the mitochondrial fusion protein OPA1 (Alexander et al 2000, 
Delettre et al 2000). Both these diseases share phenotypic similarities and may 
be mistaken for glaucoma (O’Neill et al 2011). It is also interesting that murine 
RGCs have been found to be more sensitive to the downstream events of 
mitochondrial fragmentation and pro-apoptotic stimuli than other neuronal 
populations (Kamei et al 2005), thus emphasising the potential importance of 
mitochondrial integrity in preventing or delaying glaucomatous optic 
neuropathies.  
Importantly, mitochondrial dysfunction has been implicated in RGC loss in 
experimental animal models of glaucoma (Tatton et al 2001, Ju et al 2008, 
Mittag et al 2000) and in transformed ganglion cell cultures (Ju et al 2007). Pre-
existing mitochondrial dysfunction, either congenital or acquired, has been 
proposed to increase the vulnerability of RGCs to stress from other risk factors, 
including raised IOP, vascular insufficiency and light exposure (Kong et al 
2009). In the case of raised IOP, Kong et al have shown recently that a mouse 
with neuronal expression of a mutant polymerase gamma gene (POLG) has 
increased mtDNA mutations in the retina and a greater injury response when 
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subjected to acute IOP elevation (Kong et al 2011). Experimentally increased 
IOP has also been shown to result in reduction in ATP levels both in RGC-5 cells 
(Ju et al 2007) and in animal models (Baltan et al 2010). This finding suggests 
that OXPHOS impairment limits the optic nerve’s ability to withstand injury 
from raised IOP and could contribute to the pathogenesis of the glaucoma, 
especially in the presence of such insults. 
It is also notable that, as discussed later in section 1.5.5, ageing is a major risk 
factor for OAG and, since mitochondrial function declines with ageing 
(Kopsidas et al 1998, Li et al 2013), it has been proposed that mitochondrial 
dysfunction could serve as one of the links between ageing and glaucoma 
(Lascaratos et al 2012). In post-mitotic non- replicating cells, including the 
neurons of the retina, the mtDNA, in contrast to the nuclear DNA, is 
continuously replicated as mitochondria are turned over, increasing the 
likelihood of ongoing replication errors and mtDNA mutations. Therefore, 
mtDNA changes are considered relevant to the mitochondrial theory of ageing 
(Druzhyna et al 2008, Harman 1972, Moosmann et al 2008) particularly as 
somatic mutations can be propagated during replacement of the mitochondria 
(Liang et al 2003). Indeed, mtDNA mutations have been shown to accumulate 
with age (Wei 1992), a phenomenon which may in part be a consequence of 
the age-related diminishment of autophagic activity (Terman 1995), the 
process that sequesters and degrades organelles and macromolecular 
constituents of cytoplasm for cellular restructuring and repair. Moreover, 
mitophagy (the autophagic destruction of mitochondria) may be important for 
the elimination of dysfunctional mitochondria and mutated mtDNA (Weber et 
al 2010); certain mtDNA mutations decrease recognition signals for mitophagy 
and, therefore, accumulate with age (Lemasters 2005). Age-associated mtDNA 
mutations include large-scale deletions and point mutations (Corral-Debrinski 
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et al 1992, Lin et al 2002), as well as oxidative modification with the formation 
of 8-hydroxy-2′-deoxyguanosine (Wei 1998). The mutant mtDNA often coexists 
with the wild-type mtDNA in affected tissues, a condition termed 
heteroplasmy (Lightowlers et al 1997). The clinical severity of glaucoma may 
therefore be correlated with the proportion of the mutant mtDNA in the target 
tissue, the type of mutations, the pattern of distribution of the mutant mtDNA 
and the energy demand of the RGCs.  
 
1.3.2 Reactive oxygen species 
ROS, at low levels, are considered critical signalling molecules, while oxidative 
stress refers to excessive levels of ROS that arise from the imbalance between 
the processes that generate ROS and those responsible for their removal 
(Chrysostomou et al 2013). Oxidative stress damages macromolecules 
including DNA, proteins and lipids and is thought to contribute to the 
pathogenesis of a number of age-related neurodegenerative diseases (Schapira 
1996). Raised IOP is a major risk factor for RGC loss in glaucoma and, in several 
animal glaucoma models, increasing IOP led to the development of oxidative 
stress. For example, elevated IOP following intracameral hyaluronic acid 
injection in rats has been shown to result in a significant decrease in retinal 
antioxidants and an increase in retinal lipid peroxidation (Moreno et al 2004), 
while ocular hypertension in rats in other studies has also led to a marked 
increase in ROS and nitrite levels, lipid peroxidation (Ferreira et al 2010, Ko et 
al 2005) and protein oxidation localised to the inner retinal layers containing 
the RGCs (Tezel et al 2005). 
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It is also important to note that the pathways leading to RGC injury under 
conditions of oxidative stress are likely to be complex, varied and interrelated, 
and it is often difficult to distinguish cause from consequence (Fig 1.12). For 
example, ROS have been shown to be implicated indirectly in RGC damage by 
causing vascular changes that disrupt the autoregulation of blood flow to the 
optic nerve, impaired aqueous humour outflow as a result of oxidative injury 
to the trabecular meshwork (Izzotti et al 2006) and aberrant immune 
responses and glial cell dysfunction (Tezel 2009), as discussed later (1.3.7-
1.3.8) in more detail. Moreover, ROS are able to activate apoptotic pathways 
when in excess and have been found to affect RGCs directly, by triggering 
apoptosis in vitro via caspase-independent pathways (Li et al 2008). In another 
study, reduction of ROS generation temporarily protected RGCs from apoptosis 
(Tezel et al 2004), while Martin et al have shown that oxidative stress alters 
retinal glutamate/glutamine cycling, leading to the accumulation of neurotoxic 
levels of glutamate (Martin et al 2002), as described in more detail in section 
1.3.5 below.  
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Fig 1.13: RGC death and axon degeneration represent the principal event in the 
course of glaucoma. The mechanisms that control the loss of this specific 
neuron population remain largely unclear. From a pathophysiological point of 
view, the main steps in glaucoma pathogenesis include raised IOP, ischaemia, 
glial cell activation, apoptosis and structural optic nerve head changes. A 
common denominator (highlighted in red) is the free radical-generated 
oxidative damage, which is known to influence these glaucomatous targets 
(Sacca et al 2008). 
 
1.3.3 Apoptosis - necrosis 
The hallmarks of apoptosis are condensation of nuclear and cytoplasmic 
contents, nuclear DNA fragmentation, cell blebbing and autophagy of 
membrane-bound bodies. This process typically requires energy and is 
characterised by clearly distinguishable changes in the nucleus, but not in the 
cytoplasmic organelles, at least in the initial stages (Kroemer et al 1995, Wyllie 
et al 1980). Apoptosis appears to occur via different pathways. A 
mitochondrion-mediated (intrinsic) pathway has been described, where an 
external insult - such as elevated cytosolic calcium - acts to cause a release of 
cytochrome c, located in the inner membrane space of the mitochondria. 
Cytosolic cytochrome c can then bind apoptotic protease-activating factor 1 
(APAF-1), which in turn binds to the inactive form of caspase-9 (Fig 1.13). This 
complex “apoptosome” can then activate a cascade of events, including the 
activation of caspase-3, and ultimately results in the hallmarks of apoptosis 
(Acehan et al 2002). Mitochondrion-mediated activation of caspase-9 can also 
occur via extracellular receptor-mediated signals (extrinsic pathway) to target 
various ligands - such as Bid and Bax - to the mitochondrion, thereby causing 
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cytochrome c release (Luo et al 1998). Under certain circumstances, a separate 
mitochondrial-independent pathway also operates, which involves the 
activation of caspase-8 and caspase-3 (Stennicke et al 1998). In addition, a 
caspase-independent/mitochondrial-dependent pathway exists where 
apoptosis-inducing factor (AIF), confined to mitochondria, is released and 
translocates to the nucleus to cause chromatin condensation and DNA 
degradation (Susin et al 1996). The activation of the tumour suppressor protein 
p53 has also been proposed as one of the molecular events leading to the up-
regulation of the pro-apoptotic gene bax and down-regulation of the anti-
apoptotic gene brl-2, thus causing changes in mitochondria that ultimately 
activate caspases and induce neuronal apoptosis in glaucoma (Nickells et al 
1999). 
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Fig 1.14: Schematic view of the main mitochondria-dependent and -
independent (through caspase-8) apoptotic pathways. Mitochondria-
dependent apoptosis often involves the release of cytochrome c and the 
activation of caspase-9, but can also occur through mitochondrial release of 
cleaved AIF or ROS. AIF, apoptosis-inducing factor; PARP, poly(ADP-ribose) 
polymerase 1; ROS, reactive oxygen species; APAF-1, apoptotic protease-
activating factor 1; Cyt c, cytochrome c; Bid, BH3 interacting-domain; Bax, Bcl-
2-associated X; TNF-a, tumour necrosis factor-a; Bcl-2, B-cell lymphoma 2 
(Osborne 2008). 
Necrosis is characterised by a compromised membrane integrity caused by ATP 
energy depletion; swelling eventually occurs and the mitochondria become 
dysfunctional. Eventually, the cell lyses and lysosomal enzymes are released 
into the extracellular space. Unlike apoptosis, changes in the nucleus of a 
necrotic cell appear relatively unremarkable, at least during the early stage, 
but there is some swelling associated with the nuclear membrane followed by 
a scattering of materials into small masses (Wyllie et al 1981). The main factors 
thought to differentiate between apoptosis and necrosis are summarised in Fig 
1.14 below. Since the rate of glaucomatous damage is relatively slow, it is 
hypothesised that very few RGCs would be expected to be found actually dying 
from apoptosis. In support of this, several studies have indeed shown that the 
number of TUNEL positive ganglion cells in glaucomatous patients is small, 
although it is greater than in control retinas (Kerrigan et al 1997, Okisaka et al 
1997). Another study has also shown that immunoreactivity for the 
inflammation-associated enzyme, cyclo-oxygenase-2, in the human 
glaucomatous optic nerve is unchanged compared with controls (Neufeld et al 
1997). This argues for an absence of inflammation and endorses the idea that 
ganglion cell death in glaucoma is by apoptosis. It is, however, possible that in 
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reality apoptosis and necrosis form a continuum at the extremes of a 
biochemically overlapping death pathway rather than being totally separate 
modes of death with only limited molecular and cellular biological overlap 
(Raffray et al 1997). 
Necrosis Apoptosis 
• Occurs in groups of cells • Occurs in isolated cells  
• Gene expression not a • Genetically controlled 
 prerequisite • Precise internucleosomal cleavage of 
• Late stage random DNA  DNA 
 cleavage • No inflammation 
• Inflammatory response • Phagocytosis of apoptotic bodies by 
• Phagocytosis of debris by macrophages  tissue cells and/or macrophages 
Fig 1.15: Factors thought to differentiate between necrosis and apoptosis 
(Osborne et al 1999). 
 
 
1.3.4 Neurotrophic factor deprivation 
Axonal injury is known to result in retrograde neuronal degeneration (Silveira 
et al 1994). A common explanation for neuron degeneration after axotomy is 
that the cell body is deprived of growth factors that it receives from the target 
field. Consistent with this idea is the finding that ganglion cell degeneration 
can be partially prevented by intravitreal administration of large doses of 
growth factors, such as fibroblast growth factors (Sievers et al 1987), nerve 
growth factor (Carmignoto et al 1989) and ciliary neurotrophic factor (Mey et 
al 1993). Since axons within the rat optic nerve show a capacity for regrowth 
following transection (Villegas-Pérez et al 1988, Bray et al 1991), and certain 
growth factors promote this growth and survival (Thanos et al 1989), the 
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suggestion has been made that ganglion cells die in glaucoma because of a lack 
of specific growth factors.  
Brain derived neurotrophic growth factor (BDNF) has been particularly 
discussed in this respect because this neurotrophin and its high affinity 
receptor TrkB are associated with ganglion cells. Moreover, BDNF is known to 
be transported by the CNS neurons (Di Stefano et al 1992) and when BDNF is 
injected into the superior colliculus it reduces developmental ganglion cell 
death (Ma et al 1998). It has been suggested that in glaucoma the retrograde 
transport of growth factors from the brain to the ganglion cell somata is 
altered resulting in RGC death. BDNF transport in the optic nerve head has 
indeed been found to be altered after chronic IOP elevation in monkeys (Pease 
et al 2000) and after acute IOP elevation in rats (Quigley et al 1976, Quigley et 
al 2000), and intravitreal injection of BDNF reduces ganglion cell degeneration 
(Mansour-Robaey et al 1994). Similar RGC rescue was observed using viral 
vectors to achieve continuous synthesis of BDNF in the retinas of rats with 
experimental glaucoma (Martin et al 2003). Partial rescue of RGCs was also 
reported after the application of ciliary neurotrophic factor in ocular 
hypertensive (Ji et al 2004) and axotomised adult rat eyes (Van Adel et al 
2003). It has, however, also been reported that ganglion cell numbers are 
unaffected in knockout mice lacking BDNF, suggesting that a decrease in the 
BDNF activity in a healthy retina may have little effect on ganglion cell survival 
(Callerino et al 1997), while, in another study, RGC apoptosis was observed 
before axonal transport obstruction and alterations in neurotrophin levels 
(Johnson et al 2000). 
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1.3.5 Glutamate excitotoxicity 
ROS-induced neuronal damage can cause cell death accompanied by a release 
of glutamate into the extracellular space. Glutamate is the major 
neurotransmitter of the retina and is produced by a variety of retinal neurons 
that include PRs, bipolar cells, amacrine cells and ganglion cells. Glutamate is 
released from synapses under normal physiological conditions to act as a 
neurotransmitter and is immediately inactivated thereafter by being taken up 
by retinal astrocytes and Müller cells (Rauen et al 1998, Bouvier et al 1992, 
Barnett et al 2000). However, should the extracellular concentration of 
glutamate become abnormally high, glutamate can elicit a toxic effect on the 
RGCs (Lipton et al 1994). Importantly, elevated glutamate levels have been 
found in the vitreous of glaucoma patients and in animal models of glaucoma 
(Brooks et al 1997), although subsequent investigations could not corroborate 
the initial findings (Carter-Dawson et al 2002, Wamsley et al 2005). 
Glutamate activates two classes of glutamate receptors: ionotropic and 
metabotropic. There are three subtypes of ionotropic glutamate receptors 
found on neurons, identified by their preferred agonists: N-methyl-D-aspartate 
(NMDA), alpha-amino-3 hydroxy 5-methyl 4-isoxandeproprionic acid (AMPA) 
and kainate (KA). The ionotropic receptor subtype that appears to be primarily 
involved in excitotoxicity is the NMDA receptor. AMPA/KA receptors are often 
situated presynaptically, which on stimulation leads to an excessive activation 
of postsynaptic NMDA receptors, thus playing a part in the cascade of events 
involving the role of NMDA receptors in RGC excitotoxicity (Mosinger et al 
1991). The NMDA receptor is a ligand-gated ion channel, which is activated 
physiologically by glutamate. Glycine modulates the influence of glutamate 
positively, acting as a co-agonist. Activation of the NMDA receptor results in 
  
depolarisation of the neuron
When the extracellular concentration of glutamate is elevated above a certain 
level, the receptor is hyperstimulated with an excess of calcium and sodium 
entering the RGCs not only via the NMDA channels but also via voltage
dependent Na
+
 and Ca
2+
 channels (Bonne et al 1997).
also leads to an accumulation of the cation within the mitochondria thereby 
disturbing its oxphos processes and thus decreasing the synthesis of ATP 
(Kruman et al 1998, Fiskum et al 2000). Consequently,
ensues leading to lactate accumulation, metabolic acidosis, compromised 
buffering capacity within the cell and eventually neuronal death.
available ATP is also known to cause dysfunction of the sodium
ATPase pump and the calcium pump, as well as reversal of glutamate uptake 
(Osborne et al 2004). 
There is also evidence for ROS causing an increase in glutamate levels by 
preventing the deamination   of   glutamate   by   the   mitochondrial   enzyme   
glutamate   dehydrogenase 
nitrogen is channelled through glutamate, which is then normally deaminated 
in the mitochondria. However, excessive amounts of ROS may hinder this 
process, since they can cause local damage to the (iron
mitochondrial respiratory enzymes, mtDNA damage (Carelli et al 2004) and 
mitochondrial membrane destruction by lipid peroxidation (Kowaltowski et al 
2001, Kowaltowski et al 1999).
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Fig 1.16: The reaction catalysed by the mitochondrial glutamate 
dehydrogenase. 
 
1.3.6 Hypoperfusion and ischaemia of the optic nerve 
The word ischaemia was coined by Virchow, who combined the Greek iskho, 
meaning “I hold back”, with háima, meaning “blood”. Hence, ischaemia refers 
to a pathological situation involving an inadequacy (not necessarily a complete 
lack of) blood flow to a tissue, thus depriving the tissue of three requirements: 
oxygen, metabolic substrates and removal of waste products. In experimental 
studies, multiple retinal ischaemic models have been described to result in loss 
of RGCs (Akiyama et al 2002,  Goto et al 2002, Lafuente et al 2002, Wang et al 
2002, Chidlow et al 2003, Inoue-Matsuhisa et al 2003). A link between 
ischaemia and excitotoxicity has also been proposed, as in ischaemia 
extracellular transmitter levels (particularly glutamate and GABA in case of the 
retina) are known to be elevated (Louzada-Junior et al 1992, Neal et al 1994) 
and cells that are excessively affected by these transmitters would be most 
likely to be susceptible (Fig 1.16) (Kalloniatis 1995, Osborne et al 1999). The 
particular susceptibility of neurones of the inner retina, and RGCs in particular, 
to ischemia is thought to be partly due to the fact that these cells express high 
levels of ionotropic glutamate receptors (Brandstatter et al 1994), as discussed 
previously (1.3.5). There is also evidence that magnocellular neurons are 
damaged more effectively than parvocellular neurons in glaucoma (Quigley et 
al 1987, Luo et al 2001), although this is considered controversial. This 
difference has been suggested to occur as a result of the greater NMDA 
receptor density on the magnocellular neurons, which also appear to be more 
susceptible to NMDA toxicity (Sucher et al 1997). 
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Fig 1.17: The importance of the balance between excitatory and inhibitory 
neurotransmitter input to retinal neurons. Under physiological conditions, the 
balance between inhibitory (e.g. GABA) and excitatory (e.g. glutamate) input to 
neurones is un-important: cellular functioning remains normal. When the 
neuron is subjected to an ischaemic or hypoxic insult, however, then survival 
may be favoured by the summed relative proportion of inhibitory to excitatory 
receptors expressed at synaptic terminals. Susceptibility to the insult will be in 
the order of 1>2>3>4 since the relative proportion of inhibitory receptors 
increases in that order (Osborne et al 2004). 
Moreover, several non-ocular features consistent with vasospasm (eg, 
migraine, Raynaud’s phenomenon) reportedly occur at higher frequency in 
patients with NTG, suggesting a role for vascular factors and decreased 
perfusion of the optic nerve in the pathogenesis of glaucoma. Calcium channel 
blockers may improve the perfusion of the optic nerve by vasodilation of the 
cerebral vasculature. Interestingly, glaucoma patients treated with this class of 
drugs were noted to experience fewer ONH and VF changes than those not 
taking the medication (Kitazawa et al 1989, Netland et al 1993, Sawada et al 
  
75 
 
1996). Also, nimodipine, a calcium channel blocker, has been shown to acutely 
improve contrast sensitivity in patients with NTG, further supporting the 
importance of vascular factors in glaucoma (Bose et al 1995).  
 
1.3.7 Glial cell activation 
Glial cell activation may be an important factor contributing to RGC death in 
glaucoma. Under normal conditions, glial cells support neuronal function 
through a variety of mechanisms, as described in section 1.1.5. Glial fibrillary 
acidic protein (GFAP), an intermediate filament, is a cell specific marker that 
distinguishes astrocytes from other glial cells. It is expressed by retinal 
astrocytes under normal conditions, but its synthesis is significantly elevated in 
glaucoma by astrocytes and Muller cells (Fig 1.17) (Wang et al 2000). Increased 
retinal expression of GFAP appears to be an early event in the pathogenesis of 
glaucoma; in animal models, it can be observed as early as 4 days after the 
induction of elevated IOP, before widespread RGC apoptosis (Woldemussie et 
al 2004). 
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Fig 1.18: Immunohistochemical localisation of glial fibrillary acidic protein 
(GFAP) in the normal (A) and glaucomatous (B) rat retina. In the healthy retina, 
GFAP is restricted to retinal astrocytes (arrow). IOP elevation induces glial cell 
activation and synthesis of GFAP by Muller cells (arrowheads); GCL, ganglion 
cell layer; INL, inner nuclear layer; ONL, outer nuclear layer (Kuehn et al 2005). 
This activation of retinal glial cells is thought to result in the active synthesis of 
substances that are harmful to RGCs, such as cytokines, reactive oxygen 
species or nitric oxide. Interestingly, studies on primary co-cultures of RGCs 
and glial cells suggest that tumour necrosis factor alpha (TNFa), a 
proinflammatory cytokine, is secreted by glial cells in response to elevated 
pressure to cause the apoptotic death of RGCs (Tezel et al 2000). Exposure of 
RGCs to TNF has been shown to reduce their mitochondrial membrane 
potential (Tezel et al 2004), while intravitreal injections of TNFa have been 
shown to cause degeneration of the optic nerve (Madigan et al 1996). 
  
77 
 
Moreover, an immunohistochemical study of human eyes with and without 
glaucoma showed that TNFa is synthesised by retinal glial cells in glaucoma and 
that the TNFa receptor is present on RGCs (Tezel et al 2001). 
Another glial cell–mediated apoptotic stimulus may be the increased 
production of nitric oxide (NO). NO serves a variety of physiologic functions, 
including regulation of vascular tone, neurotransmitter release and synaptic 
plasticity. Excessive levels of this molecule can lead to cell death in a variety of 
cell types, including RGCs (Morgan et al 1999). NO has been found to inhibit 
mitochondrial complexes I and IV (Cleeter et al 2001), while excess plasma NO-
mediated neurotoxicity (Liu et al 2003) and elevated levels of NOS activity have 
been implicated in glaucomatous optic neuropathy in humans (Liu et al 2000, 
Neufeld et al 1997) and in animal glaucoma models (Shareef et al 1999, 
Franco-Bourland et al 1998). Inhibition of NO production appears to reduce 
RGC damage in a rat model of glaucoma (Neufeld et al 1999, Neufeld et al 
2002). Increased NOS levels, however, were not detected, and inhibition of 
NOS did not confer protection to RGCs, in a different rat model of glaucoma 
induced by hypertonic saline injection into the episcleral veins (Morrison et al 
2005, Pang et al 2005). 
 
1.3.8 Abnormal immune response 
Evidence from clinical and experimental studies implicates the involvement of 
the immune system in glaucoma (Tezel et al 2004, Tezel et al 2007, Grus et al 
2008, Wax et al 2000) and other neurodegenerative diseases (Scofield 2004). 
Glaucoma is marked by consistent profiles of up- and down-regulated serum 
antibodies against retinal and optic nerve antigens (Grus et al 2008, Wax et al 
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2001, Yang et al 2001). In more detail, antibodies against ocular antigens that 
have been shown to play a possible neurodegenerative role in glaucoma 
include antibodies against heat shock proteins (HSPs) (Tezel et al 2000), alpha-
fodrin (Grus et al 2006), rhodopsin (Romano et al 1995), γ-enolase (Maruyama 
et al 2000), glutathione-S-transferase (GST) (Yang et al 2001), TNF-α (Tezel et al 
2001), antiphosphatidylserine (Kremmer et al 2001) and γ-synuclein 
(Surgucheva et al 2002). Importantly, another recent finding was a higher 
likelihood of glaucoma progression in patients with raised anticardiolipin 
antibodies (Chauhan et al 2008). Moreover, in NTG elevated serum titres of 
autoantibodies against small HSPs (25 to 30 kDa) (Tezel et al 2000, Tezel et al 
1998) and anti-Ro/SS-A have been found (Wax et al 1998). HSP-27 antibodies 
are known to trigger apoptotic cell death in RGCs in culture by inactivating or 
attenuating the ability of native HSP-27 to stabilise the actin cytoskeleton 
(Tezel et al 2000). In a more recent study by Reichelt et al, raised 
autoantibodies against histone-H4 were identified in POAG patients, while a 
decrease in the level of antibodies against the retinal S-antigen was also noted 
in this group (Reichelt et al 2008). Furthermore, the sera of NTG and POAG 
patients have been found to exhibit increased levels of soluble interleukin 2 
receptors (Yang et al 2001), known to be elevated in autoimmune diseases 
(Mariotti et al 1992, Ferrarini et al 1998).  
Autoantibodies to ONH proteoglycans in the sera of patients with glaucoma 
have also been reported (Tezel et al 1999). Proteoglycans perform various 
functions, including the formation of a spatial framework to support the optic 
nerve and blood vessels. It has therefore been suggested that an immune 
response directed against proteoglycans may weaken the extracellular matrix 
supporting the lamina cribrosa and induce or increase optic nerve cupping. 
Proteoglycans are also present in the cell walls of blood vessels and their 
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dysfunction could contribute to the development of splinter optic disc 
haemorrhages or disturbances in the autoregulation of blood flow in glaucoma 
(Tezel et al 1999). 
 
1.4 Major susceptibility factors for glaucoma onset from large 
epidemiological studies 
 
Progression from the healthy status to OAG has been assessed by longitudinal 
population-based studies in which a randomly chosen population living in a 
well-defined geographical area is examined at baseline, and re-examined after 
a certain period of time (Coleman et al 2008). One of the advantages of 
population-based epidemiological studies, unlike case-control studies, is the 
lack of control selection bias, in which the characteristics of the controls differ 
significantly from the characteristics of the population that is the target of 
inferences drawn from the study results. Below, the main risk factors are 
presented for glaucoma identified from the Barbados Incidence Study of Eye 
Diseases (BISED) on the African descent population in Barbados (Leske et al 
2008), the Melbourne Visual Impairment Project (VIP) on white patients in 
Melbourne – Australia (Le et al 2003), the Rotterdam Eye Study (RES) on white 
patients in Rotterdam – Netherlands (deVoogd et al 2006, Muskens et al 2007), 
and other epidemiological studies. The BISED, VIP and RES studies estimated 
the incidence of OAG over 9, 5 and 6.5 years, respectively. 
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1.4.1 Baseline IOP 
Baseline IOP was identified as one of the main risk factors for glaucoma in all 
three studies (BISED, VIP and RES), with the average baseline IOP being 
18.0mmHg (SD 4.1), 15.1mmHg (SD 3.1) and 15.0mmHg (SD 3.1), respectively. 
Notably, a 10% to 14% increased risk of developing OAG was found in subjects 
with baseline IOPs ≥1mmHg higher than the average for the population over 
the following 5 to 9 years. 
 
1.4.2 Age 
Age at baseline was highlighted as a major risk factor for glaucoma in the BISED 
and RES studies, where the risk of developing OAG increased by 4% and 6%, 
respectively, in subjects who were 1 year older at baseline. The baseline mean 
age was 56.9 years (SD 11.3) in the BISED (Leske et al 2008) and 65.7 years (SD 
6.9) in the RES (Muskens et al 2007). Also, in the VIP, where the baseline mean 
age was 58.7 years (SD 11.4), subjects with an age of 70-79 years old at 
baseline had a 12-fold increased 5-year risk of developing OAG compared to 
subjects aged 40-49 years old (Le et al 2007). In the population-based 
Baltimore Eye Survey, white people and African-Americans aged 70 years or 
older were 3.5 and 7.4 times more likely to have glaucoma than white people 
and African-Americans aged 40–50 years, respectively (Tielsch et al 1991). 
Additional evidence for the association between ageing and the increasing 
prevalence of OAG was also provided by the Blue Mountains Eye Study in 
Australia (Mitchell et al 1996) and the Los Angeles Latino Eye Study (LALES) 
(Varma et al 2004).  
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1.4.3 Systemic hypertension 
The Baltimore Eye Survey reported a positive, although non-significant 
association of SBP and DBP with POAG in elderly individuals, but found a 
possible protective role of systemic hypertension in younger ages (Tielsch et al 
1995). The Egna-Neumarkt study reported correlation between hypertensive 
POAG and systemic hypertension, regardless of the age of patients (Bonomi et 
al 2000). Moreover, the LALES, a large (n=6130) population-based study of 
adult Latinos, identified high SBP and mean arterial pressure (MAP) to be 
associated with a higher prevalence of OAG, while in the same study low DBP, 
DPP, SPP and were also linked to OAG (Memarzadeh et al 2010). In contrast, 
the 9-year follow-up from the Barbados Eye Study did not confirm the role of 
systemic hypertension as a risk factor for glaucoma (Leske et al 1995, Leske et 
al 2001) and revealed a weak negative association with SBP [RR= 0.91 (95% CI 
0.84, 1.00) per 10 mmHg] (Leske 2009). Blood pressure and IOP have been 
reported to be positively associated (Hennis et al 2003, Klein et al 2005) and, 
since increased IOP is a risk factor for POAG (Sommer et al 1991), it is possible 
that increased BP and POAG could also be associated through this BP-IOP 
relationship. Thus, the reported link between BP and POAG may be 
confounded by IOP. 
 
1.4.4 Family history 
In the Baltimore Eye Survey, first-degree relatives of patients with POAG had 
2·9 times greater odds of having glaucoma than non-relatives (Tielsch et al 
1994). In a population-based familial aggregation study in Rotterdam (Wolfs et 
al 1998), the lifetime risk of glaucoma was 9.2 times higher in siblings and 
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offspring of glaucoma patients than in siblings and offspring of controls. Family 
history was also identified as a risk factor for OAG in the BISED [RR: 2.4, 95% CI 
(1.3-4.6)]. 
 
1.4.5 Other 
Other risk factors found in the BISED were a thinner CCT [RR: 1.41, 95% CI 
(1.01-1.96) per 40µm thinner] and lower MOPP [RR: 2.6, 95% CI (1.4-4.6)] 
(Leske et al 2008). These results were not repeated in either the VIP or the RES 
studies. However, the RES reported an association between the use of 
systemic calcium channel blockers for the treatment of systemic hypertension 
[RR: 1.9, 95% CI (1.1--3.3)] and the development of OAG (Muskens et al 2007). 
Moreover, the VIP reported a markedly increased risk of OAG in individuals 
with pseudoexfoliation [RR: 11.2, 95% CI (2.0-63.3)] and large cup-to-disc ratios 
(>0.7) [RR: 7.9, 95% CI (4.4-14.1)], while the use of systemic alpha-blockers was 
also significantly associated with the onset of OAG [RR: 4.8, 95% CI (1.2-18.8)] 
(Le et al 2003). Diabetes was not a risk factor in any of the three studies 
(BISED, RES, VIP) (deVoogd et al 2006).  An additional demographic risk factor 
for OAG from the Baltimore Eye Survey (Tielsch et al 1991) and other studies 
(Leske et al 1994, Mason et al 1989) was African descent, with African-
Americans being four times more likely to have glaucoma than white people. 
 
 
 
  
83 
 
1.5 Major susceptibility factors for glaucoma progression from large clinical 
trials and smaller studies 
 
Risk factors for the progression of OAG have been explored in four large 
multicenter randomised clinical trials: the Collaborative Normal Tension 
Glaucoma Study (CNTGS) (CNTGS AJO 1998), the Early Manifest Glaucoma Trial 
(EMGT) (Heijl et al 2002), the Advanced Glaucoma Intervention Study (AGIS) 
(AGIS AJO 2000) and the Collaborative Initial Glaucoma Treatment Study 
(CIGTS) (Lichter et al 2001). To date, although several risk factors for OAG 
progression have been established, some of the results have been inconsistent. 
This may be explained partly by differences in study designs, the variety of 
definitions used for glaucoma, and the fact that few variables have been 
included consistently in risk factor analyses across studies (Coleman et al 
2008). The stage of OAG differed among the four trials with AGIS (MD of -10.5) 
(AGIS 1998) and CNTGS (MD of -8 dB) (CNTGS 1998) having the most advanced 
damage, and CIGTS (MD of -5.5) (Gillespie et al 2003) and EMGT (MD of -4.7 
dB) the least. Also, VF progression was defined differently between studies, 
making useful comparisons challenging. In the AGIS and EMGT, VF progression 
was defined uniquely to each study, and then treated as a binary outcome in 
assessing risk factors, while in the CIGTS the definition of progression relied on 
the mean deviation, rather than the threshold sensitivity change at two or 
more specific points (AGIS) or pattern deviation change at three or more points 
(EMGT) (Heijl et al 2008). Despite these differences in study design and 
definitions, the discrepancies between the above studies could also reflect 
differences among populations in terms of genetic predisposition and exposure 
to environmental factors. 
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1.5.1 Baseline IOP 
In the CIGTS, the level of baseline IOP, which was required by inclusion criteria 
to be at least 20 mmHg, was not significantly associated with subsequent VF 
loss. However, the range (maximum IOP – minimum IOP) of the six IOP 
measurements taken at baseline, which varied from 0.5 to 25 mmHg with a 
median of 6.5 mmHg, did relate to subsequent VF progression (Musch et al 
2009). In more detail, as the range of the six baseline IOPs increased, VF loss 
increased (P=0.0184), while participants whose range was 8.5 mmHg or greater 
had a 96% greater risk of substantial VF loss (P=0.0006) when compared to 
those with a lesser IOP range at baseline. During follow-up, in the CIGTS, three 
IOP measures (increased maximum IOP, SD of IOP and range of IOP) were also 
significantly associated with VF progression, with higher baseline IOP being one 
of the main predictors of these three IOP measures (Musch et al 2011). In 
support of the trial findings, in a recent retrospective study involving 140 
Tunisian patients with POAG, IOP at diagnosis was statistically higher in 
subjects with VF progression, as compared to stable cases (P=0.03; OR=5.25) 
(Loukil et al 2012).  
 
1.5.2 Mean IOP 
Higher mean IOP has been shown to be predictive of progressive VF loss in 
patients with newly diagnosed glaucoma in the EMGT (HRs, 1.12–1.13 per 
mmHg higher) (Leske et al 2003, Leske et al 2007), with normotensive 
glaucoma in the CNTGS (CNTGS 1998) and with advanced glaucoma in the AGIS 
(AGIS 2000). Similarly, in a smaller prospective, randomised clinical trial 
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comparing primary laser trabeculoplasty with medication, VF decay showed 
greater correlation to mean IOP and IOP variation (range and peak) than to 
baseline IOP or degree of IOP reduction (Bergea et al 1999). The relation 
between mean IOP and VF loss in the whole group was not quite linear, with 
more decay at higher IOP levels. Moreover, two retrospective studies by 
Stewart et al reported that mean IOP, as well as the range and the average SD 
of IOP measurements over the follow-up period, significantly differed in 
progressing POAG subjects, as compared to those who were stable (Stewart et 
al 1993, Stewart et al 2000).  
 
1.5.3 Effect of treatment on IOP 
To date, the only two large, randomised, multi-center clinical trials that 
compared the reduction of IOP in OAG patients to an observation group were 
the EMGT and CNTGS, while the AGIS, the Low-Pressure Glaucoma Treatment 
Study (LoGTS) and the CIGTS compared between different treatments. In the 
EMGT, where patients were randomised to either laser trabeculoplasty plus 
topical betaxolol (n = 129) or no initial treatment (n = 126), the potential effect 
of cataracts was minimised by the emphasis on VF pattern loss. On average, 
treatment reduced the IOP by 5.1mmHg and progression was less frequent in 
the treatment group (58/129; 45%) as compared to the controls (78/126; 62%) 
(p=0.007) and occurred significantly later in treated patients (Heijl et al 2002). 
In the CNTGS, where 145 patients with progressing NTG were randomised to 
either no treatment or treatment aiming for IOP reduction of 30% within 6 
months and maintenance for 4 years by surgical and/or medical means, the 
protective effect of IOP-lowering treatment was noted only when subjects with 
cataract progression were censored or removed from the analysis (CNTGS AJO 
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1998).  In the Low-Pressure Glaucoma Treatment Study (LoGTS), no significant 
association was found between IOP and VF progression and the authors 
argued that, once the IOP is reduced to relatively low values (mean follow-up 
IOP was 14mmHg), the importance of other risk factors may become either 
more apparent or important for determining progression (De Moraes et al 
2012). 
 
1.5.4 Long- and short-term IOP fluctuation 
In the AGIS, large variations in the IOP from visit to visit were associated with 
OAG progression (Nouri-Mahdavi et al 2004), whereas in the EMGT 
fluctuations in IOP were not associated with increased risk of progression 
(Bengtsson et al 2007). Factors to account for this discrepancy would include 
the differences in the stage of the disease and in the population ethnicity 
between the two studies, as well as the fact that the EMGT analyses did not 
include post-progression IOP values, which would be biased towards larger 
fluctuations because of more intensive treatment. Although in AGIS the 
authors did not initially censor or exclude IOP measurements after the second 
or third surgical intervention, in 2008 it was reported that long-term IOP 
fluctuation was associated with VF progression in patients with low mean IOP, 
but not in patients with high mean IOP (Caprioli et al 2008). Long-term IOP 
fluctuation was also shown to act as a risk factor for progressive VF 
deterioration even in glaucoma patients with low IOPs (<18mmHg) after a 
triple procedure (phacoemulsification, posterior chamber intraocular lens 
implantation, and trabeculectomy) (Hong et al 2007b). Similarly, in 2007 a 
study by Lee et al revealed IOP SD as a predictor for glaucoma progression in 
two cohorts of glaucoma patients. After controlling for age, mean IOP, VF stage 
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and other covariates, the authors found that each unit increase in IOP SD 
resulted in 4.2 to 5.5 times higher risk of glaucoma progression (Lee et al 
2007). Moreover, O’Brien et al. found that three measures of IOP variation 
showed significant correlation with the rate of VF deterioration in 10 patients 
whose VF loss worsened during treatment: the standard error of the mean 
(SEM), the SD, and the range of IOP (O’Brien et al 1991). More recently, in the 
multicenter Latanoprost/Bimatoprost/Travoprost Study, Varma et al showed 
that the inter-visit IOP range was associated with risk factors for glaucomatous 
change, such as African-American race and high baseline IOP (Varma et al 
2008). Finally, in the CIGTS increased IOP fluctuation (SD or range) and 
maximum IOP were important predictors of progressive VF loss (Musch et al 
2011). In clinical practice, this would be easiest to measure by observing the 
inter-visit range of IOP over time, as advocated by Varma et al (Varma et al 
2009) and commented on by Katz and Myers (Katz et al 2009). 
An additional risk factor for glaucoma progression identified from 
retrospective studies was higher short-term (diurnal) IOP fluctuation (Asrani et 
al 2000, Bergea et al 1999). In the study by Bergea et al, which included 82 
OAG patients, VF decay showed a greater correlation with IOP variation (range 
and peak) and mean IOP, than with baseline IOP or degree of IOP reduction 
(Bergea et al 1999). Similarly, the study by Asrani et al, with only 64 glaucoma 
patients, showed that baseline IOP had no predictive value, while the diurnal 
IOP range and the IOP range over multiple days were significant risk factors for 
progression, even after adjusting for baseline IOP, age, race, gender and 
baseline VF damage (Asrani et al 2000). 
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1.5.5 Greater age 
Older age was reported to be associated with an increased risk of VF 
progression in the AGIS (Nouri-Mahdavi et al 2004) and the EMGT (Leske et al 
2003, Leske et al 2007), but not in the CNTGS (Drance et al 2001). In the AGIS, 
each 5 year increment in age increased by 30% the risk of a 1.0dB or greater 
worsening of the VF. In the EMGT, subjects who were 68 years or older were at 
a 51% increased risk of progression, as compared to participants <68 years old. 
In the CIGTS, older age at baseline was associated with VF progression (Musch 
et al 2009), with the age effect being modified by time (P<0.0001), such that 
the effect of age on VF loss increased over time. For every 10 year increase in 
age, the risk of a 3 dB worsening of MD increased 35% (P=0.0006). Although VF 
progression was measured in different ways in these clinical trials, the AGIS, 
EMGT and CIGTS all show more VF progression with increasing age. 
 
1.5.6 More severe visual field MD at baseline 
In the EMGT, eyes presenting with a baseline MD worse than −4.0dB 
progressed faster (P=0.05) than eyes with better MD (Leske et al 2007), while 
more advanced visual field score appeared to be protective in AGIS. This could 
have resulted from a ceiling effect, where there is little room for subjects to 
lose VF or to get worse because they are closer to the top of the scale. Similarly 
to the EMGT, in a very recent retrospective study by Loukil et al, eyes with 
initial VF defect more than 8.2dB were found 4.8 times more likely to progress 
(P=0.07), while eyes diagnosed at an early glaucoma stage had 4 times the 
chance of maintaining a stable VF (P=0.003) (Loukil et al 2012). However, 
another retrospective study by Forchheimer et al found no relationship 
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between the rate of VF change (dB/year) and the severity of the baseline VF 
MD, with the authors suggesting that more aggressive IOP lowering in eyes 
with more advanced glaucoma could have masked this relationship 
(Forchheimer et al 2011). 
 
1.5.7 Lower ocular perfusion pressure 
The EMGT showed that lower systolic perfusion pressure (SPP) (≤160 mmHg; 
HR 1.42; 95% CI 1.04–1.94) was a risk factor for progression. Similar, although 
non-significant, trends were also observed for the diastolic perfusion pressure 
(DPP) and mean ocular perfusion pressure (MOPP) (Leske 2009). One could 
argue that the association of SPP to progression was due to the effect of high 
IOP alone, regardless of systolic blood pressure (SBP), but the EMGT found that 
low SBP (≤125 mmHg; HR 0.46; 95% CI 0.21–1.02) was independently 
associated with progression, even in patients with low IOP. Low SBP is known 
to cause an increase in vascular resistance, which diminishes blood flow to the 
ONH (Hayreh et al 2001), and compensatory vasoconstriction of peripheral 
organs and tissues (Lindholm et al 2005), including the eye and the retinal and 
choroidal circulation. Another progression factor in the EMGT was history of 
cardiovascular disease, significant in patients with IOP over the median value 
(HR 2.75; 95% CI 1.44–5.26). Taken together, these results were consistent 
with the hypothesised effect of vascular factors on glaucoma progression 
(Flammer et al 2002). Similarly, in the LoGTS, lower MOPP during follow-up 
was significantly associated with VF progression and this effect was not 
significantly affected by other covariates, such as use of systemic 
antihypertensives and randomisation arm (De Moraes et al 2012). The authors 
suggested that an imbalance between IOP mechanical stress and blood supply 
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could lead to hypoxia, which might be responsible, at least partially, for axonal 
damage and RGC death (Ramdas et al 2011a). Lower DPP has also been linked 
to glaucoma (Leske et al 2001). It is interesting to note that, even in people 
without glaucoma, lower DBP (<90mmHg) secondary to antihypertensive 
treatment has been found to be associated with increased disc cupping and 
decreased rim area (Topouzis et al 2006). In the CNTGS and AGIS, no 
association between systemic hypertension and OAG progression was noted. 
 
1.5.8 Presence of pseudoexfoliation (PXF) 
PXF was a risk factor in the EMGT and was not evaluated in other large 
prospective randomised trials. In the EMGT, PXF had a prominent role in the 
higher baseline IOP group, with 18 of the 19 PXF patients progressing. Also, 
although only 4 patients with lower baseline IOP had PXF, all progressed, again 
confirming the importance of this condition on progression (Leske et al 2007). 
Similarly, in a recent retrospective study involving 140 Tunisian POAG patients, 
PXF was also identified as a risk factor for progression (OR=2.84; P=0.05) 
(Loukil et al 2012). 
 
1.5.9 Optic disc haemorrhages 
The association between splinter-shaped haemorrhages on the optic disc rim 
and glaucoma is well known (Drance et al 1989, Bengtsson et al 1981). 
Although the aetiology of disc haemorrhages is unclear, many investigators 
suspect a pathogenic link to rim notching (Airaksinen et al 1981) or a localised 
RNFL defect (Sugiyama et al 1997). In the EMGT, presence of disc 
haemorrhages at follow-up was a significant factor for progression (Leske et al 
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2003, Leske et al 2007) and was significantly associated with time to 
progression (HR=1.02; CI 1.01–1.04). In a smaller retrospective study from 
Japan on 70 NTG patients, the cumulative probability of VF progression was 
significantly greater for patients with disc haemorrhages as compared to those 
without (Ishida et al 2000). In more detail, all eyes with at least two 
occurrences of disc haemorrhage showed progression using the glaucoma 
change probability analysis, whereas only three of nine eyes showed 
progression in the non-recurrent disc haemorrhage group (P<0.0001). 
Furthermore, a significant relationship was found between the location of the 
disc haemorrhage and the area of the progression of the VF loss in 65.4% of 
progressive patients with disc haemorrhage (Ishida et al 2000). Moreover, the 
study by Rasker et al suggested that a history of disc haemorrhage increases 
the risk of progression more than 5-fold in treated patients with NTG (Rasker 
et al 1997), while similar results were also reported by Siegner and Netland in 
cases of NTG and POAG (Siegner et al 1996). Nevertheless, there are conflicting 
reports regarding the prognostic significance of disc haemorrhage, with some 
researchers believing that these are completely unrelated to VF progression 
(Hoyng et al 1992, Heijl et al 1986, Rasker et al 2000). 
 
1.5.10 Thinner central corneal thickness (CCT) 
Investigation of the effect of CCT on glaucoma progression is complicated by 
the relationship between CCT and both IOP measurement and ageing (Foster 
et al 1998). To date, it remains unclear whether CCT is indeed an independent 
risk factor for glaucoma progression, a phenotypic marker of diverse ethnic 
groups with differing inherent glaucoma risk, or just a source of error in clinical 
tonometry (Brandt et al 2007). In the EMGT, thinner CCT (HR 1.25; 95% CI 
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1.01–1.55 per 40µm lower) was a significant risk factor for progression, 
especially in patients with higher baseline IOP (HR 1.42; 95% CI 1.05–1.92 per 
40µm lower), but not lower baseline IOP (Leske et al 2007). Moreover, in 2004, 
a case-control patient population study by Kim et al demonstrated that VF 
progression in 88 patients with OAG was significantly associated with thinner 
CCT (Kim et al 2004). Similarly, in another retrospective study involving 163 
eyes with chronic PACG, patients with a thinner cornea were at greater risk for 
VF progression even if they maintained a low IOP (<18mmHg) after treatment 
(Hong et al 2007a). In a large prospective observational study by Jonas et al, 
CCT correlated significantly (P<0.001) and positively with the neuroretinal rim 
area and negatively with the amount of VF loss at the time of referral, while VF 
progression was statistically independent of CCT (Jonas et al 2005). Similarly, 
other smaller studies have also failed to find an association between CCT and 
glaucoma progression (Shah et al 2007, Chauhan et al 2005). 
 
1.5.11 Diabetes 
Diabetes as a risk factor for progressive VF loss was assessed in the AGIS 
(Nouri-Mahdavi 2004, AGIS AJO 2002) and found to not differ between those 
who progressed (21.2% were diabetic) and those who did not progress (21.5% 
were diabetic). Self-report of diabetes was associated with OAG progression in 
the CIGTS (Lichter et al 2001), but not in the CNTGS (Drance et al 2001) and 
EMGT (Leske et al 2007). In the latter study, diabetes was not listed among the 
factors evaluated for VF progression, which likely relates to the fact that only 
nine (3.5%) of the 255 enrolled participants reported a history of diabetes. In 
the CIGTS, while black subjects were over-represented among diabetics (60%, 
61/102, of diabetics were black), diabetes was more predictive of VF loss than 
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race in models with each variable included separately or combined (Musch et 
al 2009). The authors suggested as a possible explanation the fact that 
diabetics are more prone to scarring after trabeculectomy, as proposed 
previously by Hugkulstone et al (Hugkulstone et al 1993). 
 
1.5.12 Race 
In the CIGTS, while a subject’s race was not significantly associated with the 
risk or timing of cataract extraction, the impact of race as a risk factor for VF 
progression was only evident in those subjects who required cataract surgery 
during the course of follow-up. More specifically, blacks who underwent 
cataract extraction showed more VF loss than whites undergoing the same 
procedure (Musch et al 2009). According to the authors, this could relate 
either to differing thresholds for surgery or differing responses to that 
procedure. Other likely contributing factors to the greater progression of OAG 
in African-derived persons is their longer average duration of disease (2.3 years 
longer) as compared to European-derived persons, as well as differences in 
access to care and acceptance of and response to treatment (Broman et al 
2008). Similarly, in a retrospective study by Wilson et al, both VF loss at initial 
diagnosis and VF progression appeared to be worse in black patients with OAG, 
as compared to white (Wilson et al 1985). However, several other glaucoma 
studies were unable to show that race was a risk factor for disease progression 
(Katz et al 1997, Stewart et al 2000, Schulz et al 1987), while the role of 
ethnicity was not evaluated in the EMGT. 
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1.5.13 Gender 
In the AGIS, it is puzzling that male gender was a significant risk factor for VF 
progression only in the ATT (argon laser trabeculoplasty – trabeculectomy – 
trabeculectomy) sequence (AGIS 2002). Many other glaucoma studies (Ishida 
et al 1998, Martinez-Bello et al 2000, Suzuki et al 1999, Araie et al 1994, Katz et 
al 1997, Stewart et al 2000) and the TAT (trabeculectomy – argon laser 
trebeculoplasty - trabeculectomy) sequence of AGIS indicated that gender is 
not a significant risk factor for disease progression.  In contrast, two studies 
found female gender, rather than male gender, to be a risk factor for VF loss 
(Wilson et al 1982, Drance et al 2001); in one of these studies, gender was 
significant in univariate Kaplan–Meier analysis, but not in multivariate Cox 
proportional hazards analysis (Drance et al 2001). 
 
1.5.14 Myopia 
The large, abnormally shaped and tilted myopic scleral canal and the thinning 
of the myopic lamina cribrosa and peripapillary sclera are some of the 
anatomical factors thought to predispose myopic eyes to glaucomatous 
damage (Jonas et al 2004, Bellezza et al 2000). However, clinical results to date 
are not conclusive, with Jonas et al finding no significant association between 
mean visual field loss and refractive error, and suggesting that, for eyes less 
myopic than −8 D, refractive error may not contribute much to the optic nerve 
head susceptibility to IOP (Jonas et al 2002). Similarly, several Japanese studies 
have been unable to show a link between VF progression and refractive error 
(Ishida et al 1998, Suzuki et al 1999, Araie et al 1994). However, a Taiwanese 
retrospective study on 515 POAG patients demonstrated a significant 
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association between myopia greater than −6 D and VF progression (Lee et al 
2008). Similarly, Chihara et al found that moderate-to-severe myopia (>−4 D), 
but not mild myopia, was a significant risk factor for VF progression in 
glaucoma (Chihara et al 1997). 
 
1.5.15 Other 
Other risk factors for progression, identified from retrospective studies, 
include optic disc features, such as a smaller neuroretinal rim area (Jonas et al 
2004), peripapillary atrophy (Uchida et al 1998, Teng et al 2011) and the 
presence of acquired optic disc pits (Ugurlu et al 1998). It is perhaps relevant 
to note that the results of retrospective studies should be taken cautiously, 
due to limitations in study design, inadequate sample sizes, large rates of loss 
to follow-up, and other considerations. They may provide interesting and often 
clinically useful hypotheses, but need to be confirmed by larger randomised 
longitudinal studies. 
More recently, in the LoGTS a significant association was found between the 
use of topical timolol maleate 0.5% and the risk of progression in patients with 
low-pressure glaucoma compared to the use of brimonidine tartrate 0.2% 
(Krupin et al 2011), which was independent from other known risk factors for 
glaucoma progression (disc haemorrhage, older age, and lower systemic blood 
pressure) despite similar mean IOP during follow-up. This finding could suggest 
that brimonidine has an effect on IOP-independent mechanisms that decrease 
or delay the rate of VF progression in glaucoma patients with IOPs in the 
statistically normal range and that this possibly neuroprotective effect is 
independent of ocular perfusion pressure (De Moraes et al 2012). 
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Alternatively, it is possible that topical beta-blockers have no benefit or are 
detrimental. It is also particularly interesting that the brimonidine group had 
higher untreated mean and peak IOP at baseline, as well as higher peak and 
fluctuation during follow-up, and still progressed at slower rates than the 
timolol group. Use of systemic antihypertensives was also independently 
associated with disease progression in the LoGTS (De Moraes et al 2012). 
Similarly to LoGTS, in a recent retrospective study in the Tunisian population 
the use of topical beta-blockers was highlighted as a risk factor for progression 
(Loukil et al 2012). 
In the EMGT, an additional risk factor for progression was bilateral disease at 
baseline (Leske et al 2007). Also, low formal educational achievement was 
identified as a risk factor for progression in both intervention sequences in the 
AGIS, with the authors suggesting that this could be explained at least in part 
by the association between low educational achievement and cataract. This 
association has been shown in other studies (Hiller et al 1986, Kahn et al 1977, 
Leske et al 1991), although not found in the AGIS (AGIS 2001). 
 
1.6 Potential additional susceptibility factors for glaucoma development and 
progression 
 
1.6.1 Mitochondrial dysfunction and mtDNA changes 
Emerging evidence suggests that mitochondrial dysfunction may contribute to 
the pathogenesis of a range of neurodegenerative diseases (Lin et al 2006), 
including Parkinson’s disease, Alzheimer’s disease and glaucomatous optic 
neuropathy (Kong et al 2009, Lascaratos et al 2012). A maternal family history 
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of POAG is more likely than a paternal family history, suggesting a possible 
mitochondrial genetic influence (Charliat et al 1994, Mitchell et al 2002, 
Nemesure et al 1996, Shin et al 1977). This is unexpected, as there is no sex 
predilection to POAG prevalence and there is no maternal influence on IOP, 
and so Mendelian inheritance cannot explain these epidemiological 
differences. However, a study from the North East of England has failed to 
show an association between mitochondrial haplogroups and POAG in 
Caucasian patients (Andrews et al 2006). Similarly, a recent study from the 
same group involving 137 POAG patients has not found an association 
between the mtDNA haplogroups H, T, J and U and either NTG or high tension 
glaucoma (HTG), although there was a tendency for haplogroup J to be over-
represented amongst the NTG group compared with controls (Yu-Wai-Man et 
al 2010). This is an interesting observation considering the link between 
haplogroup J and increased risk of visual loss in Caucasian LHON mutation 
carriers (Hudson et al 2007) and also the role of mtDNA background in 
modulating the assembly kinetics of oxphos complexes (Pello et al 2008). 
Recently, the mtDNA haplogroups have been implicated in the pathogenesis of 
other types of glaucoma, with haplogroups T and L2 conferring susceptibility to 
pseudoexfoliation glaucoma in the Saudi Arabian population (Abu-Amero et al 
2011) and haplogroup U being associated with a reduced risk for 
pseudoexfoliation glaucoma in the German population (Wolf et al 2010).  
Other research teams have also screened glaucoma cohorts for mitochondrial 
mutations implicated in LHON. In one study involving 551 Japanese POAG 
patients and 284 controls, 5 LHON-associated mitochondrial DNA mutations 
were identified in the glaucoma group, whereas no such mutations were found 
in the control group. However, the difference was not statistically significant 
and the study was not conclusive as to whether these mtDNA mutations were 
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a risk factor for POAG (Inagaki et al 2006). Equally, in a Swiss population, no 
mtDNA mutations at nucleotides 11778, 3460 and 14484, typically associated 
with LHON, were identified amongst 54 unselected patients with NTG (Opial et 
al 2001). 
Age-associated somatic mutations in mitochondria have also been shown to 
potentially contribute to glaucoma pathogenesis. Indeed, in a study by Abu- 
Amero et al, a decrease was noted in the mitochondrial mean respiratory 
activity in 24 of the 27 POAG patients, suggesting a role for mitochondrial 
dysfunction in the pathogenesis of POAG (Abu-Amero et al 2006). Interestingly, 
the same group was unable to show significant mtDNA derangements in 
primary angle closure glaucoma (Abu-Amero et al 2007), consistent with the 
idea that anatomic factors may be more important determinants for primary 
angle closure than mitochondrial genetics. Moreover, in primary congenital 
glaucoma patients from the Indian subcontinent, 8 (22.9%) of 35 patients had 
potentially pathogenic mtDNA sequence variants (Tanwar et al 2010). It is 
important to note that these studies have been performed on mtDNA isolated 
from peripheral blood leucocytes, while tissue specific mutations in the 
trabecular meshwork, RGC compartment and optic nerve head may contribute 
more significantly to glaucoma pathogenesis. Indeed, mtDNA deletion has 
been shown to be increased more than 5-fold in the trabecular meshwork of 
POAG patients comparing to controls, accompanied by a significant decrease in 
the number of mitochondria per cell and by cell loss (Izzotti et al 2010).  
Very recently, Lee et al have shown that lymphoblasts from POAG patients 
exhibit a defect in the complex-I of the oxphos pathway, leading to decreased 
rates of respiration and ATP production (Lee et al 2012). Complex-II-driven ATP 
synthesis was not reduced in the POAG lymphoblasts, as compared to control. 
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When cells were grown in galactose media, where they were forced to rely on 
mitochondrial ATP production, no significant differences were noted between 
the control and POAG cohorts. Thus, the authors concluded that while 
complex-I defects did not impact lymphoblast growth when the cells were 
forced to rely on oxidative ATP supply, it remains possible that in the presence 
of a multitude of cellular stressors as seen in the early stages of POAG, these 
defects may lead to a bioenergetic crisis in retinal ganglion cells and an 
increased susceptibility to cell death (Lee et al 2012). 
 
1.6.2 Oxidative stress  
It is more than two decades since oxidative stress was first proposed to 
contribute to glaucoma pathogenesis (Alvarado et al 1981). In 2006, in the 
study by Abu-Amero et al, 127 different novel non-synonymous mtDNA 
changes were found in the lymphocytes of patients with POAG with none 
found in control subjects, while 22 of the identified mutations were potentially 
pathogenic (Abu-Amero et al 2006). Importantly, these POAG patients had a 
high frequency of mtDNA transversion mutations (73.5%). This is in contrast to 
LHON patients, where mtDNA transition changes comprise almost 70% of the 
mutations reported in MitoMap (Brandon et al 2005), and to NAION patients, 
where 75% of nonsynonymous mtDNA changes found are transitions (Bosley et 
al 2004). Abu-Amero et al argued that the guanine base has the lowest 
oxidation potential of the four DNA nucleobases, making G:C to T:A or G:C to 
C:G transversion mutations frequent in the setting of oxidative stress 
(Sekiguchi et al 2002). The presence of mtDNA transversions in POAG may be 
evidence of increased oxidative stress in these patients and would suggest that 
alternative mitochondrial damage and repair mechanisms are involved, which 
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may contribute to the unique optic nerve damage noted in POAG. Moreover, 
increased serum total antioxidant levels and decreased urinary 8-hydroxy-2-
deoxyguanosine, a marker of oxidative DNA damage, have been reported in 
NTG patients as compared to healthy controls, attributed by the authors to 
compensatory alterations in response to increased systemic oxidative stress in 
glaucoma (Yuki et al 2010). 
Oxidative stress in the human trabecular meshwork (TM) has also been 
implicated in the pathogenesis of OAG. More specifically, oxidative stress has 
been reported to induce human TM degenerative changes that favour 
increased IOP, with increased DNA oxidative damage noted in the TM of 
patients with POAG, as compared to controls. Interestingly, a statistically 
significant correlation was found among human trabecular meshwork DNA 
oxidative damage, VF damage and IOP (Sacca et al 2005). Hydrogen peroxide 
has also been shown to induce rearrangement of human TM cells and 
compromise their integrity (Sacca et al 2007). The human TM was found to be 
more sensitive to oxidative damage induced by hydrogen peroxide than the 
cornea or the iris, with the authors arguing that the cornea and lens are 
directly exposed to light and therefore possess antioxidant defence 
mechanisms that may not be activated in the TM (Izzotti et al 2009). The same 
group also demonstrated a link between oxidative stress and mitochondrial 
dysfunction in the TM of POAG patients by finding that the glutathione-S-
transferase (GST) M1-null genotype was associated with increased amounts of 
mtDNA deletion in the TM of these patients and a decreased number of 
mitochondria per cell, as compared with GSTM1-positive subjects (Izzotti et al 
2010). 
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More recently, the aqueous humour of ten POAG patients has been shown to 
have increased levels of glutamine synthase (GS) and nitric oxide synthase 
(NOS), as compared to an equal number of controls (senile cataract patients) 
(Bagnis et al 2012). The GS overproduction might be linked to neuronal injury 
or to the potential role of glutamate as a modulator in the ciliary body 
signalling, while the NO increase through inducible NOS could form toxic 
products changing the metabolic conditions of the TM. In the same study, a 
significant reduction was noted in the levels of antioxidant enzymes 
superoxide dismutase (SOD) and GST in the aqueous humour of POAG patients, 
as compared to controls, which, as argued by the authors, could aggravate the 
imbalance between both oxygen- and nitrogen-derived ROS production and 
detoxification (Bagnis et al 2012). The reduction in SOD could not be replicated 
in two other studies, showing a significant increase in SOD (Ghanem et al 2010, 
Ferreira et al 2004), as well as the antioxidant enzymes glutathione peroxidase 
(GPO) (Ghanem et al 2010, Ferreira et al 2004) and malondialdehyde (MDA) 
(Ghanem et al 2010), in the aqueous humour of POAG patients, as compared 
to cataract patients. No difference was noted in the activity of the catalase 
(CAT) enzyme in the aqueous humour between the two groups, in either study 
(Ghanem et al 2010, Ferreira et al 2004). The total reactive antioxidant 
potential (TRAP) was significantly lower in the aqueous humour of POAG 
patients, as compared to the cataract cohort (Ferreira et al 2004). Lower total 
antioxidant status (TAS) levels in the serum and aqueous humour of glaucoma 
patients, as compared to age-similar cataract patients, was also found in an 
Iranian cohort (Sorkhabi et al 2011). These studies only included a relatively 
small number of patients and it was not clear whether these changes were 
only a result of the glaucomatous process or contributed to the pathogenesis 
of the disease. 
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1.6.3 Corneal biomechanics 
Apart from the role of thinner CCT in glaucoma progression (1.5.10), a lower 
corneal hysteresis (CH) was also found to predict VF deterioration in a 
retrospective study, suggesting that corneal resistance itself may influence 
progression and that the CCT might be an indicator of anatomical structure 
reflecting distensibility and elasticity of ocular tissues (Congdon et al 2006). In 
more detail, each mmHg increase in CH was associated with a 20% decrease in 
progression, whereas CCT showed no association with progression. However, 
this association became non significant after adjusting for the axial length, 
which could favour a potential association between CH and the elasticity of 
other ocular tissues (Congdon et al 2006). Similarly, in a very recent 
retrospective study by De Moraes et al, a significant correlation was found 
between CH and CCT, and CH [OR (95%CI): 1.55 (1.14-2.10) per mmHg lower] 
was more strongly associated with VF progression than CCT (De Moraes et al 
2012). Notably, despite losing their strength when compared with a stronger 
variable (CH) in the multivariate analysis, both corneal resistance factor (CRF) 
and the difference between IOPcc and IOPg were associated with progression 
in the univariate analyses. 
The use of CH as a measure of corneal biomechanical properties has been 
investigated in various studies (Wells et al 2008, Ang et al 2008, Broman et al 
2007) and CH is known to decline with ageing (Kotecha et al 2006). However, 
the relationship between CH and VF progression remains obscure. In the OHTS, 
a thinner CCT may result in underestimation of the transcorneal pressure 
gradient measured by GAT and, since CCT correlates with CH, the same 
argument could also apply to the latter measurement. It is also possible that 
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the corneal biomechanical properties are a surrogate parameter of the 
susceptibility of the optic nerve to IOP-dependent and IOP-independent 
factors associated with glaucomatous loss. For example, it has been suggested 
that CH (but not CCT) is associated with increased deformation of the optic 
nerve surface during transient elevations of IOP (Wells et al 2008), while 
Bochmann et al have shown in a prospective study that acquired pit-like 
changes of the optic nerve are more frequent in eyes with lower CH 
(Bochmann et al 2008). Moreover, Leite et al in 2010 reported that healthy 
individuals of African ancestry, a group known to be at increased risk of 
glaucoma onset, showed lower CH than healthy individuals of European 
ancestry (Leite et al 2010). In addition, it has been shown that among eyes with 
asymmetric glaucomatous VF loss, CH was lower in eyes with worse VF damage 
independently of its effect on IOP measurements (Anand et al 2010). It is still 
unclear, however, whether the relationship between CH and VF loss is cause-
effect or mere association. Perhaps corneal thinning and decrease of CH could 
be a consequence of the glaucomatous process, similarly to optic disc cupping 
and nerve fibre layer loss. Ideally, prospective studies that assess the CH at 
baseline should address whether lower CH is indeed a risk factor for 
progression, as was shown with CCT in the OHTS (Gordon et al 2002). 
 
1.6.4 Genetic factors  
As discussed previously, family history is a risk factor for the development of 
glaucoma, and there is a higher prevalence in both first and second degree 
relatives of patients (Coleman et al 2008, Wang et al 2010). In 1996 and 1997, 
the first major gene loci for POAG, GLC1A and GLC1B, were described (Stoilova 
et al 1996, Stone et al 1997). The GLC1A gene encodes myocilin, the trabecular 
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meshwork-induced glucocorticoid response protein. GLC1A is mapped to 
chromosome 1 and although the exact role of myocilin in the pathogenesis of 
glaucoma is not clear (Stone et al 1997), it is thought to interact with the 
trabecular extracellular matrix affecting aqueous outflow (Fautsch et al 2000, 
Tamm 2002). The GLC1B gene, located on chromosome 2, is associated with 
normal to moderately raised IOP and optic nerve damage (Stoilova et al 1996). 
Several other genes that increase the risk of POAG have since been identified: 
The GLC1C gene, located on chromosome 3, is associated with increased IOPs 
and cup-to-disc ratios ≥0.7 or an abnormal result on a VF test (Wirtz et al 
1997). The GLC1D gene on chromosome 8 and the GLC1E gene on 
chromosome 10 are associated with mild to moderately raised IOP in 
individuals with optic nerve damage (Trifan et al 1998, Sarfarazi et al 1998). In 
1999, Wirtz et al mapped the GLC1F gene to chromosome 7 and found it to be 
associated with raised IOP or VF loss and a cup-to-disc ratio of 0.6 (Wirtz et al 
1999). 
More recently, many genetic studies in large extended pedigree families have 
demonstrated that POAG is genetically heterogeneous, with genetics linkage 
reported to at least 22 genetic loci (Fan et al 2006, Hewitt et al 2006). To date, 
the only three genes identified for POAG from these reported genetic loci are 
myocilin (MYOC, OMIM 601652), optineurin (OPTN, OMIM 602432) and WD 
repeat-domain 36 (WDR36, OMIM 609669) (Fingert et al 2002, Rezaie et al 
2002, Monemi et al 2005). The majority of these genes represent rare 
monogenic forms of glaucoma and are estimated to account for less than 10% 
of all glaucoma cases (Hewitt et al 2006).  The common forms of adult-onset 
glaucoma appear to have a complex trait inheritance and several POAG 
genome-wide association studies (GWAS) have flagged variants in CAV 1 and 2 
(Thorleifsson et al 2010, Wiggs et al 2011), TMCO1 and CDKN2B-AS1 (Burdon 
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et al 2011, Nakano et al 2012) and ZP4, PLXDC2 and DKFZp762A217 in a 
Japanese population (Nakano et al 2009), though the latter three genes were 
found not to be associated with POAG in an Indian population (Rao et al 2009).   
A single NTG paper reported common variants in SRBD1 and ELOVL5 (Meguro 
et al 2010). Because POAG is a heterogeneous disease, with some individuals 
exhibiting features, such as raised IOP, and others without these features, it 
would not be surprising if more gene loci were identified in POAG families. The 
role of genetics is also important in other types of glaucoma, such as 
pigmentary glaucoma, as described from our group in more detail elsewhere 
(Lascaratos et al 2013). 
 
1.6.5 Light 
It has long been known that exposure of biological systems to high energy 
ultaviolet (UV) light can result in the photochemical release of toxic as well as 
mutagenic end products (Smith et al 2005). Recently, however, studies have 
shown that components of the visible spectrum can be absorbed by biologic 
chromophores (Hockberger et al 1999) in cells, such as astrocytes (Jou et al 
2004) and epithelial cells (Godley et al 2005), to cause cellular dysfunction and 
even death. It is believed that the blue region of the spectrum (approximately 
400–500 nm) is particularly likely to induce these reactions, since it has 
relatively high energy and can penetrate through tissues to cells and their 
organelles. It can be theorised, therefore, that mitochondria, which are laden 
with prominent chromophores (COX, flavins and flavoproteins) may be 
affected in a detrimental way by components of visible light (Egorov et al 1999, 
Boulton et al 2001). This is supported by observations that isolated light-
exposed mitochondria release several ROS, including singlet oxygen, 
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superoxide and hydroxyl radicals (Jung et al 1990, Godley et al 2005). It is likely 
that light will have a greater detrimental effect to RGC axons than to more 
external cellular elements, in part because the RGC axons form the most 
internal layer and are rich in mitochondria and in part because absorption by 
this layer will attenuate the delivery of energy to outer layers. Mitochondrial 
dysfunction, as a result of light exposure, would be particularly problematic in 
long nerve fibres, such as those of the peripheral nervous system, or in axons 
of very narrow calibre, those with minimal or no myelin, and those with a rapid 
rate of firing. These last three features are all found in intra-retinal RGCs, 
whose high and constant firing rate increases energy demands, whose high 
surface area to volume ratio favours energy consumption over energy 
production and whose lack of myelination deprives them of the efficiency of 
saltatory conduction (Bristow et al 2002). Therefore, the retinal components 
that will be most susceptible to any possible light-induced damage are the 
intraocular ganglion cell axons and in particular, their mitochondria. 
The human retina is protected from shorter wavelength radiation by the 
cornea and lens, which absorb UV light below 400 nm (Boulton et al 2001). It is 
likely that under normal circumstances there is insufficient energy in this light 
that impinges on the retina to directly cause death of otherwise healthy 
neurons. It is more likely that light radiation may merely serve as an additional 
strain for cells already compromised in some way. In glaucoma, for example, it 
is believed that minor insults residing in the ONH serve to lower the functional 
status of affected RGC axons (Whitmore et al 2005, Quigley 1999). This 
compromised energetic state is thought to impact on selected RGCs during the 
evolution of glaucoma and the RGCs of the papillomacular bundle in patients 
with inherited mitochondrial optic neuropathies. The vasogenic hypothesis of 
glaucoma implies that RGC axons are metabolically compromised by the 
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impaired ONH blood flow, and the distribution of affected axons may be 
determined by these initiating vascular factors. It has been suggested that 
once a bioenergetic defect is established, these axons are at risk of additional 
damage through the photochemical mechanism described above. In this case, 
light damage is invoked as a mechanism which accelerates the progression of 
the established disease (Osborne et al 2006). Laboratory studies on RGC-5 cells 
in culture (Wood et al 2008) and primary rat retinal cultures (Lascaratos et al 
2007) provide support for this notion. 
 
1.7 Aims of the thesis 
The purpose of this thesis was to a) evaluate the efficacy of IOP-lowering 
treatment in delaying glaucoma progression within the United Kingdom 
Glaucoma Treatment Study (UKGTS) and investigate whether average IOP (as 
measured by GAT, DCT and ORA) during follow-up is associated with the rate 
of glaucoma progression (Chapter 3), and b) explore the role of mitochondrial 
dysfunction and oxidative stress as risk factors for glaucoma progression within 
an exploratory study (Chapter 4). 
With regards to point a) above, elevated IOP is a major risk factor for the 
deterioration of OAG and medical IOP reduction is the standard treatment, yet 
no randomised placebo-controlled study of medical IOP reduction has been 
undertaken previously. The UKGTS, a randomised, double-masked, placebo-
controlled, multicenter treatment trial for OAG, tests the hypothesis that 
treatment with a topical prostaglandin analogue, compared with placebo, 
reduces the frequency of VF deterioration events in OAG patients by 50% over 
a 2-year period. Five hundred sixteen newly diagnosed (previously untreated) 
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patients with OAG were recruited prospectively at 10 UK centres between 
2007 and 2010. The primary outcome was time to VF deterioration within 24 
months. In summary, the UKGTS is the first randomised, placebo-controlled 
trial to evaluate the efficacy of medical treatment in reducing VF deterioration 
in OAG. 
Other than raised IOP, the risk factor with the largest effect for more rapid 
progression, consistently determined from epidemiologic studies and clinical 
trials, is patient age. There is a strong rationale for considering mitochondrial 
function as a susceptibility factor given the pathological models of optic 
neuropathies caused by mitochondrial defects (Leber’s hereditary optic 
neuropathy, dominant optic atrophy). Furthermore, ageing is associated with 
structural and functional changes to the mitochondria and data from clinical 
and experimental studies have implicated mitochondrial dysfunction and 
oxidative stress in glaucoma development and progression. To address point b) 
above, an exploratory study was designed to measure for the first time 
systemic mitochondrial function and oxidative stress in a unique cohort of 
patients, contrasting individuals at the extremes of IOP susceptibility – rapidly 
progressing patients with NTG and non-progressing patients with OHT. 
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Chapter 2: Materials and Methods 
2.1 General materials 
2.1.1 General reagents 
Reagent Supplier Location 
ATP Bioluminesence Assay kit CLSII Roche Mannheim, Germany 
BCA (bicinchoninic acid) Protein Assay Kit 
Lymphoprep 
PBS (Phosphate-buffered saline) 
Thermo Scientific 
Axis-Shield 
Gibco, Life 
Technologies Ltd 
Northumberland, UK 
Oslo, Norway 
Paisley, UK 
Polyvinylidene difluoride (PVDF) membrane  
PathScan Total mTOR and Phospho-mTOR 
(Ser2448) Sandwich ELISA kit 
8-OHdG DNA Damage ELISA kit  
Fluo3, rhod2, pluronic acid, 2’, 7’-
dihydroethidium (DHE) and 
tetramethylrhodamine methyl ester (TMRM) 
Horseradish peroxidase (HRP) conjugated 
chemiluminescence kit and Hyperfilm ECL 
films  
Halt protease inhibitor cocktail 
NuPage Protein gels 
Millipore  
Cell Signaling 
Technology Inc  
Cell Biolabs Inc 
Molecular Probes, 
Life Technologies 
Ltd 
GE Healthcare Life 
Sciences 
 
Thermo Scientific 
Novex, Life 
Technologies Ltd 
Billerica, MA  
Danvers, MA  
 
San Diego, CA  
Paisley, UK 
 
 
Buckinghamshire, UK  
 
 
Rockford, IL  
Paisley, UK 
 
Table 2.1: List of general reagents, the suppliers and their location.  
Unless otherwise stated, all other chemicals were obtained from Sigma 
Chemical Co (Gillingham, Dorset, UK) and were of the best quality available. 
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2.1.2 Immunochemicals 
Immunochemical Supplier Location 
Primary (rabbit) polyclonal antibody to b-actin 
(1:5000, PC: ab8227) and primary (rabbit) 
polyclonal antibody to porin (1:1000, PC: 
ab15895) 
Primary (rabbit) polyclonal antibody to 
superoxide dismutase 2 (SOD2) (1:1000, PC: 
sc30080) and primary (rabbit) polyclonal 
antibody to TOM20 (1:1000, PC: sc11415) 
Secondary (goat) polyclonal antibodies anti-
rabbit IgG (PC: PO448) with HRP conjugate 
Abcam 
 
 
 
Santa Cruz 
Biotechnology Inc 
 
 
Dako UK 
Cambridge, UK 
 
 
 
Santa Cruz, CA 
 
 
 
Cambridgeshire, 
UK 
Table 2.2: List of immunochemicals, the suppliers and their location. 
 
2.1.3 Cell culture materials 
Cell culture material Supplier Location 
Foetal bovine serum (FBS) and foetal calf serum 
(FCS)  
75cm2 tissue culture flasks 
 
6-, 48- and 96-well plates, and eppendorfs 
 
15mls and 50mls Falcon tubes 
Petri dishes 
Single channel pipettes (Pipetman P2, P10, P100, 
P200 and P1000)  
HBSS (Hank's Balanced Salt Solution), penicillin, 
streptomycin, and RPMI (Roswell Park Memorial 
Biosera, Labtech 
International Ltd 
PAA Laboratories 
Ltd 
Greiner Bio-One 
 
BD Biosciences 
Sarstedt 
Gilson Inc  
 
Gibco, Life 
Technologies Ltd 
Uckfield, UK  
 
Somerset, UK 
 
Frickenhausen, 
Germany 
Oxford, UK 
Leicester, UK 
Middleton, WI  
 
Paisley, UK 
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Institute) 1640 medium supplemented with 
glutamax and HEPES (hydroxyethyl 
piperazineethanesulfonic acid) 
Table 2.3: List of cell culture materials, the suppliers and their location. 
 
2.1.4 Laboratory equipment  
Laboratory equipment Supplier Location 
Synergy HT multi-mode microplate reader for 
BCA, DHE and aconitase assays  
Jade tube luminometer for ATP measurements 
Beckman GPR refrigerated centrifuge 
 
Heracell 240i CO2 incubator 
FACS Calibur flow cytometer 
LS50B Luminescence Spectrometer 
Biotek 
 
LabTech 
Beckman Coulter Ltd 
 
Thermo Scientific 
BD Biosciences 
Perkin Elmer 
Bedfordshire, 
UK  
Uckfield, UK 
High Wycombe, 
UK 
Rockford, IL 
Oxford, UK 
Cambridge, UK 
Table 2.4: List of laboratory equipment, the suppliers and their location. 
 
2.1.5 Clinical devices 
The Heidelberg Retina Tomograph (HRT) was from Heidelberg Engineering 
(Heidelberg, Germany; HRT3 image acquisition software version 3.0.60). The 
Stratus Optical Coherence Tomography (OCT) and the GDx Enhanced Corneal 
Compensation scanning laser polarimetry devices were from Carl Zeiss Meditec 
(Dublin, CA; software version 5.0). The Humphrey Field Analyzer/HFA™ II-i 
Series was also from Carl Zeiss Meditec. Goldmann applanation tonometry 
(GAT) was performed with a Haag Streit slit lamp (Koeniz, Switzerland). The 
Pascal Dynamic Contour Tonometre (DCT) was from Ziemer Ophthalmic 
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Systems AG (Zurich, Switzerland) and the Ocular Response Analyzer (ORA) 
from Reichert (Buffalo, NY; software version 2.10). The Omron M7 Blood 
Pressure Monitor was from Matsusaka (Mie, Japan). The Welch Allyn 
Ambulatory Blood Pressure Monitor 6100 was from Welch Allyn UK (Aston 
Abbotts, Buckinghamshire, UK; software version 1.6.0.489). The IOL Master 
was from Carl Zeiss Meditec (Dublic, CA; software version 5.4.3.0002). The 
ultrasound pachymeter for Central Corneal Thickness (CCT) measurements was 
from DGH Technology Inc (Exton, PA). 
 
2.1.6 Participants and other materials 
1. UKGTS participants 
Five hundred sixteen newly diagnosed (previously untreated) patients with 
OAG were recruited prospectively at 10 UK centers between 2007 and 2010, as 
described in more detail in chapter 3. 
2. Participants/materials for experiments to optimise 
laboratory techniques 
Two well established immortalised human B- and T- lymphocyte cell lines (Raji 
and Jurkat, respectively) were used to optimise the experimental techniques of 
measuring mitochondrial function and oxidative stress (see section 4.1). At a 
later stage, and before embarking on the main laboratory experiments, the 
experimental techniques were also optimised using lymphocytes isolated from 
the peripheral blood of healthy volunteers (see section 4.2). 
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3. Study participants (control, NTG, OHT) for main laboratory 
experiments (mitochondrial exploratory study) 
Two cohorts of 30 consecutive subjects with normal tension glaucoma (NTG) 
and ocular hypertension (OHT) were recruited prospectively from the 
Moorfields Eye Hospital NTG and OHT clinics, respectively, for the 
mitochondrial exploratory study, as described in more detail in section 4.3. An 
equal number of age-similar subjects with normal IOP, healthy discs and no 
family history of glaucoma was also recruited as controls for the same study. 
These were either spouses or friends of patients, or were recruited from the 
Friends of Moorfields. Raji cells were used in many cases as reference (internal 
control) during the main laboratory experiments, as explained in more detail in 
section 2.3.  
 
2.2 Clinical Methods 
2.2.1 Introduction 
The clinical methods described in this section (2.2) were employed both in the 
mitochondrial exploratory study and in the UKGTS cohort, as explained later in 
more detail. The laboratory methods described in the next section (2.3) apply 
exclusively to the mitochondrial exploratory study.  
 
2.2.2 Goldmann applanation tonometry (GAT) 
In the UKGTS, two diastolic IOP readings were recorded, with a third 
measurement obtained if the difference between the first 2 was more than 
1mmHg.  In the mitochondrial pilot study, 1 diastolic IOP reading was 
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recorded. 2-hourly diurnal GAT IOP measurements (between 9 AM and 5 PM) 
were performed twice in the UKGTS [at Visit 1, six weeks after commencing the 
study drops, and at Visit 8a] and once in the mitochondrial pilot study. 
 
2.2.3 Dynamic Contour Tonometry (DCT) 
Goldmann applanation tonometry measurements are known to be affected by 
the CCT and age-related corneal stiffening (Kotecha et al 2005). Therefore, 
additional IOP measurements were made with the Pascal DCT, a more accurate 
and precise tonometry device that reduces the effects of corneal biomechanics 
during IOP measurement (Fig 2.1) (Kotecha et al 2010). Three readings with a 
quality value of 3 or better were recorded at each UKGTS visit and as part of 
the mitochondrial pilot study. Phasing with DCT was performed once in the 
mitochondrial pilot study. 
     
Fig 2.1: The Pascal DCT uses a concave tip to “contour match,” rather than 
applanate, a convex segment of the central cornea. When this match is 
achieved, the law of Pascal states that tangential forces are theoretically 
neutralised. A microchip- enabled solid-state sensing element in the tonometer 
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tip then measures IOP. The instrument then dynamically records more than 
100 IOP measurements per second, measuring IOP fluctuations throughout the 
cardiac cycle and digitally displaying the average diastolic IOP. The ocular pulse 
amplitude (OPA), the difference in IOP between systole and diastole (IOP 
systolic - IOP diastolic), is also reported and is thought to be a marker for 
overall ocular rigidity (Kanngiesser et al 2005, Pallikaris et al 2005) although it 
may also be affected by ocular blood flow. 
 
2.2.4 Perkins tonometry 
Supine IOP measurements with the Perkins tonometer were made at the 
UKGTS visit 1 and at the mitochondrial pilot study visit after the participant had 
been lying down for at least 15 minutes. 
 
2.2.5 Ocular Response Analyser (ORA) (Fig 2.2) 
The ORA is a non-contact tonometer that measures two applanation events: 
one as the air jet pressure rises and one as it falls. These applanation signals 
are used to derive a Goldmann-correlated IOP (IOPg), an IOP corrected for 
biomechanical properties (corneal-compensated IOP or IOPcc), and 
measurements related to the ocular biomechanics (corneal hysteresis or CH, 
and corneal resistance factor or CRF). Three IOPg, IOPcc, CH and CRF readings 
with good quality traces were recorded at each UKGTS visit and and as part of 
the mitochondrial pilot study. 
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Fig 2.2: The ORA uses a metered collimated air pulse to applanate the cornea 
and an infrared electrooptical system to record inward and outward 
applanation events. The air pulse deforms the cornea through an initial 
applanation event (peak 1), then beyond into concavity, and gradually subsides 
allowing the cornea to rebound through a second applanation (peak 2) (Figure 
1). Corneal hysteresis is defined as the difference in pressure between peak 1 
(P1) and peak 2 (P2). This dynamic assessment of corneal biomechanical 
properties yields metrics of both the cornea’s viscous and elastic qualities. 
Whereas CH may reflect mostly corneal viscosity, CRF, defined as a linear 
function of P1 and P2 by the formula: P1− (k × P2) where k is an empirically 
derived constant (Shah et al 2007), may predominantly relate to the elastic 
properties of the cornea. Although CH and CRF are, on average, the same for a 
normal population, they differ from person to person, providing us with 
distinct corneal information. The IOPcc is an IOP measurement thought to be 
less influenced by the cornea and derived from the equation P2 – (0.43 × P1). 
The IOPg is the average of the two pressure values derived from the inward 
and outward applanation events (P1+P2)/2. 
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2.2.6 Central Corneal Thickness (CCT) 
CCT was measured with an ultrasound pachymeter at the UKGTS visit 1 and at 
the mitochondrial pilot study visit. 
 
2.2.7 Automated perimetry 
All tests for the UKGTS were performed with the Humphrey Field Analyzer 
Mark II (or II-i) and the Swedish interactive threshold algorithm standard 24-2 
program. A reliable VF was one with a false-positive rate of less than 15% and 
20% fixation losses (for fixation losses >20%, reliability was based on subjective 
judgment, including assessment of the eye tracker trace). Unreliable tests were 
repeated, either on the same day (with a break of at least 30 minutes) or at a 
visit within 1 month. 
 
2.2.8 Progressor software 
To estimate the rate of VF progression of subjects recruited in the 
mitochondrial pilot study, the PROGRESSOR software package (Medisoft) was 
used. This package analyses VF progression using pointwise linear regression of 
sensitivity on time. The pointwise linear model has been demonstrated to 
provide a valid framework for detecting glaucomatous loss (Viswanathan et al 
1997). PROGRESSOR produces a cumulative graphical output as shown below. 
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  # 
Fig 2.3: Graphical output from the Progressor software. 
Each test location is shown as a bar graph in which each bar represents one 
test. The length of the bar relates to the depth of the defect (longer bars 
represent lower sensitivities) and the colour of the bar relates to the p value of 
the regression slope. Thus, undamaged locations are seen as series of short 
grey bars. 
 
2.2.9 Ocular biometry 
At the UKGTS visit 1 and the mitochondrial pilot study visit, refractive error was 
recorded, either with an available autorefractor or from spectacle focimetry, 
and axial length measured with the IOLMaster. 
 
2.2.10 24-hr Ambulatory Blood Pressure (ABP) 
At each UKGTS visit, blood pressure (BP) was recorded in the left arm with the 
patient seated after at least 5 minutes of rest with the Omron M7 Blood 
Pressure Monitor. 24-hour BP measurements were made at the 4-month 
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UKGTS visit and at the mitochondrial pilot study visit with the Welch Allyn 
Ambulatory Blood Pressure Monitor 6100. 
 
2.2.11 Body Mass Index (BMI) 
The height (m) and weight (Kg) of each participant for the mitochondrial pilot 
study was measured and the BMI was calculated by dividing each individual's 
weight by their height squared. Height and weight were measured in 
participants wearing light clothing and no footwear. 
 
2.2.12 Structural Imaging  
Structural imaging was carried out in the UKGTS as follows:  
1. Confocal scanning laser ophthalmoscopy was carried out using the HRT. 
Image quality of mean pixel height standard deviation (MPHSD) 40µm or less 
was required; if necessary, pupils were dilated to obtain adequate image 
quality. 
2. Scanning laser polarimetry was carried out with the GDx Enhanced Corneal 
Compensation scanning laser polarimetry device. Imaging was performed 
through an undilated pupil and a scan quality score of 8 or more was required. 
3. Optical coherence tomography (OCT) with the Stratus OCT. Images were 
acquired through dilated pupils with the fast RNFL thickness (3.4) scanning 
protocol and using the landmark function. A signal strength of 7 or more was 
required. In addition, spectral-domain OCT imaging was performed where 
available. 
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4. Monoscopic optic disc photography was used to identify disc haemorrhages. 
5. Fundus photography was performed if a patient reached a VF deterioration 
or visual acuity change end point.  
A summary of the UKGTS investigations’ schedule is shown in Table 3.2. 
 
2.3 Laboratory Methods  
2.3.1 Cell cultures 
1. Immortalised human B- and T-lymphocyte cell lines 
Both cell lines were cultured in RPMI 1640 medium, supplemented with 10% 
FCS, 2mM glutamax, 12.5mM HEPES, 50U/mL penicillin and 50μg/mL 
streptomycin in 75-cm
2
 flasks at 37°C in an atmosphere of 5% CO2. Doubling 
time of these cells was approximately 20 hours under these conditions and 
they were generally passaged at a ratio of 1:8. Cells were maintained at a 
density of approximately 1million/ml for use in experiments. The Raji cell line 
was originally derived from the B-lymphocytes of an 11-year-old Nigerian 
Burkitt's lymphoma male patient in 1963 (Karpova et al 2005), while the Jurkat 
cell line (originally called JM) was established in the late 1970s from the 
peripheral blood of a 14-year-old boy with T cell leukemia (Schneider et al 
1977). Both Raji and Jurkat are suspension cells that can grow as single, 
doublets, or form large aggregates when in culture (Fig 2.4). The cells, which 
tend to clump, are relatively large in diameter (5-8 μm) and have irregular 
indented nuclei. 
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Fig 2.4: A Raji cell line in culture (at an early cultural stage). 
2. Healthy volunteers’ and study participants’ lymphocytes 
Lymphocytes were isolated, after the removal of monocytes, from 
anticoagulated peripheral blood of healthy volunteers and study participants 
(control, NTG and OHT) using Lymphoprep (see section 2.3.2), and maintained 
in petri dishes in the incubator overnight under unstimulated conditions for 
subsequent experiments. The isolated lymphocytes were resuspended in 
phenol red-free RPMI 1640 medium supplemented with 2mM glutamax, 
12.5mM HEPES, 50U/mL penicillin and 50μg/mL streptomycin, to create a cell 
density of approximately 1million lymphocytes/ml. 
3. Treatment with rotenone and paraquat 
For some experiments, to model mitochondrial dusfunction and oxidative 
stress in our system, cells were treated with 0.5µM rotenone for 24hrs and 
with 100µM paraquat for 24hrs, respectively. This dose was based on our 
laboratory’s previous experience with these agents on different cell types and 
no dose-response experiments were conducted. Cell viability after exposure to 
these agents was assessed with trypan blue on a weekly basis prior to starting 
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the experiments and cell death was noted in less than 5% of the lymphocytes. 
Rotenone, a flavonoid often used as a pesticide, is a neurotoxin that induces 
neurodegeneration and has been used in vivo in animals and in vitro 
neurogeneration disease models to replicate certain features of Parkinson’s 
disease (PD) (Betarbet et al 2000, Inden et al 2011) and Alzheimer’s disease 
(AD) (Chaves et al 2010). Apart from the well known role of rotenone as a 
mitochondrial complex I inhibitor, it has also been shown to affect microtubule 
stability and Ca
2+
 homeostasis (Choi et al 2011), induce oxidative stress, alter 
proteasome function (Shamoto-Nagai et al 2003), and cause DNA damage, 
inflammatory response and apoptosis (Newhouse et al 2004). Paraquat, a 
quaternary ammonium bipyridyl herbicide, is known to generate reactive 
oxygen species (including superoxide anion, hydrogen peroxide and hydroxyl 
radicals) highly reactive to cellular macromolecules and cause the oxidation of 
reducing equivalents (such as NADPH and reduced glutathione) necessary for 
normal cellular function (Bus et al 1984, Lee et al 2012). 
 
2.3.2 Lymphoprep 
For the isolation of lymphocytes from anticoagulated peripheral blood, a 
ready-made, sterile and endotoxin tested solution (Lymphoprep) was used, as 
described by Thorsby and Bratlie (Thorsby and Bratlie 1970). This solution 
contains sodium diatrizoate 9.1% (w/v) and sodium diatrizoate polysaccharide 
5.7% (w/v). These compounds aggregate the erythrocytes, when mixed with 
blood, thereby increasing their sedimentation rate. The sedimentation of 
leucocytes is only slightly affected and these can be collected from the upper 
part of the tube, when the erythrocytes have settled. 
  
124 
 
Blood was collected in an EDTA (purple top) tube and transferred from 
Moorfields Eye Hospital to the Department of Clinical Neurosciences, Royal 
Free Hospital within 1-2 hours from collection. The blood was diluted by the 
addition of an equal volume of HBSS. A certain volume of the diluted blood 
was then carefully layered over half the volume of Lymphoprep in a 50mls 
Falcon tube. The tube was centrifuged at 800 x g for 20 minutes at 20°C in a 
swing-out rotor. After centrifugation the peripheral blood mononuclear cells 
(PBMCs) formed a distinct band at the sample/medium interface and were 
removed from the interface using a single channel pipette. After washing in 
HBSS twice to remove any remaining Lymphoprep solution, the PBMC from 
each patient were resuspended in medium (phenol red-free RPMI 1640 
medium, 2mM Glutamax, 12.5mM HEPES, 50U/mL penicillin and 50μg/mL 
streptomycin) to a final cell density of approximately 1million PBMC/ml. The 
PBMC in RPMI medium were incubated overnight in petri dishes with and 
without rotenone/paraquat treatment. This overnight incubation allowed 
monocytes to adhere to the petri dish walls, while lymphocytes remained in 
suspension and were easily removed on the following day for use in 
subsequent experiments. 
 
2.3.3 BCA protein assay 
The BCA Protein Assay was used to measure total protein concentration 
compared to a protein standard. This assay combines the well-known 
reduction of Cu2+ to Cu1+ by protein in an alkaline medium with the highly 
sensitive and selective colourimetric detection of the cuprous cation (Cu
1+
) by 
bicinchoninic acid (BCA) (Smith et al 1985). The first step is the chelation of 
copper with protein to form a light blue complex. In the second step of the 
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colour development reaction, BCA reacts with the reduced cuprous cation to 
form a purple-coloured reaction product (Wiechelman et al 1988). The 
BCA/copper complex is water-soluble and exhibits a strong linear absorbance 
at 562 nm with increasing protein concentrations.  
During the BCA protein assay, 5µl from each sample were added into each well 
of a 96-well plate containing 45µl of water, to produce a final volume of 50µl 
per well. A standard curve (Figure 2.5) was also prepared with the use of serial 
dilutions of Bovine Serum Albumin (BSA) (2mg/ml). Subsequently, 50µl of the 
reagent mix were added into each well and incubated at 37
o
C for 30min. A 
plate reader was used to read the 96-well plate at 562nm. 
 
A BSA (μL) 3 2 1 0 
B [BSA] mg/ml 0.12 0.08 0.04 0 
C 
Spectrophotometer 
reading or OD 
0.384 0.322 0.15 0.015 
D 
Net OD:  
OD – Background OD 
0.369 0.307 0.135 0 
Table 2.5: Data required for BSA standard curve. Row A shows the amount of 
BSA inserted in each of the BSA wells of the 96-well plate. Row B shows the 
[BSA] concentration in each of these wells. Row C shows examples of 
spectrophotometer readings (optical density - OD) for each well. Row D shows 
the net OD for each well, which is calculated by subtracting the blank OD from 
the OD of each well. The blank OD is the OD of the background (in this case 
0.015). 
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Fig 2.5: Example of a BSA standard curve, based on Table 2.5. Axis X represents 
the [BSA] mg/ml and axis Y represents the net OD. The equation shows the 
correlation between the net OD and [protein] concentration (mg/ml). 
 
Based on the BSA standard curve above, the amount of protein in each sample 
well was calculated, as shown below (Table 2.6). 
Well OD Net OD [Sample Protein] in the Well [Sample Protein] 
A 0.158 0.143 0.0413mg/ml 0.413mg/ml 
Table 2.6: Example of [Sample Protein] calculation in each well (in this case 
Well A). If the OD of the well is, for instance, 0.158, then after subtracting the 
blank OD (0.015 according to Table 2.5) the Net OD is 0.143. Using the BSA 
standard curve equation from Figure 2.5, the [sample protein] in well A is 
calculated to be 0.0413. Since the sample volume in the well represents 1/10 
of the total volume of the content of the well, the [sample protein] = 10* 
[sample protein] in the well = 0.413mg/ml. 
y = 3.1975x + 0.0109
R² = 0.9713
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2.3.4 ADP phosphorylation assay 
1. Basic principles
ADP phosphorylation describes a type of substrate
results in the formation of adenosine triphosphate (ATP) by the direct transfer 
and donation of a phosphoryl (PO
from a phosphorylated reactive intermediate
bisphosphoglycerate and phosphoenolpyruvate. 
  
Fig 2.6: Substrate-level phosphorylation generating 
In addition to the substrate
and the Krebs cycle, an alternative way to create 
takes place during the process of cellular respiration
assay is designed to measure 
given period of incubation time, based on the exogenous supply of substrates, 
such as a) glutamate-malate (
complexes II/III) and c) ascorbate
measurement of generated ATP over that period 
luminescence, where ATP reacts with luciferin to pro
tube-luminometer. The ATP Bioluminescence Assay Kit CLS II was used, which 
includes lyophilised luciferase reagent. This kit uses the ATP dependency of the 
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ATP. 
-level phosphorylation that occurs during glycolysis 
ATP is through oxphos
. The ADP phosphorylation 
complex-specific ATP synthesis in live cells over a 
for complex I), b) succinate-rotenone (
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is based on the principle of 
duce light, measured by a 
-
, which 
for 
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of extremely low concentrations of ATP
  
Fig 2.7: The ATP measurement is based o
where ATP produced by the cells reacts 
then measured by a tube-
biology). 
Prior to performing the substrate
attempted to quantify the amount of digi
ATP measurements for a given c
digitalis purpurea and is com
mitochondrial membranes,
release. 
 
 
2. Methodology
    2a) 
As mentioned in section 2.1.6
and lymphocytes from healthy volunteers were used to optimise the ADP 
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ed, oxidation of luciferin for the measurement 
 (Fig 2.7).  
 
n the principle of luminescence, 
with luciferin to produce light, which is 
luminometer (modified from http://ase.tufts.edu/ 
-linked ADP phosporylation 
tonin that would provide the max
ell type. Digitonin is a glycoside obtained from 
monly used in this assay to solubilise 
 in order to allow substrate penetration 
 
Optimisation experiments 
, the two immortalised cell lines (Raji and Jurkat) 
assay, we 
imal 
cell and 
and ATP 
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phosporylation assay. Prior to starting this assay, a digitonin titration 
experiment was performed on the cell lines to identify the optimum 
concentration of digitonin required to solubilise the mitochondrial membrane 
and enable the penetration of the substrates into the cells. 
Digitonin titration: For cell preparation, 5 million Raji and Jurkat cells from each 
flask were spun at 1000 x g for 10min. The cell pellet was washed in HBSS and 
spun again at 1000 x g for 10min. The pellet was resuspended in ATP buffer 
(150mM KCl, 2mM K2EDTA, 10mM K2HPO4, 5mM Tris base, pH 7.4). For each 
reaction (performed in triplicate) 0.25mls of reaction buffer (10mM Glutamate 
pH 7.4, 10mM Malate pH 7.4 and 1mM ADP in ATP buffer) were allowed to 
react with 0.25mls of cells suspended in ATP buffer for 20 minutes at 37°C with 
shaking. For each cell line 8 reactions were performed using 8 different doses 
of digitonin (0, 10, 25, 50, 75, 100, 150, 200µg per reaction).  The reaction was 
terminated after 20min by adding 28.5 µl of perchloric acid (70%) into each 
eppendorf. The acid was then neutralised with the addition of 76µl of 
K2CO3/TEA 3M/0.5M in two steps (38µl added twice with a 10 min gap) to 
prevent the creation of large amounts of CO2. 50µl of luciferin from the ATP 
Bioluminescence Assay Kit CLS II were allowed to react with 5µl of cell lysate 
(cells in ATP/reaction buffer after the end of the reaction) for 10 seconds and 
the emitted luminescence was measured by a Jade Tube Luminometer. The 
measurements provided by the luminometer are in RLU (relative luminescence 
units), which are arbitrary units. The digitonin titration results for Raji (Fig 2.8) 
and Jurkat (Fig 2.9) suggest that the rate of ATP synthesis was maximum when 
10-25µg of digitonin per reaction were used to solubilise the mitochondrial 
membrane and enable the penetration of the substrates, while higher 
digitonin concentrations led to a reduction in ATP synthesis. Considering the 
data from both cell lines together, 10µg of digitonin per 0.5ml reaction was 
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considered the optimum concentration to allow the substrates to penetrate 
into the cells without damaging their integrity and was used in subsequent 
experiments. 
 
Fig 2.8: Graph showing the rate of ATP synthesis for different concentrations of 
digitonin (range 0 to 200µg per reaction) in the Raji cell line. The arbitrary 
measurements provided by the luminometer are expressed in RLU (relative 
luminescence units). Error bars represent the SEM (n=3). 
0
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Fig 2.9: Graph showing the rate of ATP synthesis for different concentrations of 
digitonin (range 0 to 200µg per reaction) in the Jurkat cell line. The arbitrary 
measurements provided by the luminometer are expressed in RLU (relative 
luminescence units). Error bars represent the SEM (n=3). 
ADP Phosphorylation Assay: Cells in suspension were spun at 1000 x g for 
10min, washed in 1xPBS and spun again at 1000 x g for 10min. The pellet was 
resuspended in ATP buffer. For each reaction one eppendorf was used and 
0.25mls of reaction buffer were allowed to react for 20 minutes with 0.25mls 
of cells suspended in ATP buffer. For each cell line and for the healthy 
volunteers’ lymphocytes 3 reactions were performed for complex I, 3 for 
complexes II/III, 3 for complex IV and 2 for control (reaction buffer with no 
substrate). The corresponding reaction buffers required were as follows: 
Complex I (10mM glutamate pH 7.4, 10mM malate pH 7.4, 1mM ADP, 10 µg 
digitonin per reaction and ATP buffer), Complexes II/III (10mM succinate pH 
7.4, 10µM rotenone in ethanol, 1mM ADP, 10 µg digitonin per reaction and 
0
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ATP synthesis 
(Jurkat)
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ATP buffer), Complex IV (2mM ascorbate pH 7.4, 50µM TMPD pH 7.4, 1mM 
ADP, 10 µg digitonin per reaction and ATP buffer) and Buffer with no substrate 
(1mM ADP, 10 µg digitonin per reaction and ATP buffer). The latter served as a 
negative control, with this background measurement being subtracted from 
the complex-related measurements. The reaction was terminated after 20min 
by adding 28.5 µl of perchloric acid (70%) into each eppendorf. The acid was 
then neutralised with the addition of 76µl of 3M/0.5M K2CO3/TEA in two 
steps. 50µl of luciferin were allowed to react with 2.5µl of cell lysate for 10 
seconds and the emitted luminescence was measured by a Jade Tube 
Luminometer. Rotenone (0.5µM 24hrs), known to reduce mitochondrial 
function, was used as a positive control. 
To reduce measurement variability, repeat readings were taken and averaged. 
1.25µl of cell lysate were also tested, ensuring that the ATP readings were 
approximately half as compared to 2.5µl. Duplicate measurements were 
performed for both 2.5µl and 1.25µl. The mean of the 4 measurements taken 
per eppendorf was used for further analysis.  
In the case of the Raji and Jurkat immortalised cell lines, triplicate eppendorfs 
were used for each experimental condition (with the exception of acid control 
where duplicate eppendorfs were used), as shown schematically below (Fig 
2.10).  
Complex I              Complexes II/III         Complex IV         Neg. control (no substrate) 
                                                                                                                 
                                                                                                                  
 
 
 
RAJI 
RAJI + Rotenone 
JURKAT 
JURKAT + Rotenone 
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Fig 2.10: Schematic representation of the experimental design for the ADP 
phosphorylation assay in the Raji and Jurkat cell lines. Triangles represent 
eppendorfs. 
The same design applied to the ATP experiments on the healthy volunteers’ 
lymphocytes, where Raji cells were also used as an internal control (Fig 2.11). 
Complex I              Complexes II/III         Complex IV         Neg. control (no substrate) 
                                                                                                                 
                                                                                                                  
 
 
 
Fig 2.11: Schematic representation of the experimental design for the ADP 
phosphorylation assay in the Raji cells and the healthy volunteers’ 
lymphocytes.                                                         
The arbitrary measurements provided by the luminometer in RLU (relative 
luminescence units) were converted into ATP concentrations using a 
calibration (standard) curve upon measuring known ATP levels. The ATP 
standard was included in the kit and each bottle contained 10mg of ATP. The 
content of the bottle was dissolved in Lysis Buffer, again provided with the kit, 
to a final concentration of 1nmol ATP/ml. Next, 50μl of luciferase were allowed 
to react with 0, 1.25, 2.5, 5 and 10μl of ATP standard for 10 sec and the 
emitted luminescence was measured by a Jade Tube Luminometer. With 
increasing concentrations of ATP, different luminescence readings were 
generated, for example 0.085, 1053, 2224, 3875 and 6596, respectively (Table 
2.7). 
VOLUNTEER  
VOLUNTEER + 
Rotenone 
RAJI 
RAJI + Rotenone 
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Table 2.7: The components of an ATP standard curve. Row A shows the 
amount of ATP standard inserted into each cuvette for the creation of an ATP 
standard curve. Row B shows the [ATP] in each cuvette with ATP standard. 
Row C shows examples of luminometer readings for the respective [ATP]. 
  
Fig 2.13: Example of ATP standard curve, based on Table 2.7. The X axis 
represents bioluminescence (luminometer readings). The Y axis represents 
[ATP]. The equation shows the correlation between bioluminescence and 
[ATP]. 
Using the ATP standard curve, the [ATP] in each cuvette was calculated, as 
shown below (Table 2.8).  
 
 
y = 0.0304x - 8.4993
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ATP vs Bioluminescence
Linear (ATP vs 
Bioluminescence)
A ATP standard (μl) 0 1.25 2.5 5 10 
B [ATP] pmol/ml 0 25 50 100 200 
C 
Bioluminescence 
(Luminometer 
reading) 
0.085 1053 2224 3875 6596 
Cuvette  Bioluminescence [ATP] 
A 4250 Luminescence Units 120.7 pmol/ml 
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Table 2.8: Example of the calculation of the [ATP] in cuvette A. If the 
luminometer reading for the cuvette A is 4250 Luminescence Units, then by 
using the ATP standard curve above (Figure 2.13), the [ATP] for the cuvette A is 
estimated to be 120.7 pmol/ml. 
Next, a BCA protein assay (see section 2.3.3) was performed to the neutralised 
cell lysates, in order to express the ATP production rate in pmol of ATP/min/mg 
of cell lysate. By dividing the amount of ATP produced in each cuvette, with the 
amount of protein in each 2.5μl sample, the total ATP produced per 1ml of 
each sample was estimated (Table 2.9). 
Sample 
Luminometer 
reading 
[ATP] in 
cuvette 
[Sample 
protein] 
[ATP]/[Sample 
Protein] 
[ATP] in 1ml 
Rate of ATP 
synthesis per 
min 
A 
4250 
Luminescence 
Units 
120.7 
pmol/ml 
0.413 
mg/ml 
292.25 
pmol/mg of cell 
lysate 
116900.72  
pmol/mg of  
cell lysate 
5845.04 
pmol/min/mg 
of cell lysate 
Table 2.9: Example of calculating the rate of ATP synthesis for sample A. The 
luminometer reading for sample A is 4250 Luminescence Units (Table 2.8). The 
[ATP] in the cuvette is 120.7 pmol/ml (Table 2.8). The [protein] in sample A has 
been estimated to be 0.413mg/ml (Table 2.6). Normalisation for protein is 
performed by dividing the [ATP] in the cuvette by the [protein] in sample A. 
This gives an ATP result of 292.25 pmol/mg of cell lysate. This amount of ATP 
has been produced by 2.5μl of sample A. Therefore, the amount of ATP 
produced per 1ml of sample A, is 400* 292.25 pmol/mg of tissue= 116900.72 
pmol/mg of cell lysate. To correct for the amount of time (20min) required for 
this ATP to be produced, the [ATP] is divided by 20, giving a final rate of ATP 
synthesis of 5845.04 pmol of ATP/min/mg of cell lysate. 
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    2b) Main experiments 
As discussed in section 2.1.6, lymphocytes isolated from the study participants 
(NTG, OHT, controls) were used for the main ADP phosphorylation 
experiments. The same methodology was followed, as described for the 
optimisation experiments, with the only exception being the use of duplicate 
(instead of triplicate) eppendorfs for each experimental condition (apart from 
acid control where a single eppendorf was used), as shown schematically 
below (Fig 2.12). Raji cells were again used as an internal control helping to 
standardise the assays over time. 
 
Complex I              Complexes II/III     Complex IV           Neg. control (no substrate) 
                                                                                                                 
                                                                                                                     
 
 
                                                                                                                         
 
 
 
Fig 2.12: Schematic representation of the experimental design for the ADP 
phosphorylation assay in the Raji cells and the study participants’ (NTG, OHT, 
control) lymphocytes.                                                         
 
CONTROL  
CONTROL + Rotenone 
NTG 
NTG + Rotenone 
OHT 
OHT + Rotenone 
RAJI 
  
 
2.3.5 Mitochondrial membrane potential using flow cytometry (TMRM) 
        1. Basic principles
Energy obtained through the transfer of electrons down the electron transport 
chain is used to pump protons from the mitochondrial matrix into the 
intermembrane space of the mitochondria, creating an electrochemical proton 
gradient across the mitochondrial inner membrane
membrane potential (ΔΨm). This electrochemical proton gradient allows ATP 
synthase to use the flow of protons through the en
to generate ATP (Fig 2.14
function and the characteris
determination of mitochondrial bioenergetics and cellular metabolism
1988). To measure changes in the ΔΨm in our cells we employed the 
monovalent cationic fluorescent red dye TMRM
uncoupler FCCP was used to depolarise the mitochondria and affect their 
ability to maintain a negative ΔΨm across the mitoch
thus serving as a positive control.
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). The ΔΨm is a key indicator of mitochondrial 
ation of ΔΨm in live cells allows for an accurate 
 (Scaduto et al 1999)
ondrial inner membrane, 
 
 
 
 (Chen 
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Fig 2.14: The negative ΔΨm between the matrix and the mitochondrial 
intermembrane space allows the ATP synthase (Complex V), located on the 
inner mitochondrial membrane, to use the flow of protons (H
+
) through the 
enzyme into the matrix to generate ATP (http://www.ibguides.com/biology/ 
notes/cell-respiration). 
 
        2. Methodology 
    2a) Optimisation experiments 
As discussed in section 2.1.6, the two immortalised cell lines (Raji and Jurkat) 
and lymphocytes from healthy volunteers were used to optimise the TMRM 
assay, before embarking on the main experiments using the study participants’ 
(NTG, OHT, control) lymphocytes. 
 
Cells were spun at 1000 x g for 10min, washed in 1xPBS and spun again using 
the same settings. The pellet was resuspended in PBS to a final volume of 1ml 
per cuvette.  It is important to note that we used a relatively low concentration 
of TMRM (25nM) to ensure the staining was mitochondria specific (Cleeter et 
al 2013). At higher TMRM concentrations it is possible that non-mitochondrial 
cellular membranes may also be stained, resulting in non-specific staining. 
FCCP was used at a final concentration of 10µM. The ΔΨm was quantified by 
the steady-state fluorescence of the mitochondrial patterns produced by live 
cells stained with TMRM at room temperature for 45 min. The samples were 
read using the FACS Calibur Flow cytometer running the CellQuest software 
using the same gate and gain. Data were collected in the FL2-H channel and 
50,000 events were counted for each sample. Analysis was performed using 
the WinMDI software, version 2.5 (Joseph Trotter, La Jolla, CA).  
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In the case of the Raji and Jurkat cell lines, the following seven experimental 
conditions were represented for each of the two cell lines in each experiment 
in triplicate:  
• Cells without TMRM (negative control) 
• Cells with TMRM  
• Cells with TMRM + 0.5µM rotenone 24hrs 
• Cells with TMRM + 100µM paraquat 24hrs 
• Cells with TMRM + 10µM FCCP (positive control) 
• Cells with TMRM + 0.5µM rotenone 24hrs +10µM FCCP 
• Cells with TMRM +100µM paraquat 24hrs +10µM FCCP 
 
In all cases, the background fluorescence recorded for cells without TMRM was 
subtracted from the fluorescence measured for TMRM-stained live cells. In the 
case of the healthy volunteers’ lymphocytes, duplicate measurements were 
made for each experimental condition, as shown schematically below (Fig 
2.15). Raji cells stained with TMRM were used as an internal control helping to 
standardise the assays over time, while cells exposed to FCCP served as a 
positive control. 
                                            RAJI                      VOLUNTEER      
                      +TMRM                  +TMRM    
           
  
            +Rot                     +Rot  
 
 
                        +FCCP (TMRM)          +FCCP (TMRM) 
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Fig 2.15: Schematic representation of the experimental design for the 
mitochondrial membrane potential assay in the human volunteers’ 
lymphocytes and the Raji cells. Cells without TMRM were also used in all cases 
as background controls (not shown here). 
 
    2b) Main experiments 
As discussed in section 2.1.6, lymphocytes isolated from the study participants 
(NTG, OHT, controls) were used for the main TMRM experiments. The same 
methodology was followed, as described for the optimisation experiments. In 
the case of the study participants’ lymphocytes, duplicate measurements were 
made for each experimental condition, as shown schematically below (Fig 
2.16). In all cases, the background fluorescence recorded for cells without 
TMRM (not shown schematically) was subtracted from the fluorescence 
measured for TMRM-stained live cells. Again, Raji was used as an internal 
control, with results being expressed as the mean red fluorescence % change 
from Raji (100%) (see section 4.3.3.3). 
                 RAJI         CONTROL      NTG           OHT          
          +TMRM        +TMRM      +TMRM      +TMRM    
           
  
                     + Rot              + Rot         + Rot          + Rot 
 
 
                   +FCCP          +FCCP       +FCCP         +FCCP 
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Fig 2.16: Schematic representation of the experimental design for the 
mitochondrial membrane potential assay in the patients’ and controls’ 
lymphocytes and the Raji cells. Cells without TMRM were also used in all cases 
as background controls (not shown here). 
 
2.3.6 Dihydroethidium (DHE) staining 
         1. Basic principles 
DHE, by virtue of its ability to freely permeate cell membranes, is used 
extensively to monitor the production of superoxide free radicals. DHE present 
in the cytosol in its reduced state (prior to contact with ROS) emits a blue 
fluorescence, whereas in the presence of superoxide anions it becomes 
oxidised and converts to ethidium bromide, which enters the nucleus and 
interacts with the DNA to emit a red fluorescence (Bindokas et al 1996) (Fig 
2.17). 
     
Fig 2.17: In the presence of superoxide, cells stained with DHE emit a red 
fluorescence. 
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  2. Methodology 
    2a) Optimisation experiments 
Similarly to the ADP phosphorylation and TMRM experiments, the two 
immortalised cell lines (Raji and Jurkat) and lymphocytes from healthy 
volunteers were used to optimise the DHE assay, before embarking on the 
main experiments using the study participants’ (NTG, OHT, control) 
lymphocytes. 
Cell suspensions were spun at 1000 x g for 10min, washed in 0.1M PBS and 
spun again at 1000 x g for 10min. After resuspending the pellet in PBS the cells 
were counted and the volume of cell suspension required for each 
experimental condition was selected to achieve a final cell density of 
50,000cells/well. The final volume of cell suspension per well of the 96-well 
plate was 50µl made up in PBS. 50µl of DHE were then added into each well to 
produce final concentrations of 10µM and 20µM in the case of the Raji and 
Jurkat cells. A final concentration of 40µM was used in experiments involving 
healthy volunteers’ lymphocytes to ensure there was no limitation in substrate 
supply. The rate of red fluorescence emission after staining live cells with DHE 
was used for subsequent analysis. Duplicate wells were employed for each 
experimental condition in each experiment. A Synergy HT Microplate Reader 
was used for measuring fluorescence kinetics on the 96-well plastic plates 
using the following filter (red fluorescence): excitation 485/20 and emission 
590/25. The run time for each plate was 30 minutes with measuring intervals 
of 37 seconds. Sensitivity of 100 was used and the plate was shaken once for 2 
seconds prior to each measurement.  
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In the case of Raji and Jurkat cells, the following experimental design was 
followed (Table 2.10). Three different treatments were used as positive 
controls to generate ROS and cause oxidative stress (Li et al 2003): 5µM 
rotenone (instantly), 0.5µM rotenone for 24hrs and 100µM paraquat for 24hrs.  
 Control  
(cells without 
treatment) 
Rotenone 
0.5 µM 
24hrs 
Paraquat 
100 µM 
24hrs 
Rotenone 
5µM 
instantly 
 
DHE 
10µM 
    Raji cells 
DHE 
20µM 
    Raji cells 
DHE 
10µM 
    Jurkat cells 
DHE 
20µM 
    Jurkat cells 
Table 2.10: Schematic representation of the experimental design for the DHE 
assay in the Raji and Jurkat cells. 
In the case of healthy volunteers’ lymphocytes, four different treatments were 
used to produce ROS, and therefore an increase in DHE staining, thus serving 
as positive controls. The Raji cells served as an internal control and the 
following experimental design was followed (Table 2.11). 
 Control  
(cells without 
treatment) 
0.5 µM 
Rotenone 
24hrs 
100 µM 
Paraquat 
24hrs 
5microM 
Rotenone  
instantly 
5microM 
Rotenone 
2hrs 
 
DHE 
40µM 
     Raji cells 
DHE 
40µM 
     Volunteer 
Lymphocytes 
Table 2.11: Schematic representation of the experimental design for the DHE 
assay in the healthy volunteers’ lymphocytes and the Raji cells. 
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    2b) Main experiments 
Lymphocytes isolated from the study participants (NTG, OHT, controls) were 
used for the main DHE experiments. The same methodology was followed, as 
described for the optimisation experiments. In the study participants’ 
lymphocytes only one treatment was used to produce ROS, 0.5µM rotenone 
(24hrs), which was found from previous experiments to be associated with the 
largest increase in DHE staining in the Raji cells and healthy volunteers’ 
lymphocytes (see section 4.2.4). Again, the Raji cells served as an internal 
control helping to standardise the assays over time, with the results being 
expressed as the percentage change from Raji (100%). The following 
experimental design was followed (Fig 2.18). 
  CONTROL               NTG                   OHT                 RAJI 
                                                                                                           Cell without  
          treatment 
 
0.5µM 
Rotenone 24hrs                                                          
Fig 2.18: Schematic representation of the experimental design for the DHE 
assay in the patients’ and controls’ lymphocytes and the Raji cells (final DHE 
concentration 40µM). Circles represent wells of a 96-well plate. 
 
2.3.7 Aconitase enzymatic activity 
1. Basic principles 
Aconitase (aconitate hydratase) is an iron-sulfur protein that catalyses the 
stereo-specific isomerisation of citrate to isocitrate via cis-aconitate in the 
  
tricarboxylic acid cycle (Fig 2.19
into isocitrate, and then the isocitrate catalysed by isocitrate dehydrogenase, 
to form alpha-ketoglutarate in the presence of NADP+ (colourless). The 
resulting increase of NADPH (yellow) ca
using a plate reader. Aconitase is known to be sensitive to oxidation and thus 
reduction in its activity serves as an indicator 
the cells (Gardner et al 1994)
used as a marker of background
and human lymphocytes. Paraquat (PQ) is known to cause oxidative damage 
by generating superoxide and was used at a relatively low concentration 
(100µM, 24hrs) adequate to reduce aconitase function without killing the cells. 
It thereby served as a positive control.
 
Fig 2.19: Aconitase catalyses the stereo
isocitrate in the tricarboxylic acid 
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). In this assay citrate is catalysed by aconitase 
n be detected by spectrophotometry 
of increased oxidative damage to 
. The aconitase enzymatic activity was therefore 
 oxidative damage to the Raji and Jurkat cells, 
 
-specific isomerisation of citrate to 
(Krebs) cycle and is known to be 
 
sensitive to 
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oxidative damage. Thus, reduced aconitase activity is associated with increased 
oxidative damage in our system (modified from http://library.thinkquest.org). 
 
2. Methodology 
    2a) Optimisation experiments 
Similarly to previous experiments, the two immortalised cell lines (Raji and 
Jurkat) and lymphocytes from healthy volunteers were used to optimise the 
aconitase enzymatic assay, before embarking on the main experiments using 
the study participants’ (NTG, OHT, control) lymphocytes. 
Cells in suspension were spun at 1000 x g for 10min, washed in 1xPBS and spun 
again at 1000 x g for 10min. Each pellet was then resuspended in distilled 
water (dH2O) to a final cell density of 2million lymphocytes/ml, sufficient to 
exceed the threshold of the measurement. 207µl of cells were added into each 
well of the 48-well plate and duplicate measurements were taken for each 
experimental condition. An additional 2 wells contained only 207µl of distilled 
water without cells and acted as a negative control. 701µl of reaction buffer 
was added into each well leading to a total volume of 908µl per well. The 
reaction buffer included 0.4mM NADP, 50mM Tris-HCl pH 7.4, 5mM tri-Na 
Citrate, 0.6mM MgCl2 and 0.1% Triton X-100 (final concentrations). 1 unit of 
citrate dehydrogenase per reaction was also added to the reaction buffer. The 
Synergy HT Microplate Reader, prewarmed at 37°C, was used for measuring 
absorbance kinetics on the 48-well plastic plate, at 340nm. Both the reaction 
buffer and the cells were placed in an incubator at 37°C prior to each 
measurement to optimise the reaction kinetics. Run time for each plate was 30 
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minutes with measuring intervals of 37 seconds. A BCA assay was performed to 
estimate the amount of protein in each sample and normalise the readings. 
Raji and Jurkat cells were treated with 100µM paraquat for 24hrs and 0.5µM 
rotenone for 24 hrs to measure the susceptibility of lymphocytes to oxidative 
stress. Cell density was checked in the flasks treated with rotenone and PQ 
prior to starting each experiment to ensure no excessive cell loss. The following 
six experimental conditions were explored: 
 Raji control 
 Raji + 0.5 µM Rotenone 24hrs  
 Raji + 100µM PQ 24hrs 
 Jurkat control 
 Jurkat + 0.5 µM Rotenone 24hrs  
 Jurkat + 100µM PQ 24hrs 
 
In the case of the healthy volunteers’ lymphocytes, the experimental design is 
shown in Fig 2.20. Cells were again treated with paraquat (100µM 24hrs), as a 
positive control, and Raji cells without PQ treatment were used as a reference 
(internal control). 
      VOLUNTEERS                     RAJI                            No cells 
+/-100µM PQ 24hrs        +/-100µM PQ 24hrs        (Negative control)              
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Fig 2.20: Schematic representation of the experimental design for the 
aconitase assay in the human volunteers’ lymphocytes and the Raji cells. 
Circles represent wells of the 48-well plate. Duplicate measurements were 
taken for each experimental condition. 
 
    2b) Main experiments 
Lymphocytes isolated from the study participants (NTG, OHT, controls) were 
used for the main aconitase experiments. The same methodology was 
followed, as described for the optimisation experiments. In the case of the 
study participants’ lymphocytes, the experimental design is shown in Fig 2.21. 
Again, paraquat (100µM 24hrs) served as a positive control and Raji cells 
without PQ treatment served as an internal control helping to standardise the 
assays over time. 
         CONTROL                          NTG                             OHT 
+/-100µM PQ 24hrs        +/-100µM PQ 24hrs        +/-100µM PQ 24hrs              
 
              
 
 
             RAJI                            No cells 
                  (Neg. control) 
 
Fig 2.21: Schematic representation of the experimental design for the 
aconitase assay in the patients’ and controls’ lymphocytes and the Raji cells. 
Duplicate measurements were taken for each experimental condition. 
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2.3.8 Western blot analysis to quantify protein levels 
1. Basic principles 
The separation of charged molecules in solution in response to an electric field 
is called electrophoresis. A very common method for separating proteins by 
electrophoresis uses a discontinuous polyacrylamide gel as a support medium 
and sodium dodecyl sulfate (SDS) to denature the proteins. The method is 
called sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
(Schapiro et al 1967). The rate of migration of the charged molecules depends 
on the strength of the field, on the size and shape of the molecules, as well as 
on the viscosity and the temperature of the medium in which the molecules 
are moving (Weber et al 1969). 
Proteins need to be transferred to membranes from gels so as to allow various 
probes to interact with individual macromolecules. The most used type of 
probes to interact with immobilised proteins are antibodies with specific 
affinity to given antigens. This can be implemented by incubating a membrane 
with transferred fractionated protein from a gel in a diluted antibody solution 
to recognise a defined protein (Fig 2.22). This is followed by washing of the 
membrane and incubation with a conjugated secondary antibody. Exposure to 
ECL (enhanced chemiluminescence) reagent allows the protein bound to the 
secondary antibody to emit light, captured on an x-ray film. A defined specific 
protein can then be quantified by densitometry. 
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Fig 2.22: Detection of protein on a gel by Western blotting. Proteins on an SDS-
polyacrylamide gel are transferred to a sheet of nitrocellulose paper and 
stained by a specific antibody. MW, molecular weight; Ab, antibody  
 
2. Methodology 
Cells in suspension were spun at 1000 x g for 10min, washed in 1xPBS and spun 
again at 1000 x g for 10min. The pellets were then lysed on ice with 50 µl of 
10mM Tris pH7.5 and 1% (v/v) Triton X-100, and centrifuged at 15000 x g for 
10 min. The supernatant was then aliquoted. Protein levels in the lysates were 
assayed with a BCA kit. Lysates were diluted so each lane was loaded with the 
same amount of protein. Lysates were mixed with loading dye and reducing 
agents according to the Novex system (Life Technologies) and heated at 70oC 
for 10 minutes. Lysates were then loaded on a 4-12% NuPage gel and 
electrophoresed in the MES buffer at 200V for 35 minutes. Proteins were 
blotted onto PVDF membranes, blocked in non-fat milk (5%) in 1xPBS and then 
incubated with the primary antibody for 1hr in 1xPBS with 2.5% milk and 0.2% 
Tween-20. After washing with 1xPBS with 0.4% Tween-20 twice, the blot was 
incubated with HRP labelled secondary antibody for 1hr in 1xPBS with 2.5% 
milk and 0.2% Tween-20. The bound antibody was detected using the ECL 
Separated 
proteins 
on gel 
Transfer of 
proteins to 
membrane 
Detection of a 
defined protein 
based on MW 
Detection with 
a specific Ab 
Analysis of 
content of protein 
by densitometry 
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Chemiluminescence kit. Membranes were exposed to the Hyperfilm ECL film 
for the appropriate duration. Primary antibodies to actin, SOD2, TOM20 and 
porin were used, as detailed in section 2.1.2. Band intensity was quantified 
using Image-J (NIH, Bethesda, http://rsbweb.nih.gov/ij/).  The intensity of the 
band for the protein of interest was divided by the intensity of the band for b-
actin (loading control) in the same lane to quantify the amount of the protein 
(Fig 4.29).   
 
2.3.9 Citrate synthase enzymatic activity 
1. Basic principles 
Citrate synthase is a pace-maker enzyme in the Krebs cycle (citric acid cycle) 
and is localised in the mitochondrial matrix. CS is nuclear encoded, synthesised 
on cytoplasmic ribosomes and transported into the mitochondrial matrix. 
Thus, CS enzymatic activity is commonly used as a quantitative measurement 
for the content of intact mitochondria (Holloszy et al 1970, Williams et al 
1986), although this role of CS has been questioned in developmental (Drahota 
et al 2004) and age-related studies (Marin-Garcia et al 1998). In the latter 
study, the developmental increase in CS activity noted in cardiac tissue during 
the progression from early childhood to adulthood paralleled increasing CS 
polypeptide content, but was not related to overall increases in mitochondrial 
number or in cardiac mitochondrial respiratory enzyme activity (Marin-Garcia 
et al 1998). 
2. Methodology 
Cell suspensions were spun at 1000 x g for 10min, washed in 1xPBS and spun 
again at 1000 x g for 10min. The pellets were then lysed on ice with 50 µl of 
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10mM Tris pH7.5 and 1% (v/v) Triton X-100 and centrifuged at 15000 x g for 10 
min. The supernatant was then aliquoted. For samples from each participant, 
10µl of supernatant was mixed with 240µl of reaction mix (0.1M Tris-HCl pH=8, 
0.2M acetyl coenzyme A, 0.2M DTNB, 0.1M oxaloacetic acid and 0.1% Triton X-
100 in dH2O). The assay was performed on a 96-well plate using a Synergy HT 
plate reader preheated to 30oC.  250µl of the reaction mixture was added to 
each well, while blanks consisting of reaction mix without cell lysates were also 
assayed. The protein concentration for each sample was measured using the 
BCA kit described in 2.2.3. Citrate synthase enzymatic activity was calculated as 
nmol/min/mg protein.   
 
2.3.10 Calcium mobilisation 
1. Basic principles 
Calcium (Ca
2+
) homeostasis is fundamental for cell metabolism, proliferation, 
differentiation, and cell death. Elevation in intracellular Ca
2+
 concentration is 
dependent either on Ca
2+
 influx from the extracellular space (which has a 
concentration of around 1-2mM) through the plasma membrane or on Ca2+ 
release from intracellular Ca
2+
 stores, such as the endoplasmic reticulum (ER) 
with concentrations of 250-600μM (Giorgi et al 2009). Mitochondria are major 
components of calcium
 
signalling, capable of modulating both the amplitude 
and the spatio-temporal patterns of Ca
2+
 signals. Mitochondrial Ca
2+
 uptake is 
due to the large electrochemical gradient provided by the negative inner 
mitochondrial membrane potential, usually between -150 and -180 mV, and is 
thus dependent on the integrity of the ΔΨm. Mitochondrial Ca
2+
 uptake has 
therefore been used as another measurement of mitochondrial function and is 
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known to play a key role in the regulation of many cellular functions, ranging 
from ATP production to cell death (Patergnani et al 2011). An increase in 
mitochondrial Ca
2+
 activates several dehydrogenases and carriers, inducing an 
increase in the respiratory rate, H
+
 extrusion and ATP production. However, 
Ca
2+
 overload or prolonged increase in mitochondrial Ca
2+
 leads to the opening 
of the mitochondrial permeability transition pore (mPTP) and causes cell death 
either by energetic collapse and ATP depletion or by initiating mitochondrial 
swelling, cytochrome c release and apoptotic cascades (Giorgi et al 2008, 
Abramov et al 2003), although Ca
2+
 can also inhibit apoptotic cell death 
(Reimertz et al 2001). 
Ionomycin is a Ca
2+
 ionophore often applied to cells in order to increase 
cytosolic Ca2+ and induce Ca2+-dependent processes in the mitochondria in situ. 
Ionomycin, at concentrations less than 1µM, is thought to act primarily at the 
level of the internal Ca
2+
 stores, mainly the ER, and not the plasma membrane 
(Morgan et al 1994). However, actions of Ca
2+
 ionophores in intact cells are 
more complex, given the diversity of ionic gradients between the different 
membrane-bound compartments within the cell. It has also been reported that 
ionomycin at a standard dose of 10µM can cause mitochondrial depolarisation 
in intact cells, although this was often modest and highly variable and 
dependent on the prior state of mitochondrial calcium loading (Abramov et al 
2003). The concentration used in our experiments was only 0.06µM and is less 
likely to have impacted significantly on mitochondrial function. Rhod2 and 
fluo3, two fluorescent Ca2+ indicators, were employed for measurements of 
mitochondrial and cytosolic Ca
2+
, respectively (Kao et al 1989, Minta et al 
1989). Rhod2 is a rhodamine-based dye and its ester forms are known to be 
cationic, resulting in potential-driven uptake into the mitochondria and its use 
as a selective indicator for mitochondrial calcium (Hoth et al 1997, Babcock et 
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al 1997). Pluronic acid was used to facilitate dye entry, eliminating any possible 
hydrolysis of the dyes by external esterases, and more efficient loading while 
maintaining cell integrity. 
2. Methodology 
One million cells were spun at 1000 x g for 10min and the pellet was 
resuspended in 0.5ml HBSS to which fluo3, rhod2 and pluronic acid were 
added to a final concentration of 5µg/ml, 5µg/ml and 0.025%, respectively.  
After incubating at room temperature for 30min, the cells were spun at 1000 x 
g for 10min, the supernatant removed, and the pellet resuspended in HBSS and 
incubated at room temperature for another 30min to remove any dye that was 
nonspecifically associated with the cell surface. The cells were again spun at 
1000 x g for 10min, the pellet resuspended in 2ml HBSS and the cell suspension 
loaded into a cuvette.  Measurements of resting fluorescence for fluo3 (fluo3 
Fo) and rhod 2 (rhod2 Fo) were made within 30mins with a fluorometer and 
corrected for protein level, as measured with a BCA kit. For rhod2, the 
fluorescence excitation and emission maxima were 552nm and 581nm, 
respectively. For fluo3, the fluorescence excitation and emission maxima were 
506nm and 526nm, respectively. After measuring the resting fluorescence, 
ionomycin was added (final concentration 0.06µM) for kinetic measurements 
(Fig 2.23). Upon ionomycin treatment, a significant rise was noted in both the 
cytosolic (expressed as the change in fluo3 fluorescence upon ionomycin 
treatment divided by the baseline fluo3 fluorescence: fluo3 ΔF/Fo) and 
mitochondrial (rhod2 ΔF/Fo) calcium (acute phase). This was followed by a 
more chronic phase of slow rise (chronic phase) and the rate of increase in the 
rhod2 fluorescence during this phase was divided by the rate of increase in the 
fluo3 fluorescence (Δrhod2 chr/ Δfluo3 chr). This observed preferential 
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coupling between increases in cytosolic and mitochondrial Ca
2+
 is one 
proposed mechanism to coordinate mitochondrial ATP production with cellular 
energy demand (Robb-Gaspers et al 1998). 
  
Fig 2.23: Example of resting fluorescence and kinetic fluorescence 
measurements upon ionomycin treatment for Participant B. Rhod2 is shown in 
red and fluo3 in blue. The y axis represents the intensity of fluorescence and 
the x axis the time (in sec). The purple arrow represents the timepoint when 
ionomycin was added. 1 represents the baseline (resting) fluorescence for 
fluo3 (fluo3 Fo), 2 represents the acute phase, where fluo3 staining rises 
suddenly upon ionomycin treatment (fluo3 ∆F/Fo) and 3 represents the 
chronic phase of slow rise in the fluo3 fluorescence. 
 
2.3.11 Enzyme-linked immunosorbent assay (ELISA) 
1. Basic principles  
The Enzyme-Linked Immunosorbent Assay (ELISA) is a commonly used 
technique for the determination of known analytes. The success of an ELISA 
1 
3 
2 
Ionomycin 
     Participant A                              Participant B                               Participant C 
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assay is dependent upon the underlying level of immunoreactivity of the 
capture and detection antibodies to the target analyte. The basic principles of 
ELISA are described in more detail in the legend of Fig 2.24 below.
  
  
Fig 2.24: The basic principles of ELISA. In Step 1, the capture antibody is applied 
to the well of a microtitre plate and binds to the plate via passive absorption. A 
blocking solution [typically milk protein (casein), BSA or fish gelatine] is also 
applied, which adheres to any vacant sites on the plastic surface of the well 
that are not occupied by capture antibodies, thereby minimising the effect of 
non-specific binding by other reagents to the plate surface during subsequent 
incubation steps. Excess blocking agent is removed, the plate is rinsed and the 
test sample is added. Wash steps are incorporated between all incubation 
steps to minimise the background signal due to non-specific binding. In Step 2, 
the target analyte in the test sample is bound by the capture antibody that is 
anchored to the plate. After the incubation step with the test sample, the plate 
is washed prior to the addition of the enzyme-linked detection antibody 
(commonly used enzymes include horseradish peroxidise, alkaline phosphatase 
or β-D-galactosidase) (Step 3). These enzymes are proteins that catalyse the 
  
157 
 
hydrolysis of a chromogenic substrate, such as 3, 3’, 5, 5’-tetramethylbenzidine 
(TMB), which undergoes a colourimetric change measurable using a 
spectrophotometric plate reader at specified wavelengths (Step 4). With the 
catalysis of the traditional chromogenic substrates, the reaction is terminated 
by the addition of a stop solution prior to measuring the absorbance of each of 
the wells of the microtitre plate (modified from Analytical Methods Committee 
Technical Briefings, No 45, 2010). 
 
2. Background and Methodology for mTOR ELISA 
The mammalian target of rapamycin (mTOR) is a highly conserved 
serine/threonine kinase that controls cell growth and metabolism in response 
to nutrients, growth factors, cellular energy and stress (Khalil et al 2012). Two 
structurally and functionally distinct multiprotein complexes are found: a) 
mTOR Complex 1 (mTORC1) is inhibited by rapamycin and mediates temporal 
control of cell growth by regulating translation, transcription, ribosome 
biogenesis, nutrient transport and autophagy, through the downstream targets 
4E-binding protein 1 (4E-BP1) and p70 S6 kinase (Fig 2.25); b) mTOR Complex 2 
(mTORC2) is rapamycin insensitive and mediates spatial control of cell growth 
by regulating the actin cytoskeleton. Such a physiological response is important 
for cell adaptation under stress and protection from death. 
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Fig 2.25: The mTOR pathway. Growth factor induced activation of 
phosphoinositide 3-kinase (PI3K) and protein kinase B (PKB or AKT) leads to 
increased activity of the mammalian target of rapamycin (mTOR). This 
subsequently leads to increased phosphorylation of the eIF4E binding protein-
1 (4EBP1) and activation of the p70 ribosomal S6 protein kinase (p70S6K), both 
of which are important steps in the stimulation of protein translation (Navé et 
al 1999). mTOR is also regulated upstream by PTEN (phosphatase and tensin 
homologue deleted on chromosome ten); TKR: tyrosine kinase receptor. 
As discussed in section 1.6.1, systemic mitochondrial dysfunction has been 
implicated as a potential susceptibility factor for glaucoma, given the role of 
increasing age as a major risk factor for glaucoma and the fact that ageing is 
well known to be associated with structural and functional changes to the 
mitochondria (Kong et al 2009, Yu-Wai-Man 2012, Lascaratos et al 2012). It is 
well established that upon stress, cells suppress the mTOR signalling in order 
to maintain energy homeostasis for survival. mTOR colocalises with the outer 
mitochondrial membrane (Desai et al 2002) and mTOR suppression has been 
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found to result in increased autophagy, reduced mitochondrial function 
(Ramanathan et al 2009) and decreased mitochondrial respiration (Schieke et 
al 2006). This direct effect of mTOR on mitochondrial function is thought to be 
mediated to a certain extent by its ability to form complexes with the 
mitochondrial outer membrane proteins Bcl-xl (B-cell lymphoma-extra large) 
and VDAC1 (voltage-dependent anion-selective channel protein 1) 
(Ramanathan et al 2009). Importantly, mTOR has also been shown to affect 
cellular metabolism by means of the transcriptional control of mitochondrial 
oxidative function through a YY1-PGC1α (yin-yang 1-peroxisome-proliferator-
activated receptor coactivator 1α) transcriptional complex (Cunningham et al 
2007). Based on this link between mTOR activity and mitochondrial function, 
the mTOR activity in the lymphocytes of our study participants was measured 
to explore the potential role of this kinase in mitochondrial dysfunction in 
glaucoma. mTOR is known to be phosphorylated at Ser2448 via the PI3 
(phosphoinositide 3)-kinase/Akt signaling pathway (Fig 2.25) (Navé et al 1999). 
The mTOR activity in these experiments was expressed as the ratio between 
phosphorylated (active) mTOR and total mTOR.  
In more detail, the PathScan Total mTOR and Phospho-mTOR (Ser2448) 
Sandwich ELISA kits were used to measure total and phospho-mTOR, 
respectively. Unlike previous experiments and in order to maintain the 
phospho-activity, peripheral blood mononuclear cells (PBMCs) isolated from 
our study participants were not incubated overnight. Immediately after 
isolation of the PBMCs, 1 million cells were spun at 1000 x g for 10min, washed 
in PBS and spun again using the same settings. The pellet was resuspended in 
100μl of lysis buffer provided with the kit. The lysate was then 
microcentrifuged at 15000 x g for 10 min at 4°C and the supernatant 
transferred to a new tube and stored at -80
o
C for future analysis. 100 µl of the 
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cell lysate were added into each well of a 96-well plate pre-coated with mTOR 
mouse antibody, sealed with tape and incubated at 4°C overnight. After 
washing twice with wash buffer supplied with the kit (200µl each time per 
well), 100 µl of mTOR rabbit antibody was added to each well to detect the 
captured mTOR protein. After a second incubation at 37°C for 1hr and repeat 
wash, 100 µl of anti-rabbit IgG, HRP-linked antibody was added to each well to 
recognise the bound detection antibody. The plate was again incubated at 
37°C for 30min, washed as previously and 100 µl of TMB substrate was added 
to each well, in order to develop the colour (blue). The plate was again 
incubated at 37°C for about 10min to reach the desired colour intensity and 
the reaction was terminated by the addition of an acidic STOP solution, which 
changed the solution colour from blue to yellow. The absorbance for the 
developed colour was proportional to the quantity of mTOR protein and a 
plate reader was used to read the 96-well plate at 450nm. 
 
3. Background and Methodology for 8OHdG ELISA 
For several decades 8-OH-deoxy-Guanosine (8OHdG) has been considered a 
pivotal indicator of oxidative stress and more specifically oxidative DNA 
damage (Ames et al 1991, Loft et al 1992). Among all purine and pyrimidine 
bases, guanine is the most prone to oxidation, upon which a hydroxyl group is 
added to the 8th position of the guanine molecule (Cadet et al 2000) to 
produce the oxidatively modified product 8OHdG (Fig 2.26). This DNA 
alteration can induce point mutations, such as G-C transversions, but also the 
formation of apurinic/apyrimidinic sites. Although specific repair pathways are 
recognised for these lesions (Floyd et al 1990), whenever these mechanisms 
are overwhelmed by excessive levels of 8OHdG, stable DNA alterations can 
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occur. Upon DNA repair, 8OHdG is known to be excreted in the urine and 
urinary 8OHdG is widely used as a biomarker of generalised cellular oxidative 
stress (Patel et al 2007). Elevated urinary 8OHdG has been found in patients 
with various types of cancer (Chiou et al 2003, Wu et al 2004), cardiovascular 
disease (Negishi et al 2001) and diabetes, while the level of urinary 8OHdG was 
also found to be correlated with the severity of diabetic nephropathy (Hinokio 
et al 2002). Increased 8OHdG has also been, interestingly, linked to ageing 
(Hamilton et al 2001) and neurodegeneration (De Flora et al 1996). Smoking 
has also been shown to increase the levels of 8OHdG in several studies (Pilger 
et al 2001, Pourcelot et al 1999, Howard et al 1998), although this was not 
repeatable in other studies (Musarrat et al 1996, Wu et al 2004).  
   
Fig 2.26: Chemical structure of 8OHdG and its analogues: (A) structure of an 
unmodified guanine base; (B) structure of an oxidised base; (C) analogue of 
8OHdG derived from RNA, called 8OHG; (D) structure of 8OHdG derived from 
DNA (Wu et al 2004). 
In 2003, elevated 8OHdG was noted for the first time in the TM of 42 glaucoma 
patients (angle recession, neovascular, juvenile, pseudoexfoliative syndrome 
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and POAG), as compared to 45 age-similar controls (Izzotti et al 2003). 
Interestingly, oxidative DNA damage among these patients correlated 
significantly with IOP fluctuation and maximum IOP values, as well as with VF 
damage in the POAG subgroup, suggesting a role for localised oxidative stress 
in glaucoma pathogenesis. 8OHdG levels were also significantly higher in the 
TM of patients with the GSTM1 gene deletion, which has been associated with 
an increased risk of cancer and atherosclerosis. The finding of increased 
oxidative DNA damage in the human TM in glaucoma was later confirmed by 
another study from the same group focusing on POAG patients, where 
elevated 8OHdG (5-fold) was found in 17 glaucoma patients, as compared to 
21 controls (Sacca et al 2005). In another study from Iran, the aqueous levels of 
8OHdG were found to be significantly (2.1 fold) higher in 28 glaucoma patients 
(15 with POAG and 13 with pseudoexfoliative glaucoma) as compared to 27 
age-similar cataract patients (p=0.002), while the serum levels of 8OHdG in the 
glaucoma group were only marginally higher (p=0.046) than in the cataract 
group (Sorkhabi et al 2011). Also, recently, urinary 8OHdG was reported to be 
reduced in 43 NTG patients as compared to 40 healthy controls, indicating, 
according to the authors, a compensatory response to increased systemic 
oxidative stress in glaucoma (Yuki et al 2010). The measurement of urinary 
8OHdG in this study was employed as an additional measure of generalised 
oxidative stress in our cohort and was performed with the use of a previously 
described competitive ELISA kit (Subash et al 2010). 
Similarly to the ELISA steps presented above for mTOR, 50μl of each sample 
diluted to 1:80 and 1:320 were added into an 8OHdG/BSA conjugate coated 
96-well plate. After a 10min incubation, 50μl of the anti-8OHdG monoclonal 
antibody were added and incubated for 1hr. After washing, 100μl of the HRP 
conjugated secondary antibody were loaded and the plate was incubated for 
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another hour. After washing, 100µl of substrate solution were added to 
develop the colour and after about 10min the reaction was terminated by 
adding 100μl of stop solution. The absorbance was read on a plate reader at 
450nm. A first morning mid-stream urine sample was collected from each 
participant and the level of 8OHdG was corrected for urine creatinine and 
expressed in ng/mg creatinine. Each sample was assayed in duplicate and the 
quantity of 8OHdG in each sample was determined by comparing its 
absorbance with that of an 8OHdG standard curve. The detection range of the 
ELISA assay was 0 to 20 ng/ml and all of the 8OHdG measurements were 
performed within 3 months of urine collection. 
 
2.3.12 Other laboratory tests (vitamins, homocysteine, urate) 
The following laboratory tests were performed by TDL (The Doctors’ 
Laboratory), Whitfield Street, London W1T 4EU: plasma homocysteine, urate, 
serum folate, red blood cell (RBC) folate, vitamin B12 (cobalamin), vitamin A 
(retinol), vitamin B6 (pyridoxine), vitamin C (ascorbate) and urine creatinine. 
Peripheral blood was collected at Moorfields Eye Hospital from the 
mitochondrial study participants and sent to TDL for further analyses. EDTA 
blood in a purple top tube was collected for the homocysteine, RBC folate and 
B6 measurements, while for the remaining measurements blood was collected 
in serum separator tubes (SSTs - yellow top). For vitamin measurements, the 
samples were protected from light by wrapping the tubes in aluminium foil.  
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2.4 Statistical analysis 
In the UKGTS, the sample size estimation, randomisation, and study design 
were based on the patient as the unit of observation; the event time to 
deterioration was defined by the first deterioration in either eye. For eye-
based analyses, two approaches were taken: (1) worse eye analysis (Kamal et 
al 2003) and (2) analysis of both eyes. Except for patients for whom no data 
were available, analyses were carried out on all patients in the treatment 
group to which they were randomised, using all the available data up to the 
point that they withdrew, to retain the validity of the randomisation process. 
For the analysis of the UKGTS baseline characteristics, summary measures for 
continuous variables have been presented as mean and standard deviation 
(SD) for normally distributed measures and as median and interquartile range 
(IQR) for data that are not normally distributed. Frequencies (n) and 
percentages (%) were used for categorical variables. A two sample t-test was 
used to compare the mean values for continuous variable and a chi-square test 
for categorical variables. The STATA software (version 11, StataCorp LP) was 
employed for data analysis by the trial statisticians.  
The primary UKGTS analysis concerned the incidence of primary deterioration 
events in latanoprost-treated eyes versus placebo-treated eyes over 24 
months after entry to the trial. Survival analysis, conducted by a statistician, 
compared the differences in time from baseline to the event of confirmed VF 
deterioration between treatment groups and a Kaplan-Meier survival curve 
was constructed. Treatment effect was estimated as a hazard ratio with 95% 
confidence intervals computed by a Cox proportional hazards model. The 
survival analysis took into account subjects who were observed only for part of 
the trial period. A comparison of the proportion of subjects with deterioration 
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events in the treatment groups was made using univariate tests. In a clinical 
trial over a 2-year time frame, patients inevitably were lost to follow-up and 
reasons for loss to follow-up were investigated. Summary measures for 
continuous normally distributed outcome measures were differences in means 
and 95% confidence intervals for differences in means. Nonparametric 
equivalents were used for non-normally distributed outcome measures. For 
categorical variables, the Pearson’s chi-square test or Fisher exact test was 
used.  
For the IOP-related UKGTS analysis in section 3.5, the Pearson’s correlation 
coefficient, also known as Pearson's R, was used as a measure of the strength 
and direction of the linear relationship between the median IOP and MD slope. 
The Akaike Information Criterion (AIC) value was used by the study statistician 
to compare models. The AIC, originally developed by Hirotugu Akaike in 1974 
(Akaike 1974), is considered a measure of the relative goodness of fit of a 
statistical model, and is grounded in the concept of information entropy, in 
effect offering a relative measure of the information lost when a given model is 
used to describe reality. Therefore, the AIC values provide a means for model 
selection and models with smaller AIC values are preferred. However, the AIC 
‘raw’ values make it difficult to unambiguously interpret the observed AIC 
differences in terms of a continuous measure, such as probability. Therefore, 
Akaike weights are also presented for each model, which can be directly 
interpreted as the probabilities of each model being the most likely model to 
describe the relationship (Wagenmakers et al 2004). In this case, the models 
with higher Akaike weights are preferred.   
In chapter 4, the Wilcoxon signed rank test, a non-parametric counterpart of 
paired t-test, was used by the candidate for comparisons between two groups. 
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For comparisons between all three groups (control, NTG, OHT) in the 
mitochondrial pilot study, the Kruskal Wallis test was used as the equivalent of 
one-way non-parametric ANOVA. Clinical data are presented as mean ± 
standard deviation (SD) for normally distributed measures and as median ± 
interquartile range (IQR) for data that are not normally distributed. 
Experimental data are presented as median ± IQR. For the western blotting 
data the densitometric reading of the protein of interest was expressed as a 
percentage of the control gene product (b-actin). Box plots for the 
mitochondrial pilot study were prepared by the candidate using the SPSS 20.0 
Inc software (IBM, Somner, NY). In all experiments a p-value of <0.05 was 
generally considered statistically significant. 
 
2.5 Ethics approval 
Consent was obtained from all the participants for the mitochondrial pilot 
study and the relevant Ethics Committee approval (REC Ref: 11/H0715/10) was 
granted. For the UKGTS, ethics committee approval was granted by the 
Moorfields and Whittington Research Ethics Committee on June 1, 2006 (REC 
Ref: 09/H0721/56) and an independent data and safety monitoring committee 
was appointed by the steering committee. Both studies adhered to the tenets 
of the Declaration of Helsinki. 
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Chapter 3: Intraocular pressure as a risk factor for glaucoma progression in 
the UKGTS 
3.1 Introduction 
In 1993, Rossetti et al, in a systematic review of the literature, identified the 
paucity of evidence for the medical management of OAG and OHT (Rossetti et 
al 1993); their report stimulated the initiation of a number of treatment trials. 
A more recent Cochrane systematic review of medical interventions for OAG 
and OHT found evidence to support the use of IOP-lowering treatment to 
prevent the onset of VF loss in patients with OHT (Vass et al 2007), but 
identified no randomised, placebo-controlled trials assessing VF preservation 
in OAG. The authors concluded: “There is especially no evidence of a protective 
effect of prostaglandins. Further efforts should be directed to proving visual 
field preservation for these drugs.” The UKGTS is the first randomised, double-
masked, placebo controlled trial for the medical treatment of OAG and 
assesses the impact of treatment with prostaglandin analogues on VF 
preservation. 
To date, medical treatment trials in OAG have compared a treatment with 
either no treatment or an active control, but not with a placebo (Vass et al 
2007). Randomised, double masked, placebo controlled trials provide the 
highest level of evidence to guide clinical practice. Unmasked studies tend to 
be biased towards beneficial effects only if the outcomes are subjective and 
especially if there is inadequate allocation concealment. There are only 2 
published trials comparing medical IOP-lowering treatment of OAG with no 
treatment (Holmin et al 1988, Leske et al 1999). These studies were unmasked 
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and had an objective primary outcome measure (computerised perimetry). The 
study by Holmin et al was very small (only 16 patients enrolled). To date, the 
best evidence for the beneficial effect of IOP-lowering treatment in OAG with 
established VF loss comes from the EMGT (Leske et al 1999), where patients 
with early OAG were randomised to argon laser trabeculoplasty plus betaxolol 
(n=129) or no immediate treatment (n=126) and were examined every 3 
months for a median of 6 years (Heijl et al 2002). 
With conventional trial design, the typical observation period for therapeutic 
trials in OHT and OAG with VF deterioration as an outcome has been 5 years or 
longer (Heijl et al 2002, CNTGS 1998, Kass et al 2002, Musch et al 1999, Kamal 
et al 2003). Long observation periods increase the cost of clinical trials, delay 
evidence in establishing efficacy for new treatments and considerably increase 
the cost for development of new therapies. There is, therefore, a great need 
for trial designs that reduce the observation period required. The UKGTS has 
two principal novel design features that may make much shorter observation 
periods possible. The first modifies the frequency and interval of VF tests to 
maximise power to measure the velocity of deterioration; the justification for 
measuring deterioration velocity is that OAG is a chronic progressive disease, 
so that more rapid deterioration infers greater vision loss over longer 
observation periods. The second includes quantitative imaging of the ONH and 
RNFL structure. To date, all clinical trials in OAG with VF deterioration as an 
outcome have used a VF change event criterion as an end point (CNTGS 1998, 
Musch et al 1999, AGIS 1994, Leske at al 2003, Krupin et al 2005); the velocity 
of VF deterioration itself has yet to be used as a trial outcome. The velocity of 
deterioration has been used as an outcome in clinical trials of other chronic 
progressive conditions seeking to identify disease modifying effects of therapy 
(Cheah et al 2011). The UKGTS study design allows a comparison of study 
  
170 
 
power when data analysis is based on survival analysis and on deterioration 
velocity. 
OAG deterioration is characterised by changes in visual function and in the 
structure of the ONH and RNFL (Read et al 1974). Visual function outcomes 
generally are regarded to be more relevant to the patient. Some clinical trials 
have included both vision function and ONH structure end points (Kass et al 
2002, Read et al 1974). However, agreement between structural and functional 
measurements of deterioration is poor over short periods (relative to the time 
course of the disease) (Artes et al 2005, Strouthidis et al 2006), so the 
application of structure end points in a clinical trial of therapy makes it difficult 
to evaluate the true effect of treatment on vision function. Over short periods, 
even clinically significant vision function deterioration may be masked by 
measurement imprecision, resulting in failure to identify the deterioration. 
Provided structural and functional parameters are sufficiently well correlated 
(and cross-sectional studies across the disease spectrum suggest this is the 
case) (Bartz-Schmidt et al 1999, Schlottmann et al 2004), analysis of structural 
parameter outcomes in the same model as outcome measurements of visual 
function may increase the power of a clinical trial to identify treatment effects 
in the preferred domain (visual function). Modeling of joint outcomes has 
shown potential in other diseases (Wilson et al 2000). In the UKGTS, the trial 
end point was VF deterioration, but frequent quantitative imaging was 
undertaken, for the first time in a medical treatment trial for OAG, to permit 
analysis of joint outcomes. 
Apart from establishing the VF-preserving effect of a prostaglandin analogue, 
the UKGTS also aimed to quantify important risk factors for OAG deterioration. 
As discussed in more detail in section 1.5, known risk factors for deterioration 
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are higher IOP, greater subject age, lower ocular perfusion pressure, presence 
of pseudoexfoliation, optic disc hemorrhages and thinner CCT. Known risk 
factors have low power to predict OAG deterioration and patients deteriorate 
at varying rates at all levels of IOP, suggesting that factors other than IOP 
influence susceptibility for OAG deterioration. In the UKGTS, new potential risk 
factors are investigated and existing risk factors are measured with greater 
precision than previously. In the EMGT, no deterioration was detected in 38% 
of untreated subjects over a follow-up period of 6 years (Heijl et al 2002), and 
in the CNTGS 50% of untreated normal-tension glaucoma patients showed no 
deterioration over 5 years (CNTGS 1998). A secondary goal of the UKGTS was 
to evaluate whether risk profiling and stratifying patients is able to identify 
which patients do not need immediate treatment and which patients may 
benefit from more vigorous treatment. 
 
3.2 The UKGTS design and methodology 
Study Design 
The UKGTS was a multicenter, randomised, double-masked, placebo-controlled 
medical treatment trial for OAG. Eligible patients were randomised in a 1:1 
ratio to receive either latanoprost 0.005% or placebo once in the evening in 
both eyes for 24 months or until reaching an end point. After 24 months, 
subjects who had not reached an end point were invited to continue for a 
further 24 months either with latanoprost (open-label) or without treatment 
(no drops) to provide greater power for risk factor analyses (the UK Glaucoma 
Risk Factor Study). 
Objectives 
  
172 
 
Primary: The primary objective was to test the hypothesis that medical 
treatment with a topical prostaglandin analogue reduces the incidence of VF 
deterioration events compared with placebo by 50% over a 2-year observation 
period.  
Secondary: Secondary objectives were: (1) to evaluate the velocity of 
deterioration as a trial outcome, (2) to evaluate quantitative imaging 
measurements as additional trial outcomes, (3) to identify risk factors for OAG 
deterioration, (4) to establish whether initial observation, rather than 
immediate treatment, is feasible for selected patients, and (5) to evaluate the 
association of VF loss with measures of quality of life (QoL). 
Eligibility Criteria 
Eligibility criteria were modeled on those for the EMGT. OAG was defined as 
glaucomatous VF defects (defined below) in at least 1 eye with corresponding 
damage to the ONH (cup-to-disc ratio of ≥0.7, focal narrowing of the neural 
rim, or both), with an open angle on gonioscopy and the absence of retinal or 
neurologic condition that could account for VF loss. A glaucomatous VF defect, 
for trial inclusion, was defined as a reproducible (in at least 2 consecutive 
reliable post screening VFs) reduction in sensitivity at 2 or more contiguous 
points with P<0.01 loss or more, 3 or more contiguous points with P<0.05 loss 
or more, or a 10dB difference across the nasal horisontal midline at 2 or more 
adjacent points in the total deviation plot (Greaney et al 2002). 
Inclusion Criteria 
Inclusion criteria were the following: newly detected, previously untreated 
OAG (including primary OAG, NTG and pseudoexfoliation glaucoma) in either 
eye; age older than 18 years; Snellen visual acuity of 20/40 or better; VF mean 
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deviation (MD; location-weighted mean difference from average age-corrected 
VF sensitivity) of 2 post-screening VFs differing by no more than 3 dB, for an 
MD of better than -6.0 dB, or by no more than 4 dB, for an MD worse than -6.0 
dB; and the ability to give informed consent and to attend for the duration of 
the study. 
Exclusion Criteria 
Exclusion criteria were the following: moderately advanced VF loss (MD worse 
than -10 dB in the better eye or worse than -16 dB in the other eye) or a threat 
to fixation (a paracentral point with sensitivity of <10 dB in both the upper and 
lower hemifields) in either eye; IOP of >35mmHg on 2 consecutive occasions in 
either eye or mean (2 visits) baseline IOP of ≥30mmHg; inability to perform 
reliable VF testing; poor-quality Heidelberg Retina Tomograph (HRT) images 
(see section 2.2.12), cataractous lens gradings of more than N1, C2, or P1 
according to the Lens Opacities Classification System III grading; previous 
intraocular surgery (other than uncomplicated cataract extraction more than 1 
year previously); and diabetic retinopathy. 
Recruitment  
Consecutive potentially eligible patients were identified at the new patient 
clinics of participating centers (Table 3.1). Potentially eligible subjects attended 
a training visit where VF tests were repeated twice and ONH imaging was 
performed; the results of these tests were assessed for eligibility at the 
accredited Moorfields Eye Hospital Reading Centre. After eligibility was 
confirmed and informed consent was obtained, a study identification number 
was assigned by the Moorfields Clinical Trials Unit. Patients were enrolled 
between 1 December 2006 and 16 March 2010. 
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Participating Centres Local Principal 
Investigator 
Screening start 
date 
Screening end 
date 
Moorfields Eye Hospital Professor DF Garway-
Heath 
December 2006 March 2010 
Aberdeen Royal 
Infirmary 
Professor A Azuara-
Blanco 
March 2007 March 2010 
Addenbrookes Hospital Professor K Martin December 2008 March 2010 
Birmingham Heartlands 
and Solihull 
Mr I Cunliffe 
Mr A Negi 
May 2007 March 2010 
Bristol Eye Hospital Mr J Diamond 
Dr P Spry 
November 2007 March 2010 
Cheltenham General 
Hospital 
Professor A McNaught December 2007 March 2010 
Hinchingbrooke Hospital Professor R Bourne April 2007 March 2010 
Huddersfield/Halifax Mr N Anand February 2009 March 2010 
Norfolk and Norwich 
University Hospital 
Mr DC Broadway February 2007 March 2010 
Sunderland Eye 
Infirmary 
Mr S Fraser March 2007 March 2010 
West of England Eye 
Unit, Exeter 
Mr D Byles January 2009 March 2010 
Table 3.1: The UKGTS participating centres. 
Randomisation 
A randomisation schedule was drawn up by the statisticians in the R&D 
Department at Moorfields Eye Hospital using randomised permuted blocks of 
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varying centres with stratification by center. The randomisation schedule then 
was sent to the Pharmaceutical Manufacturing Unit for labeling of treatments. 
The unit of randomisation was the patient, with both eyes allocated to 
receiving treatment.  
Allocation Concealment 
Pfizer provided latanoprost and placebo drops in identical containers with tear-
off labels identifying the container contents; the tear-off labels were removed 
by the Moorfields Pharmaceutical Manufacturing Unit and were replaced with 
the study identification number (according to the randomisation schedule) 
before packaging. The randomisation codes were held securely by the 
Moorfields Pharmaceutical Manufacturing Unit and Moorfields R&D 
Department and were not available to study personnel. In an attempt to 
maintain masking, investigators were encouraged not to tell patients their IOP 
measurements. On exiting the study (at deterioration or at 24 months), 
patients were asked to guess whether they had been taking the active or 
placebo drops.  
Formulation 
The active formulation was as follows per 1 ml: latanoprost, 50µg; 
benzalkonium chloride 0.20mg; sodium chloride; sodium dihydrogen 
phosphate monohydrate; disodium phosphate anhydrous; and water for 
injection. The placebo formulation was as follows per 1 ml: benzalkonium 
chloride 0.20mg; sodium chloride; sodium dihydrogen phosphate 
monohydrate; disodium phosphate anhydrous; hydrochloric acid; sodium 
hydroxide; and water for injection. 
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Adherence 
Trial participants were asked at each visit whether they had taken the study 
drops the previous evening and how frequently they thought that they had 
forgotten their drops.  
Blinding 
This was a double-masked study. In an attempt to maintain masking, 
investigators were encouraged not to tell patients their IOP measurements. 
Adverse Events 
The trial manager monitored adverse events and reported them immediately 
to the Data and Safety Monitoring Committee. Serious adverse events were 
reported to the Medicines and Healthcare Products Regulatory Agency. 
Quality Assurance 
Eligibility and deterioration status were assessed independently at the 
Moorfields Eye Hospital Reading Centre. Data collection was standardised and 
procedures for all investigations were set out in the trial Manual of Procedures 
and the Manual of Standard Operating Procedures. Technicians and clinicians 
performing the investigations underwent training and certification before 
initiation of recruitment. Case report forms were collected at the Data Centre 
and primary data entry into the electronic database was performed by the trial 
manager; primary outcomes were double-data entered by a data entry clerk. 
The trial manager monitored adherence to trial protocols, and completeness 
and validity of data and contacted sites, to recover missing data. 
Participant flow 
A diagram describing participant flow can be found below (Fig 3.1). 
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UKGTS Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Investigations 
Fig 3.1: The UKGTS participant flow diagram. *Reasons for loss to follow-up are 
presented in table 3.8. 
 
 
Analysed (n=242) 
♦ Excluded from analysis (no study visits) 
(n=16) 
Lost to follow-up (n=61)* 
Allocated to Group B (n=258) 
♦ Received allocated intervention (n=258) 
♦ Did not receive allocated intervention (n=0) 
Excluded (n=261) as not meeting 
inclusion criteria or declined to 
participate  
Assessed for eligibility (n=777) 
Allocation 
Analysis 
Follow-Up 
Randomised (n=516) 
Enrollment 
Allocated to Group A (n=258) 
♦ Received allocated intervention (n=258) 
♦ Did not receive allocated intervention (n=0) 
Lost to follow-up (n=66)* 
Analysed (n=242) 
♦ Excluded from analysis (no study visits) 
(n=16) 
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The UKGTS schedule of investigations is given in Table 3.2 below. 
Table 3.2: The UKGTS schedule of investigations; GAT: Goldmann Applanation 
Tonometry; LOCS: Lens Opacities Classification System; DCT: Dynamic Contour 
Tonometre; IOP: intraocular pressure; ORA: Ocular Response Analyzer; CCT: 
central corneal thickness; HRT: Heidelberg Retina Tomography; OCT: Optical 
Coherence Tomography; GDxECC: scanning laser polarimetry enhanced corneal 
compensation; BP: blood pressure. 
 Training 
Visit 0 
Week 
-8 
Visit 
1 
Month 
0 
Visit 
2 
Month 
2 
Visit 
3 
Month 
4 
Visit 
4 
Month 
7 
Visit 
5 
Month 
10 
Visit 
6 
Month 
13 
Visit 
7 
Month 
16 
Visit 
8a 
Month 
18 
Visit 
8b 
Month 
18 
Visit 
9 
Month 
20 
Visit 
10 
Month 
22 
Visit 
11 
Month 
24 
Phenotyping              
Screening              
Consent 
Randomisation 
X             
Visual Fields X2 X2 X2 X X X X X2 X2 X2 X X X2 
Visual Acuity X X X X X X X X X X X X X 
Standard 
clinical  
exam,  
including GAT 
X X X X X X X X X X X X X 
Questionnaire  
(visual 
function 
health status) 
 X       X    X 
LOCS III lens 
grading 
X        X    X 
Pascal DCT  X X X X X X X X X X X X 
IOP: ORA  X X X X X X X X X X X X 
Biometry, inc 
CCT 
 X            
HRT X X3 X2 X X X X X2 X3 X2 X X X 
Disc 
photography 
 X X X X X X X X X X X X 
GDxECC  X3 X2 X X X X X2 X3 X2 X X X 
OCT  X5 X3 X3 X3 X3 X3 X3 X5 X3 X3 X3 X5 
Phasing  X       X    X 
24-hour  BP     X          
Phlebotomy 
for DNA, B12, 
folate, HbA1c 
  X           
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Eleven visits over 24 months were planned, with VF and imaging tests 
clustered at the beginning and end of the observation period, as statistical 
modelling demonstrates that clustering increases the precision of estimates of 
the velocity of deterioration (Crabb et al 2009). Additional tests were clustered 
at the 18-month time point to assess whether trial durations could be reduced 
further. The maximum interval between visits was 3 months. 
Additional Investigations for Secondary Analyses 
Blood tests related to cardiovascular and neurodegenerative risk: Blood 
samples to assess various lipid (total cholesterol, low-density lipoprotein 
cholesterol, high-density lipoprotein cholesterol and triglycerides) and non-
lipid (including fasting glucose, glycosylated hemoglobin, vitamin B12, red cell 
folate, homocysteine, high-sensitivity C-reactive protein and thyroid function) 
risk factors were obtained (Herrmann et al 2011). The rationale for these 
investigations is that glaucoma, as a neurodegenerative condition, may share 
risk factors for cognitive decline of degenerative or vascular origin (Solfrizzi et 
al 2006). Additional samples were taken for future DNA and proteomics 
analyses. 
Cardiovascular history and examination: A history was taken to elicit evidence 
for hypertension, stroke, generalised arteriosclerosis, smoking, alcohol intake, 
migraine, Raynaud’s phenomenon, diabetes mellitus, use of BP medications 
and statins. In addition to BP measurements, height, weight and waist 
circumference measurements were obtained. 
End Points 
End points included (1) visual field deterioration (therapeutic end point); (2) 
IOP of >35mmHg on 2 successive occasions (safety end point); and (3) decline 
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of best-corrected visual acuity to less than 20/60 (non-glaucomatous end 
point). On the basis of fundus photographs and the pattern of VF loss, 2 
independent glaucoma fellowship-trained ophthalmologists confirmed that the 
VF deterioration was consistent with OAG, rather than a non-glaucomatous 
process such as vein occlusion, stroke or age-related macular degeneration. 
Outcome Measures 
The primary outcome was time to confirmed VF deterioration. VF deterioration 
was based on the GPA pattern deviation maps and defined as, in either eye, at 
least 3 test points showing significant negative change compared with baseline 
(P<0.05), at the same location in 2 consecutive VFs (tentative deterioration) 
and deterioration according to the same criterion present in the next 2 VFs 
(confirmed deterioration). In more detail, if tentative deterioration was 
identified, confirmation tests were performed within 1 month and, if the same 
criteria were satisfied in these confirmation tests, then the patient was 
considered to have progressed. An exit visit was scheduled within 1 month of 
the confirmation visit. Two VFs were performed at this visit and then 
treatment started (or augmented). The tests after the confirmation tests were 
included in the analysis of the velocity of VF deterioration, but not in the 
analysis of incident deterioration.  
The secondary outcomes were velocity of uniocular and binocular VF loss, rate 
of confocal scanning laser ophthalmoscopy neural rim area loss, rate of RNFL 
loss (OCT and scanning laser polarimetry) and change in IOP from baseline at 4 
and 24 months (or time of deterioration). 
The outcomes for the substudy investigations were (1) the identification of risk 
factors for glaucomatous deterioration, including IOP level, IOP fluctuation, 
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age, race, degree of glaucoma damage at baseline (MD in dB), and other ocular 
and systemic variables, and (2) the association of visual function with measures 
of QoL. 
Trial Size 
The trial sample size was based on the outcome of the EMGT (Heijl et al 2002): 
Deterioration rates at 24 months were 24% in the untreated group and 11% in 
the treated group, and IOP reduction was 25% in the treated group. 
Latanoprost typically achieves a 20% to 30% IOP reduction, depending on the 
baseline IOP. Based on 90% power (1–β) at a 2-sided error α=0.05 to detect the 
difference between 24% and 11% in incident deterioration over a 24-month 
follow-up, 193 patients were needed in each arm (386 total). Allowing for a 
25% attrition over the study period, 516 patients needed to be recruited to the 
study. 
Protocol Amendments 
Trial size: At the initiation of the trial, the sample size was determined for an 
outcome at 18 months, based on the EMGT (15% vs. 7%, 85% power, 2-sided 
error α=0.05, and an attrition rate of 15%). Because recruitment was slower 
than expected, the sample size was recalculated in October 2008 for an 
outcome at 24 months (24% vs. 11%, 90% power, 2-sided error α=0.05, and an 
attrition rate of 15%), and additional study sites were added. The sample size 
was revised further in June 2009, because of a greater than anticipated 
attrition rate. 
Primary outcome: The trial size was determined from the results of the EMGT. 
The primary outcome of the EMGT was based on the Humphrey Field Analyzer 
GPA pattern deviation maps and defined as at least 3 test points showing 
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significant negative change (P<0.05), as compared with baseline, at the same 
locations in 3 consecutive VFs in the 30-2 VF. Because the UKGTS used 24-2 VF 
testing, the EMGT criterion is more stringent than intended and would have 
resulted in fewer end points than anticipated for the sample size calculation. A 
less stringent end point (defined above) was adopted and used throughout the 
study. 
Primary analysis: After the publication of the National Institute for Clinical 
Excellence Guidelines, “Diagnosis and Management of Chronic Open Angle 
Glaucoma and Ocular Hypertension,” the independent Data and Safety 
Monitoring Committee requested an interim analysis in January 2011 based on 
time to event, rather than difference in proportions with an event in either 
arm (the analysis on which the trial was powered). The Steering Committee 
therefore formally adopted time to event for the primary analysis, and 
difference in proportions for a secondary analysis, in the Statistical Analysis 
Plan. 
Trial Sponsor and Funding 
The trial sponsor was Moorfields Eye Hospital NHS Foundation Trust. The 
principal funding was through an unrestricted Investigator-Initiated Research 
grant from Pfizer Inc, with supplementary funding from the UK’s National 
Institute for Health Research Biomedical Research Centre at Moorfields Eye 
Hospital and UCL Institute of Ophthalmology. Carl Zeiss Meditec provided 6 
prototype GDx Enhanced Corneal Compensation scanning laser polarimetry 
devices and 4 Stratus OCT devices, Heidelberg Engineering provided 3 HRTs, 
and OptoVue provided 2 RTVue OCTs for the duration of the study. The 
funding organisations had no role in the design or conduct of this research. 
Trial registration no: ISRCTN96423140. 
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Trial Organisation 
The Trial Steering Committee monitored and supervised the trial and 
commented on any proposed major protocol amendments. The study was 
coordinated by the clinical trials manager in the Clinical Trials Unit at 
Moorfields Eye Hospital. The trials manager monitored recruitment, data 
completeness and quality, study end points, and adverse events and produced 
monthly trial progress reports for the Data and Safety Monitoring Committees. 
The Data Centre is located in the Glaucoma Research Unit, Moorfields Eye 
Hospital. The Visual Fields Reading Centre is located at the Reading Centre, 
Moorfields Eye Hospital. Operational data and safety monitoring was 
undertaken by the Moorfields Eye Hospital Research Governance Committee. 
 
3.3 The UKGTS baseline data 
Introduction  
The purpose of this section is to report and discuss the baseline characteristics 
of the UKGTS cohort. In the present study, baseline characteristics were 
evaluated by patient (Tables 3.4 and 3.5) and by eye (Tables 3.6 and 3.7). For 
eye-based baseline data, two approaches were taken: 1) analysis of all eligible 
eyes (Table 3.6) and 2) ‘worse’ eye analysis (Table 3.7) to compare the baseline 
characteristics between the worse and better MD eyes. 
Baseline IOP data represent the mean of two pre-allocation diastolic 
measurements by GAT. A third measurement was obtained, if the difference 
between the first two was more than 1 mmHg. For the baseline VF data, the 
mean of the two baseline (post-allocation) VFs performed at Visit 1 was used, 
while for the 32 patients who failed to attend Visit 1 the mean of the two 
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screening VFs is presented. Where the Humphrey Field Analyzer (HFA) 
software excluded a baseline VF, due to learning effects or high false positive 
rates, the mean of the baseline VFs selected by the HFA software are 
presented. The baseline spherical equivalent (SE) calculation (algebraic sum of 
the value of the sphere and half of the value of the cylinder) was based on the 
refractive error recorded in the case report form from either an autorefractor 
or from spectacle focimetry. Where neither of these was recorded, the trial 
lens correction used to perform the VFs was used to estimate the SE in 86 
eligible eyes, based on the age of the patient.  
Source of referrals 
The main source of referrals in the UKGTS was optometrists (88%), while only a 
small percentage of patients were referred from their general practitioner (GP) 
(3%) or through the hospital (8%) (Table 3.3). 
Referral Source Patients Participated  n (%) 
GP 
Hospital 
Optometrist 
Unknown 
15 (3%) 
43 (8%) 
454 (88%) 
4 (1%) 
Table 3.3: Source of referral across all UKGTS sites. 
Participant flow 
Out of 777 subjects assessed for eligibility, 261 were excluded as not meeting 
the inclusion criteria or declined to participate (see Fig 3.1 above); 66.4% of 
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the patients screened took part in the UKGTS.  The 516 eligible patients were 
randomised to latanoprost or placebo. 
 
Baseline patient characteristics (Tables 3.4 and 3.5) 
  (n=516) 
n (%) Mean ± SD 
Centre:   
MEH 91 (17.6%)  
ARI 42 (8.1%)  
NNUH 83 (16.1%)  
BHS 74 (14.4%)  
CGH 24 (4.7%)  
BEH 26 (5%)  
SEI 32 (6.2%)  
HH 109 (21.1%)  
AH 21 (4.1%)  
WEEU* 
H&H 
2 (0.4%) 
12 (2.3%) 
 
Family history of glaucoma:   
None 348 (67.4%)  
1st–degree relative 
Other family history 
Unknown 
164 (31.8%) 
2 (0.4%) 
2 (0.4%) 
 
Age (years):  66 ± 11 
20-29 2 (0.4%)  
30-39 4 (0.8%)  
40-49 40 (7.8%)  
50-59 97 (18.8%)  
60-69 181 (35%)  
70-79 
≥80 
162 (31.4%) 
30 (5.8%) 
 
Gender:   
Female 243 (47.1%)  
Male 273 (52.9%)  
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Education achieved: 
Up to age 16 
Up to age 18 
Apprenticeship/certificate/diploma 
Degree 
Unknown 
  
244 (47.3%)  
33 (6.4%) 
137 (26.6%) 
96 (18.6%) 
6 (1.1%) 
 
Ethnicity:   
White 465 (90.1%)  
Black 27 (5.2%)  
Asian 16 (3.1%)  
Other 
Unknown 
3 (0.6%) 
5 (1%) 
 
History of:   
Blood loss 35 (6.8%)  
 
Myocardial infarction 
 
28 (5.4%)  
Obstructive pulmonary disease 31 (6%)  
 
Diabetes mellitus 
 
Concomitant neurological disease 
(Parkinson’s, Alzheimer’s, multiple sclerosis, 
deafness)   
54 (10.5%) 
 
 
65 (12.6%) 
 
Medication use:   
Antihypertensives 207 (40.1%)  
Corticosteroids 
Statins 
45 (8.7%) 
140 (27.1%) 
 
Other (insulin, oestrogen etc.) 304 (58.9%)  
Table 3.4: Baseline clinical characteristics of all the randomised UKGTS patients 
(n=516). (MEH: Moorfields Eye Hospital, ARI: Aberdeen Royal Infirmary, NNUH: 
Norfolk and Norwich University Hospital, BHS: Birmingham Heartlands and 
Solihull, CGH: Cheltenham General Hospital, BEH: Bristol Eye Hospital, SEI: 
Sunderland Eye Infirmary, HH: Hinchingbrooke Hospital, AH: Addenbrookes 
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Hospital, WEEH: West of England Eye Unit, H&H: Huddersfield/Halifax) *two 
patients were recruited at WEEH and they were followed up for only two visits. 
The eleven initial participating centres across the UK with the corresponding 
patient cohorts are presented in Table 3.4. Almost 70% of the participants 
were recruited and followed up in one of the following four centres: 
Moorfields Eye Hospital, Norfolk and Norwich University Hospital, Birmingham 
Heartlands and Solihull Hospital, and Hinchingbrooke Hospital.  
The 516 participants had a mean (±SD) age of 66±11 years. The age distribution 
of all randomised patients at baseline is shown in Fig 3.2.  
 
Fig 3.2: Age distribution of patients (n=516) at baseline. 
There were slightly more male patients in our cohort (52.9%). Almost a third 
(32.2%) had a family history of glaucoma.  The vast majority in our cohort were 
white (90.1%).  The health status of the participants was generally good; 28 
(5.4%) had a history of myocardial infarction, 54 (10.5%) of diabetes mellitus; 
31 (6%) obstructive pulmonary disease and 65 (12.6%) concomitant 
neurological disease (Parkinson’s, Alzheimer’s, multiple sclerosis or deafness).  
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Use of antihypertensives was noted in 207 (40.1%) patients; corticosteroids in 
45 (8.7%); statins in 140 (27.1%) and other medications in 304 (58.9%).  
The measurement of blood pressure, anthropometric measures (body mass 
index, waist circumference, waist-hip ratio), and the evaluation of history of 
hypertension, general arteriosclerosis (stroke, angina and intermittent 
claudication), vasospasm, migraine and Raynaud’s phenomenon were 
undertaken during the first post-treatment allocation study visit; the baseline 
characteristics for the UKGTS participants attending at least one post-
allocation visit (n=484) are summarised in Table 3.5 below.  
  (n=483) 
n (%) 
Mean ± SD 
Median (IQR) 
Systolic blood pressure (mmHg)  136 ± 20 
Diastolic blood pressure (mmHg)  81 ± 11 
Body mass index   26.9 (23.9 to 30.1) 
Waist circumference (cm)  98 (88 to 107) 
Waist-hip ratio  0.91 (0.84 to 0.96) 
Hypertension:   
Receiving treatment, or 
Systolic >160mmHg, or Diastolic >95mmHg 
279 (57.8%)  
History of:   
 
General arteriosclerosis (stroke, angina or 
intermittent claudication) 
 
Vasospasm, migraine or Raynaud’s 
phenomenon 
 
38 (7.9%) 
 
 
 
229 (47.4%) 
 
Table 3.5: Baseline characteristics of all the UKGTS participants that attended 
at least one post-allocation visit (visit 1) (n=484). 
The median (IQR) body mass index, calculated as the weight in kilograms 
divided by the height in metres squared, in our cohort was 26.9 (23.9 to 30.1). 
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The median (IQR) waist-hip ratio, calculated as the ratio of the circumference 
of the waist in centimetres to that of the hips, was 0.91 (0.84 to 0.96). History 
of hypertension, defined as systolic blood pressure greater than 160 mmHg or 
diastolic blood pressure greater than 95 mmHg or antihypertensive treatment 
history (Leske et al 1999), was noted in 279 (57.8%) patients. History of general 
arteriosclerosis (stroke, angina or intermittent claudication) was found in 38 
(7.9%) patients, while evidence for vasospasm, migraine and/or Raynaud’s 
phenomenon was reported for 229 (47.4%) subjects. 
 
Baseline characteristics for all eligible eyes (n=777) (Table 3.6) 
 
n (%) 
Mean ± SD 
Median (IQR) 
Eyes enrolled of a patient:   
Both eyes 265  
Right eye only 117  
Left eye only 130  
Refractive error (D):   
< -1 254 (32.7%)  
-1 to 1 333 (42.9%)  
> 1 
 
190 (24.4%) 
 
 
Best-corrected visual acuity:  1 (0.67 to 1.2) 
<0.5 
0.5 to 0.66 
1 (0.1%) 
18 (2.3%) 
 
0.67 to 0.9 238 (30.7%)  
≥1.0 
Unknown 
517 (66.5%) 
3 (0.4%) 
 
Axial length (mm)  24.1 ± 1.3 
SAP MD (dB): All eyes   -2.9 (-1.6 to -4.8) 
Better eye  -2.0 (-1.2 to -3.3) 
Worse eye  -3.5 (-2.1 to -5.9) 
GAT IOP (mmHg)*:  19.5 ± 4.5 
<15 102 (13.1%)  
15-19 334 (43.0%)  
20-24 240 (30.9%)  
25-29 88 (11.3%)  
≥30 13 (1.7%)  
Any iridotrabecular contact 74 (9.5%)  
Van Herick grade:   
0-5% 0 (0%)  
≥ 5% 2 (0.3%)  
≥15% 23 (2.9%)  
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≥25% 166 (21.4%)  
≥40% 
Unknown 
578 (74.4%) 
8 (1%) 
 
Trabecular pigmentation grade:   
0-1 607 (78.1%)  
2 142 (18.3%)  
3 
Unknown 
22 (2.8%) 
6 (0.8%) 
 
Any peripheral anterior synechiae 5 (0.6%)  
Krukenberg spindle:   
0 760 (97.8%)  
1 9 (1.2%)  
2 4 (0.5%)  
3 3 (0.4%)  
4 
Unknown 
0 (0%) 
1 (0.1%) 
 
Posterior embryotoxon 
(quadrants): 
  
0 763 (98.2%)  
1 10 (1.3%)  
2 1 (0.1%)  
3 1 (0.1%)  
4 
Unknown 
0 (0%) 
2 (0.3%) 
 
Iris colour:   
Blue 363 (46.7%)  
Blue/green 65 (8.4%)  
Green 29 (3.7%)  
Hazel 114 (14.7%)  
Light brown 116 (14.9%)  
Dark brown 
Unknown 
86 (11.1%) 
4 (0.5%) 
 
Transillumination – mid-peripheral 16 (2.1%)  
Transillumination – sphincter 6 (0.8%)  
Iris thickness:   
Thick 34 (4.4%)  
Normal 702 (90.4%)  
Hypoplastic 
Unknown 
40 (5.1%) 
1 (0.1%) 
 
Pseudoexfoliation:   
0 760 (97.8%)  
1 3 (0.4%)  
2 
Unknown 
1 (0.1%) 
13 (1.7%) 
 
LOCS lens grading:   
N>1 19 (2.4%)  
C>2 1 (0.1%)  
P>1 0 (0%)  
Table 3.6: Baseline clinical characteristics for all eligible eyes (n=777) in 
enrolled patients (D: dioptres, SAP: standard automated perimetry, GAT: 
Goldmann applanation tonometry, LOCS: Lens Opacities Classification System, 
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N: nuclear, C: cortical, P: posterior subcapsular). *27.4% of the participants had 
IOP>21mmHg at baseline. 
The number of right and left eyes meeting the study eligibility criteria at 
baseline was almost equal, while both eyes met eligibility criteria in over two 
thirds (68.2%) of subjects. Approximately a third of the eligible eyes (32.7%) 
had a myopic refractive error [SE<-1D] and about a quarter (24.4%) were 
hypermetropic (SE>1D). The vast majority of patients (97.2%) had a best-
corrected visual acuity (BCVA) of 0.67 or better. The mean (±SD) axial length 
was 24.1±1.3mm.  
Two baseline VFs were performed in each eye at visit 1 (first post-allocation 
visit). Amongst the UKGTS eligible eyes, the median (IQR) for the mean MD 
(average of the two baseline visual fields for each eye) of the better and worse 
eyes was -2.0dB (-1.2 to -3.3) and -3.5dB (-2.1 to -5.9), respectively. The 
median (IQR) for the mean MD of all eligible eyes was -2.9dB (-1.6 to -4.8). In 
the case of the right eyes, the mean difference (95% CI) between the two 
baseline VFs was 0.16dB (0.04, 0.28), with the first VF being slightly more 
sensitive than the second. In the left eyes, which were tested after the right 
eyes, this difference was slightly larger at 0.31dB (0.20, 0.42). The baseline VFs 
comprised 874 eyes (90.5%) with VFs taken on the same day and 92 eyes 
(9.5%) with the second VF taken on a subsequent occasion, because the 
second field at the baseline visit was excluded by the perimeter software 
because of learning effects. Of the baseline VFs, the first had only slightly 
higher sensitivity than the second in the right eye, suggesting that any learning 
and fatigue effects, in patients with the level of experience represented in this 
cohort, are evenly balanced. The difference was slightly larger in the LE, which 
was tested after the RE, suggesting a small fatigue effect. The perimeter 
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software removed some VFs considered to show learning, likely contributing to 
an impression of a slight overall fatigue effect. The good agreement found 
between the first and second VFs suggests that performing duplicate VFs on 
the same day is probably compatible with clinical practice. 
The mean (±SD) GAT IOP for all eligible eyes was 19.5±4.5 mmHg. The baseline 
GAT IOP distribution in all eligible eyes is shown in Figure 3.3. 87% of eligible 
eyes had a baseline IOP of less than 25mmHg and 56.1% of less than 20mmHg. 
  
Fig 3.3: Baseline intraocular pressure distribution in all eligible eyes (n=777). 
Any iridotrabecular contact was noted in almost a tenth of all eligible eyes 
(9.5%), while peripheral anterior synechiae (0.6%) and a posterior 
embryotoxon of any grade (1.5%) were rare in our cohort. The vast majority of 
cases had ‘wide’ open angles, with only 3.3% having a Van Herick grade of less 
than 25%. Significant trabecular pigmentation was uncommon (2.8%), with the 
majority of eligible eyes (78.1%) having either no, or very mild, pigmentation. 
Similarly, a Krukenberg spindle of any grade and mid-peripheral iris 
transillumination were found in only 2.1% of the UKGTS eligible eyes. The most 
common iris colour was blue (46.7%), followed by light brown (15.0%) and 
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hazel (14.7%). Eligible eyes with any degree of pseudoexfoliation (0.5%) and 
iris sphincter transillumination (0.8%) were very rare in this UK cohort. 
Protocol violations were noted in one eye with BCVA worse than 0.5, in one 
eye with baseline MD<-16dB, and in 19 eyes with nuclear cataract (N)>1 and 
one eye with cortical cataract (C)>2.  
 
Better versus worse MD eyes  
 Better MD (n = 516) Worse MD (n = 516) 
n (%) 
 
Mean ± SD 
 
n (%) 
 
Mean ± SD 
 
Number of 
right eyes 
312 (60.5%)  204 (39.5%)  
Axial length  24.07 ± 1.26  24.11 ± 1.29 
*GAT IOP 
(mmHg): 
 18.9 ± 4.1   19.9 ± 4.7  
<15 80 (15.5%)  65 (12.6%)  
15-19 228 (44.2%)  209 (40.5%)  
20-24 166 (32.2%)  163 (31.6%)  
25-29 41 (7.9%)  66 (12.8%)  
≥30 1 (0.2%)  13 (2.5%)  
CCT (µm)  542 ± 34  541 ± 34 
PXF present 3 (0.6%)  2 (0.4%)  
Table 3.7: Baseline characteristics of the better MD versus worse MD eyes in 
the UKGTS (GAT: Goldmann applanation tonometry, CCT: Central corneal 
thickness, PXF: Pseudoexfoliation). 
The baseline characteristics of the better MD versus worse MD (n=516) eyes in 
the UKGTS are presented in Table 3.7. Right eyes were more likely to have a 
better MD at baseline (60.5%) (p<0.0001).   The mean IOP (±SD) at baseline 
was lower in the better (18.9±4.1mmHg) than the worse (19.9±4.7mmHg) MD 
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eyes (p=0.0053).  More than half of both the better (59.7%) and worse MD 
(53.1%) eyes presented with an IOP of less than 20mmHg at baseline. Axial 
length   and central corneal thickness (CCT) were very similar between the 
better and worse MD eyes, while pseudoexfoliation (PXF) was very rare in both 
groups. 
 
Discussion 
The primary source of referrals in the UKGTS was community optometrists 
(88%). This is in contrast with the EMGT where the majority of subjects (85%) 
were recruited by actively screening 70% of the local population fulfilling the 
age criteria for eligibility. Recruitment from clinical centres (6.6%) and 
practitioners (8.6%) in the EMGT represented the minority of cases, similarly to 
the UKGTS, where only 8% of the study patients were referred from the 
hospital and 3% from their GP. 
More than half of the UKGTS patients had both eyes eligible, unlike the EMGT 
where only 24% of cases were bilateral. A refractive error more myopic than -
1D at baseline was found in 32.7% of our cohort and was more common that in 
the EMGT (13%). Hypermetropia of more than 1D was over-represented in the 
EMGT cohort (57%), as compared to the UKGTS (24.4%). As expected for a 
clinical trial recruiting newly diagnosed OAG cases, and given the eligibility 
criteria, the BCVA was equal or better than 0.67 in the majority of our cohort 
(97.2%), similarly to the EMGT (99%). The mean axial length in the UKGTS 
(24.1±1.3mm) was slightly longer than the average reported for a British 
population in the EPIC-Norfolk study (23.8mm males, 23.3mm females) (Foster 
et al 2010), thus reflecting the higher percentage of axial myopia in our cohort. 
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A possible explanation for the difference is the referral source (optometry), 
with myopes being more used to visiting optometry for refractive error 
correction than emmetropes or low hypermetropes, who may be more likely 
to buy off-the-shelf reading glasses.  
The median (IQR) MD for all UKGTS eligible eyes was -2.9dB (-1.6 to -4.8), and 
represents earlier disease than in the EMGT (MD of -4.7 dB) and the CIGTS (MD 
of -5.5dB) (Gillespie et al 2003) cohorts, while the AGIS (MD of -10.5dB) (AGIS 
1998) and CNTGS (MD of -8dB) (CNTGS 1998) included subjects with more 
advanced glaucomatous damage at baseline. The IOP distribution in the UKGTS 
showed that 86.9% of eligible eyes had a baseline IOP<25mmHg, which is in 
line with the EMGT (80%). The mean IOP (±SD) at baseline was 19.5±4.5mmHg, 
a little lower than in the EMGT (20.7±4.1mmHg). As expected, the UKGTS 
mean IOP was higher than the one recorded at baseline in studies focusing on 
normal tension glaucoma, such as the CNTGS (16.1±2.3mmHg for the control 
and 16.9±2.1mmHg for the treated group). The early stage of the glaucoma 
and relatively low IOP at diagnosis suggests remarkably sensitive case-finding 
by community optometrists in the UK. 
The vast majority of eligible eyes had wide open angles (≥40%) on Van Herick 
grading (74.4%), similarly to the EMGT (82%). Significant trabecular 
pigmentation was relatively uncommon, both in our cohort (2.8%) and in the 
EMGT (6%). Pseudoexfoliation was extremely rare in our cohort (0.5%), unlike 
the EMGT or the CIGTS, where it was noted in 8% of eligible eyes and 4.8% of 
enrolled patients, respectively. However, unlike the EMGT and the other major 
glaucoma clinical trials, the UKGTS is the first to report detailed baseline 
phenotypic data, to include the Krukenberg spindle grade, embryotoxon grade, 
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presence of any iridotrabecular contact, and iris thickness, colour and 
transillumination.  
The mean age of the participants was 66 years and was almost identical with 
the mean age of participants in the CNTGS (CNTGS 1998) and very similar with 
the EMGT mean age of 68.1 years (Leske et al 1999). Both genders were almost 
equally represented in our cohort, as opposed to the EMGT where participants 
were predominantly female (66%). Family history of glaucoma was relatively 
common in our study, with almost one third of the participants reporting a first 
degree relative with the disease. This was almost identical with the family 
history rate reported in the CIGTS (Musch et al 1999) but higher than the 
EMGT (Leske et al 1999), where a positive family history was noted in only one 
fifth of the participants. With regards to education, almost half of the UKGTS 
participants did not pursue education beyond the age of 16, while in the AGIS 
almost three quarters (71.3%) of the subjects had not been to any college or 
graduate school. The vast majority in our cohort was white, similar to the 
Swedish cohort described in the EMGT. Unlike the CIGTS and AGIS (AGIS 1994), 
where a substantial proportion of the study groups (38% and 56%, 
respectively) were black, only 5.2% of the UKGTS participants were black, the 
second most common ethnicity in our cohort.   
Hypertension (defined as in the EMGT to allow for comparisons) at baseline 
was more common in our cohort (57.8%) than in the EMGT (38%) and the AGIS 
(50%). The mean systolic and diastolic blood pressures in the UKGTS (136±20 
and 81±11mmHg, respectively) were lower as compared to the EMGT 
(148.0±18.8 and 85.7±10.3mmHg, respectively). This is likely explained by the 
fact that more than a third of our participants were on antihypertensive 
medications, as compared to only 24% in the EMGT, while the nowadays 
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widely prescribed statins were taken by more than a quarter of the UKGTS 
patients. The median body mass index (BMI) was 26.9 in our cohort, suggesting 
that the majority of patients were overweight (BMI>25), in line with the latest 
Health Survey for England (HSE), showing that in 2009, 61.3% of adults in 
England were overweight. Similarly to the BMI results, the waist 
circumference, thought to assess the proportion of body fat located intra-
abdominally, as opposed to subcutaneously, and to better reflect 
cardiovascular risk  (Lean et al 1995), was also found to be higher in the UKGTS 
cohort (median 98cm), as compared to the recommended limits (<94 for men 
and <80cm for women). The median waist-hip ratio (WHR), considered a more 
efficient predictor of mortality in older people than waist circumference or BMI 
(Price et al 2006), was 0.91 in our cohort, suggesting that the majority of 
UKGTS patients has abdominal obesity (defined as a WHR >0.90 for males and 
>0.85 for females by the World Health Organisation) (WHO 2008).  
History of myocardial infarction was similar in the UKGTS (5.4%) and EMGT 
(6%) cohorts, while diabetes mellitus was more frequent in the UKGTS (10.5%) 
than in the EMGT (4%) cohort, but less frequent when compared to the AGIS 
(20%). Obstructive pulmonary disease was also more frequent in our study 
population (8%) as compared to the EMGT (1%). General arteriosclerosis 
(defined more broadly than in the EMGT to include stroke, angina and/or 
intermittent claudication) was noted in more patients (7.9%) in the UKGTS 
than in the EMGT (5%). Moreover, almost half of our participants reported a 
history suggestive of peripheral vasospasm, migraine and/or Raynaud’s, while 
these conditions were only encountered in 19% of cases in the EMGT.  In the 
UKGTS, recognised standardised protocols were used to elicit a history of these 
conditions, such as the Rose questionnaire for angina and intermittent 
claudication (Rose et al 1977), the International Headache Society diagnostic 
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criteria for migraine (IHS 1988) and protocols derived from well established 
definitions for vasospasm and Raynaud’s (Flammer et al 2001). Concomitant 
neurological disease was reported in 12.6% of the UKGTS cohort, which is 
higher than that reported in the literature for the UK population (6%) 
(MacDonald et al 2000). 
Left eyes were slightly more likely to be associated with a worse MD at 
baseline in our cohort, in line with a retrospective cross-sectional study in NTG 
that found the left eye 2.1 times more likely to present a greater field defect 
than the right eye (Poinoosawmy et al 1998). In contrast, in high tension 
glaucoma right and left eyes had an equal chance of being the side of more 
advanced field damage (Poinoosawmy et al 1998). The mean IOP at baseline 
was 1mmHg lower in the better (18.9±4.1mmHg) as compared to the worse 
(19.9±4.7mmHg) MD eyes, as expected by the link between raised IOP and 
glaucoma, although other studies have suggested only poor correlation 
between IOP and VF damage (Greenfield et al 2007, Orgul et al 1994b). Just 
over half of both the better and worse MD eyes demonstrated an IOP of less 
than 20mmHg at baseline, largely in line with the EMGT where 46% of eligible 
eyes fell below this same IOP threshold. The mean CCT in our cohort was 
consistent with the mean CCT reported in epidemiological studies (Wolfs et al 
1997) and meta-analyses (Doughty et al 2000).  
In summary, the UKGTS is the first randomised, placebo-controlled trial to 
evaluate the efficacy of medical treatment in reducing VF deterioration in OAG.  
The outcome will provide evidence for the efficacy of the most widely 
prescribed class of IOP-reducing medication (prostaglandin analogues) in 
preserving the visual field in patients with glaucoma; it will also allow the 
quantification of risk factors for deterioration, enabling more precise risk 
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profiling of patients and the development of patient management protocols. 
Some groups of patients were under-represented in our cohort, such as those 
with high IOP (>30mmHg) or pseudoexfoliation, and black subjects. However, 
the study will provide useful information on the effectiveness of IOP-lowering 
treatment in the majority of patients with OAG.  
 
3.4 Time to confirmed VF deterioration in the UKGTS 
In January 2011, the Data and Safety Monitoring Committee (DSMC) requested 
an interim analysis. This revealed a significant difference between treatment 
arms and the DSMC requested that the trial be terminated. Patients were 
scheduled for exit visits over the following 6 months. 
Survival analysis showed a statistically significant difference in the time from 
baseline to the event of confirmed VF progression between the two groups 
over 24 months following entry to the trial (p=0.001). The adjusted Hazard 
Ratio by site was 0.48 (95% CI 0.31, 0.74) (Fig 3.4). A statistically significant 
difference in the time from baseline to the event of confirmed VF progression 
was also noted at 18 months (p=0.049). 
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Fig 3.4: Kaplan-Meier curve showing the time from baseline to the event of 
confirmed VF progression for the placebo (A) and latanoprost (B) groups. 
Out of 516 patients, 55 were excluded from the survival analysis (28 from the 
placebo and 27 from the latanoprost group), due to insufficient data to obtain 
an endpoint. In more detail, amongst the 55 patients, 32 did not attend the 1
st
 
post treatment allocation visit (visit 1) and 23 only attended visit 1, but no 
further visits.  
As shown in Table 3.8 below, only 7 patients showed a possible or established 
reaction to a study drug for which they had to be withdrawn from the study. 
No serious adverse events definitely related to the study intervention were 
noted. 2 cases of life-threatening events were reported and included an 
asthma attack and a suspected stroke. 
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Reasons (n = 127) n (%) 
Adverse reaction to study drug  
(possible or established) 7 (5.5%) 
32 (25.2%) 
7 (5.5%) 
11 (8.7%) 
70 (55.1%) 
Ill health 
Death 
Ocular co-morbidity* 
Other 
 
Table 3.8: Reasons for loss to follow-up in the UKGTS (*includes cataract, angle 
closure or uveitis).   
 
3.5 IOP as a risk factor for glaucoma progression 
3.5.1 The effect of treatment on IOP  
The IOP change from the pre-allocation visit to the first visit post-allocation is 
shown in Table 3.9 below. 
 Placebo (A) Latanoprost (B) 
IOP before allocated treatment 19.4 ± 4.7 19.0 ± 4.6 
IOP at 1
st
 visit post-allocation 18.8 ± 5.2 14.5 ± 3.3 
Table 3.9: IOP (±SD) in mmHg before and at the 1st visit after treatment in 
Groups A and B. 
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3.5.2 Is average IOP (as measured by GAT, DCT and ORA) associated 
with the rate of glaucoma progression?  
In the EMGT, the mean GAT IOP during the follow-up period was positively 
associated with the risk for progression, with an average 12% increase with 
every mmHg of mean IOP higher (HR 1.12, 95% CI 1.07–1.16, p<0.0001) (Leske 
et al 2007). Also, mean GAT IOP was a significant predictor of progression in 
both the higher (≥21mmHg) and lower baseline IOP groups, indicating very 
clearly the relevance of follow-up IOP in patient management, regardless of 
the IOP levels at baseline. CCT was another significant predictor for 
progression in the EMGT, with an average 25% increase with every 40µm 
reduction in CCT (HR: 1.25, 95% CI 1.01–1.55, p=0.0422). However, CCT was 
not evaluated in the EMGT as an independent risk factor and was only 
highlighted as a significant predictor, when controlling for the effects of mean 
follow-up GAT IOP. Unlike previous large clinical trials in glaucoma, in the 
UKGTS IOP data were collected at each visit by three devices: GAT (2 
measurements per visit within 1mmHg), DCT (3 measurements per visit), and 
ORA (IOPcc and IOPg; 3 measurements per visit). Additional GAT IOP 
measurements were available for visits 1 and 8 (phasing visits), where 10 
measurements were performed; two at each of the following time points: 9am, 
11am, 12pm (midday), 2pm and 4pm. Also, data were collected on CCT (3 
measurements at visit 1), and ORA CH and CRF (3 measurements per visit).  
The purpose of this analysis was 1) to assess the association between median 
GAT IOP over the follow-up period and the rate of progression (change in MD 
over time) for each participant and whether including covariates CCT or CH in 
the GAT IOP model improves prediction and 2) to evaluate which IOP model 
(GAT, DCT, IOPcc, IOPg) better predicts glaucoma progression and to what 
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extent the inclusion of covariates in each of the above models (CCT, CRF, CH 
and AL) improves prediction. Only DCT values with a quality score of 1 or 2 
were included in the analysis and only participants with VF data available over 
at least 5 clinic visits (n=379) were considered, to provide a more precise 
measure of visual field progression rate.  
The Pearson’s R of MD slope against median GAT IOP across all the UKGTS sites 
was 0.250 (p<0.001), suggesting that the GAT IOP measurement was 
significantly, but weakly, correlated with visual field progression (AIC=1337.0, 
Akaike weight=0.48) (Fig 3.5).  
 
Fig 3.5: Graph showing the median GAT IOP across all visits against the MD 
slope for each participant (n=379) for all the UKGTS sites. 
In line with the EMGT analysis for CCT, when CCT was included in the model 
with GAT IOP to predict the MD slope, the AIC value was found to be 
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marginally lower (AIC=1336.8) and the Akaike weight marginally higher (Akaike 
weight=0.52), suggesting that the addition of CCT slightly improves the GAT 
prediction model. However, although GAT IOP remained a significant predictor 
of progression in the GAT+CCT model, the CCT was not (P = 0.137). To test the 
hypothesis that CCT is an independent predictor of progression, the MD slope 
was plotted against CCT across all the UKGTS sites. CCT was not correlated to 
the MD slope (R = 0.02) and was not a significant predictor of progression 
(AIC=1361.4, Akaike weight ~0) (Fig 3.6). In light of this finding, it could be 
argued that the benefit gained by including CCT in the GAT IOP model most 
likely arises from the reduction in the GAT measurement error associated with 
CCT, rather than any genuine association between CCT and glaucoma 
progression.  
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Fig 3.6: Graph showing the median CCT across all visits against the MD slope 
for each participant (n=379) for all the UKGTS sites. 
During the second stage of the analysis, the different IOP models (GAT, DCT, 
IOPcc, IOPg) were compared in their ability to predict glaucoma progression. 
The Pearson’s R of MD slope against GAT, DCT, IOPcc and IOPg across all the 
UKGTS sites, was 0.250, 0.199, 0.276 and 0.239, respectively (p<0.001 in all 
cases), suggesting that the IOP measurements by all devices were significantly 
correlated with visual field progression (Fig 3.7).  
  
Fig 3.7: Graph showing the median IOP (GAT, DCT, IOPcc, IOPg) across all visits 
against the MD slope for each participant (n=379) for all the UKGTS sites.
As expected, and similarly to GAT IOP, the correlation was negative in all cases, 
showing that an increase in median IOP is associated with a more negative MD 
slope, suggesting faster VF progression. The correlation was significant, but 
weak, for all the IOP measures tested, wit
correlation, as compared to GAT, DCT and IOPg. 
The AIC value for each model was used to compare models, where the 
outcome variable was MD slope and the predictor variable was median follow
up IOP, as measured by GAT, DCT and ORA
IOPcc and IOPg models were similar: 1337, 1346, 1331 and 1339, respectively. 
The lowest AIC value was for IOPcc, suggesting that less information is lost 
when the IOPcc model is used to predict VF progression. The Akaike 
206 
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for the GAT, DCT, IOPcc and IOPg models were 0.0574, 0.000579, 0.922 and 
0.0197, respectively, suggesting that the IOPcc model has a 92.2% probability 
of being the ‘best’ model.  
When data were analysed for each site separately, IOPcc was not the most 
likely model for most of these sites, with sites A1, B2, F6 and G7 having DCT as 
the preferred model, and sites D4, E5, H8 and M12 having GAT as the 
preferred model (Table 3.10).  
Site 
Number 
of 
patients 
GAT DCT IOPcc IOPg 
A1 71 0.230 0.455 0.237 0.078 
B2 29 0.232 0.303 0.231 0.233 
C3 78 0.230 0.144 0.343 0.283 
D4 45 0.965 0.003 0.018 0.015 
E5 21 0.435 0.111 0.384 0.070 
F6 10 0.160 0.551 0.150 0.139 
G7 24 0.117 0.467 0.093 0.324 
H8 78 0.555 0.040 0.148 0.257 
J9 16 0.247 0.226 0.281 0.246 
M12 7 0.268 0.245 0.266 0.221 
Table 3.10: Akaike weights for each IOP model (GAT, DCT, IOPcc, IOPg) per site 
with the model having the largest Akaike weight being highlighted in bold. 
An example of a site where DCT was the preferred model is shown below (Fig 
3.8).
  
Fig 3.8: Graph showing the median IOP (GAT, DCT, IOPcc, IOPg) across all visits 
against the MD slope for each participant (n=71) for site A1 (Moorfields).
However, across all sites, IOPcc was by far the most likely model, a
the Akaike weights. This may be explained by the observation that the 
relationship between IOPcc and the MD slope was much more consistent 
across sites (data not shown). These results suggest there may be differences 
between sites in the way DC
while ORA IOPcc may be less operator
IOP measurements recorded per visit were required by the Standard Operating 
Procedures to be within 1mmHg. This may have increased the
measurement, which may in turn have increased the strength of the 
correlation between GAT IOP and the MD slope relative to DCT and ORA. No 
such requirement applied to the DCT or ORA measurements.
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In the third stage of the analysis, each of the aforementioned linear models 
(GAT, DCT, IOPcc, IOPg) was re-examined, with CCT, CH, CRF and AL included as 
covariates, and a backward stepwise AIC approach was employed to remove 
non-significant predictors of VF progression. In the case of the GAT linear 
model, when CCT, CH, CRF and AL were included as covariates, this model 
reduced to GAT IOP and CH as significant predictors (AIC=1331.0), suggesting 
that CCT, CRF and AL added no additional information regarding progression 
rate. For the DCT model, the model reduced to CRF and CH only (AIC=1337.3), 
suggesting that CCT, DCT IOP and AL were non-significant predictors when CRF 
and CH were available. In the case of the IOPcc model, this reduced to only 
IOPcc, suggesting that all the other parameters were non-significant predictors 
in the presence of IOPcc, thus reinforcing the idea that corneal parameters 
have been taken into account in the IOPcc measurement (AIC=1331.4). In the 
case of IOPg, the model reduced to IOPg, CH and CRF (AIC=1333.6). The AIC 
value for the GAT IOP-CH model was smaller than any other model, but only 
marginally less than the IOPcc model. However, it is generally accepted that 
the most robust model is the one that provides an adequate account of the 
data while using a minimum number of parameters (Myung et al 2000). 
Considering this trade-off between descriptive accuracy and parsimony, it 
could be argued that the model with IOPcc as the only predictor remains the 
preferred model of progression. 
In the UKGTS, the IOPcc, a measurement where metrics of corneal 
biomechanics are adopted in the IOP calculation, was the best predictor of 
progression across all sites. This may be the case, either because it provides a 
more accurate or consistent measure of IOP or because it may better reflect 
ocular susceptibility to IOP, to the extent that susceptibility is influenced by the 
material properties of the eye and reflected in the corneal biomechanics. 
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Moreover, IOPcc appears to be less dependent on the operator, as shown by 
the relatively consistent relationship between IOP and progression rate across 
sites.  
In controlled experiments, DCT IOP has been shown to be the most accurate 
and precise IOP measurement, displaying the best repeatability and 
reproducibility (Kotecha et al 2010) and to have the lowest association with 
CCT (Boehm et al 2008). This is due to the use of a curved contact surface, 
which the contour of the cornea matches during measurement. The effects of 
capillary forces, corneal rigidity and thickness are reduced during contact 
matching. These beneficial properties of DCT are only apparent at some sites 
when sites are considered individually, suggesting possible differences in 
calibration and/or operation across the UKGTS sites. Also, upon the inclusion of 
covariates (CCT, CH, CRF, AL), the DCT model was reduced to only CRF and CH. 
This may suggest that DCT IOP provided no additional information of 
progression rate over and above CRF and CH. However, to reiterate, the 
relationship between DCT IOP and the MD slope was variable across sites, 
while the relationship between ORA measurements (including CH and CRF) and 
MD slope was more consistent, which may contribute to this finding.  
That DCT IOP did not contribute to progression rate when CRF and CH were in 
the model may imply that ‘corneal factors’ are also important predictors of 
progression. However, the ‘corneal factors’ given by the ORA (CH and CRF) 
themselves vary with IOP (Kotecha et al 2006), so cannot be regarded as 
reflecting ocular material properties independently of IOP.  
The reduction of the GAT model (when CCT, CH, CRF and AL were included as 
covariates) to GAT and CH as significant predictors, would suggest that CH 
provides a better model fit than CCT. This is further confirmed by directly 
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comparing the AIC values of the GAT IOP + CH model (AIC=1331.0) and the GAT 
IOP + CCT model (AIC=1336.8); the Akaike weights were 0.95 and 0.05, 
respectively, when these models were compared. This superiority of CH over 
CCT in improving the GAT model prediction may suggest that CH better reflects 
the GAT IOP measurement error than CCT or that CH provides an additional 
measure of IOP susceptibility. To explore this further, GAT IOP + CCT as 
predictors of DCT IOP were compared with GAT IOP + CH as predictors of DCT 
IOP. As DCT measurement is thought to be less influenced by corneal 
biomechanics, the covariate resulting in the better prediction of DCT IOP by 
GAT IOP may be the one which best reflects the IOP measurement error due to 
ocular biomechanics. The AIC for the GAT IOP + CH model (1725.6) was 
significantly better than the GAT IOP + CCT model (1735.3), with Akaike 
weights of 0.99 and 0.01, respectively. This suggests that CH was a much better 
predictor of the differences between GAT and DCT IOPs, thus reinforcing the 
idea that CH explains GAT measurement errors, rather than susceptibility to 
IOP. Future work will explore the association between additional covariates 
(CRF and AL) and both IOP and glaucoma progression. Also, the role of the 
diurnal IOP variation and of the DCT ocular pulse amplitude in glaucoma 
progression will be investigated.  
3.6 Discussion 
Primary outcome 
The UKGTS is the first randomised, placebo-controlled trial to show the efficacy 
of medical IOP-lowering treatment in reducing VF deterioration in OAG. 
Limitations and generalisability 
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The intensive testing and visit schedule contributed to a high attrition rate 
(almost 25%), potentially limiting the generalisability of the findings. Patient 
masking may have been imperfect because of the effects on IOP, eyelash 
growth and iris colour change, but the extent of masking at the end of the 
study has yet to be analysed. 
Agreement between baseline VFs 
In the case of the right eyes, the mean difference (95% CI) between the two 
VFs taken at the baseline visit was 0.16dB (0.04, 0.28), with the first VF being 
slightly more sensitive than the second. In the left eyes, this difference was 
slightly larger at 0.31dB (0.20, 0.42). The baseline VFs comprised 874 eyes 
(90.5%) with VFs taken on the same day, while for 92 eyes (9.5%) the second 
visual field was taken on a subsequent occasion, because the second field at 
the baseline visit was excluded by the perimeter software due to learning 
effects. Of the baseline VFs, the first had slightly higher sensitivity than the 
second in the right eye (0.16dB), suggesting that any learning and fatigue 
effects, in patients with the level of experience represented in this cohort, are 
evenly balanced. The difference was slightly larger in the LE (0.31dB), which 
was tested after the RE, suggesting a small fatigue effect. The perimeter 
software removed some VFs considered to show learning, likely contributing to 
an impression of a slight overall fatigue effect. The good agreement found 
between the first and second VFs, suggests that performing duplicate VFs on 
the same day is probably compatible with clinical practice. 
Interpretation of trial design novelties 
The UKGTS has the shortest observation period of all OAG therapeutic trials 
with a VF outcome to date. This was achieved simply by inflating the sample 
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size so that differences in the rate of incident deterioration between treatment 
groups could be identified at the 2-year time point, based on the outcome of 
the EMGT. However, the trial was designed to assess novel data analysis 
methods, which may further reduce the trial duration or sample size required 
to identify treatment effects (Chauhan et al 2008a); these design features are 
related to VF test frequency and interval, selected to maximise the accuracy of 
estimates of the VF deterioration velocity, and to the inclusion of quantitative 
imaging of ONH and RNFL structure. Shorter trial durations would reduce 
considerably the cost of drug development and would increase the likelihood 
of new therapies being brought to patient benefit. 
Several clinical trials in OHT and OAG have included structural endpoints (Leske 
et al 2003), based on subjectively-identified change in stereoscopic ONH 
photographs. The OHTS included quantitative imaging in a subset of patients. 
The UKGTS is the first clinical trial in OAG to include quantitative imaging in all 
participants. Structural outcomes were not trial endpoints, so that treatment 
effects on visual function could be assessed without the censoring effect of 
endpoints based on structural deterioration. However, it is possible to assess 
whether the inclusion of structural measures as joint outcomes increases 
statistical power to identify treatment effects and risk factors; statistical 
methods have been developed to enable the modelling of joint outcomes 
(Harvey et al 2003) and have shown promise in the analysis of longitudinal VF 
and imaging data in glaucoma (Russell et al 2012). Based on the improved risk 
profiling, the relationship between risk and velocity of VF deterioration, and 
the variability of VF measurements, it is expected that protocols specifying the 
optimal follow-up frequency and intervals will be developed so that clinically 
meaningful deterioration can be identified in a timely fashion. 
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Chapter 4: Mitochondrial dysfunction, oxidative stress and other risk factors 
for glaucoma progression in a pilot study 
4.1 Immortalised human B- and T- lymphocyte cell lines  
4.1.1 Introduction 
The immortalised human B- (Raji) and T- (Jurkat) lymphocyte cell lines were 
used in this section as a model to test and demonstrate that the four 
experimental techniques described below are suitable for measuring 
mitochondrial dysfunction (ADP phosphorylation assay and mitochondrial 
membrane potential) and oxidative stress (aconitase activity and 
dihydroethidium staining) in lymphocytes. The lymphocyte cell lines were 
treated with rotenone to model mitochondrial dysfunction and paraquat to 
model oxidative stress, as described in the section 2.3.1. The results on the Raji 
and Jurkat cell lines are presented below. 
 
4.1.2 ADP Phosphorylation Assay (complexes I, II/III and IV) 
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Fig 4.1: The rate of ATP synthesis by complexes I, II/III and IV in the two cell 
lines, with and without treatment with 0.5µM rotenone for 24 hrs and 100µM 
paraquat for 24 hrs. The ATP synthesis rate is expressed in pmol/min/mg 
lysate. Error bars represent the SEM (n=12); *p<0.05, **p<0.01, ***p<0.001, 
NS: not significant, c1: complex I, c2/3: complex II/III, c4: complex IV, rot: 
rotenone, pq: paraquat. 
Complex I: A statistically significant reduction in the rate of ATP synthesis by 
complex I was noted in both Raji (from 8928±935 pmol/min/mg to 413±98 
pmol/min/mg) and Jurkat cells (from 8043±1511 pmol/min/mg to 1210±215 
pmol/min/mg) upon treatment with 0.5µM rotenone for 24hrs. A statistically 
significant reduction was also found after treatment with 100µM paraquat for 
24hrs in the Raji cells (from 8928±935 pmol/min/mg to 2409±746 
pmol/min/mg), but not in the Jurkat cells (from 8043±1511 pmol/min/mg to 
4270±1425 pmol/min/mg).   
Complexes II/III: Raji cells demonstrated a statistically significant reduction in 
the rate of ATP synthesis by complexes II/III, upon treatment with 0.5µM 
rotenone (from 3799±351 pmol/min/mg to 1430±213 pmol/min/mg) and 
100µM pq (from 3799±351 pmol/min/mg to 881±215 pmol/min/mg) for 24 
hrs. The effect on the Jurkat cells was not significant, with 0.5µM rotenone 
causing a reduction from 4954±637 pmol/min/mg to 3909±182 pmol/min/mg 
and 100µM pq from 4954±637 pmol/min/mg to 1802±624 pmol/min/mg.  
Complex IV: Similarly to complexes II/III, a statistically significant reduction in 
the rate of ATP synthesis by complex IV was noted in the Raji cells upon 
treatment with 0.5µM rotenone (from 609±60 pmol/min/mg to 82±11 
pmol/min/mg) and 100µM pq for 24hrs (from 609±60 pmol/min/mg to 110±43 
pmol/min/mg). The effect on the Jurkat cells was not significant, with 0.5µM 
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rotenone causing a reduction from 502±64 pmol/min/mg to 248±32 
pmol/min/mg and 100µM pq from 502±64 pmol/min/mg to 149±74 
pmol/min/mg. 
Discussion: Rotenone, a known complex I inhibitor (Choi et al 2011), was found 
to cause a statistically significant reduction in the rate of ATP synthesis by 
complex I in both cell lines. In the case of complexes II/III and IV, the effect of 
rotenone was still significant in the Raji cells, but not the Jurkat cells, 
suggesting that the inhibitory effect of rotenone on complex I in the Raji cells 
could also influence the activity of the other complexes. Paraquat significantly 
reduced the ADP phosphorylation rate by all complexes only in the Raji cells, 
but not the Jurkat cells. The effect of rotenone and paraquat on the ATP 
synthesis rate in all the different complexes appears greater in the Raji than in 
the Jurkat cells. 
 
4.1.3 Mitochondrial Membrane Potential (steady-state TMRM staining) 
Addition of 25nM TMRM caused a shift of the peak of the histogram to the 
right (Fig 4.2 a, b). Addition of 0.5µM rotenone over 24hrs caused a shift of the 
histogram to the left in the Raji cells (b, c), whereas addition of 100µM PQ over 
24hrs did not cause a significant shift to the histogram peak (b, d). 10µM FCCP 
caused a significant shift to the left, both in the absence (b, e) and presence of 
rotenone (c, f) and PQ (d, g). 
  
Fig 4.2: Representative histograms in the Raji cells for each of the seven 
experimental conditions (a-
events included in the gated area (green arrows in figure a).
used in all experiments. 
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Fig 4.3: Representative histograms in the Jurkat cells for each of the seven 
experimental conditions (a-
events included in the gated
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(FCCP) caused a statistically significant reduction in TMRM staining in both cell 
lines (Raji cells showed a change from 67±3% to 10±4% and
73±6% to 27±11%).  
Fig 4.4: Change in the % gated events in the Raji and Jurkat cells upon 
treatment with 0.5µM rotenone for 24
and upon treatment with FCCP (in red). Error bars represent the 
(n=7);**p<0.01, ***p<0.001, NS: not significant
 
Discussion: Flow cytometry appears to be a useful method for measuring 
steady-state TMRM staining that represents the 
potential in Raji and Jurkat cells
mitochondria-specific and the uncoupler FCCP acted as an effective positive 
control leading to the depolarisation of the mitochondria and causing the 
TMRM staining to dissipate. Rotenone, a known complex I inhibitor, led to a 
statistically significant reduction in TMRM staining in both Raji and Jurkat cells.  
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Paraquat did not significantly affect the TMRM staining in both cell lines. 
Similarly to the ADP phosphorylation assay, the Raji cells were more sensitive 
to rotenone and paraquat than the Jurkat cells. 
 
4.1.4 Dihydroethidium (DHE) staining 
A statistically significant increase in rate of superoxide production (as 
demonstrated by the increase in DHE staining) was noted in the Raji cells upon 
treatment with 0.5µM rotenone for 24hrs (194±20% for 10µM DHE and 
185±11% for 20µM DHE in Fig 4.5 and Fig 4.6, respectively), 100µM PQ for 24 
hrs (188±20% for 10µM DHE and 227±46% for 20µM DHE) and 5µM instant 
rotenone (229±19% for 10µM DHE and 292±28% for 20µM DHE). The Jurkat 
cells showed a smaller increase in the production of superoxide than the Raji 
cells in all three experimental conditions: rotenone 24hrs (142±15% for 10µM 
DHE and 141±13% for 20µM DHE), paraquat 24hrs (145±14% for 10µM DHE 
and 141±17% for 20µM DHE) and instant rotenone (151±18% for 10µM DHE 
and 179±39% for 20µM DHE). 
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Fig 4.5: Graph representing the percentage change in the rate of DHE oxidation 
comparing to control (100%) upon treatment of the Raji and Jurkat cells with 
0.5µM rotenone for 24 hrs (n=8), 100µM paraquat (PQ) for 24 hrs (n=6) and 
5µM instant rotenone (n=8). Error bars represent the SEM; *p<0.05, **p<0.01, 
***p<0.001, 10µM DHE was used. 
 
Fig 4.6: Graph representing the percentage change in the rate of DHE oxidation 
comparing to control (100%) upon treatment of the Raji and Jurkat cells with 
0.5µM rotenone for 24hrs (n=8), 100µM paraquat (PQ) for 24hrs (n=6) and 
5µM instant rotenone (n=8). Error bars represent the SEM; *p<0.05, **p<0.01, 
***p<0.001, 20µM DHE was used. 
Discussion: Rotenone administered instantly at a relatively high concentration 
(5µM) acted as an effective positive control, leading to a statistically significant 
increase in DHE staining in both cell lines using two different DHE 
concentrations (10µM and 20µM). Paraquat, known to generate ROS, also 
caused a statistically significant increase in the rate of red fluorescence 
emission in both cell lines. Similarly, rotenone over 24hrs caused a statistically 
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significant increase in DHE staining, mediated by its ability to inhibit complex I, 
cause mitochondrial dysfunction and thus oxidative stress. The Raji cells were 
more sensitive than the Jurkat cells to rotenone and paraquat treatment, 
although the effect was statistically significant in both cell lines. 
 
4.1.5 Aconitase enzymatic assay 
A statistically significant reduction in the aconitase enzymatic activity was 
noted in both the Raji and Jurkat cell lines comparing to control, when the cells 
were treated with rotenone and paraquat (Fig 4.7). 
 
Fig 4.7: Graph showing the change in aconitase enzymatic activity in the Raji 
and Jurkat cells after treatment with 0.5µM rotenone and 100µM paraquat 
over 24hrs (n=15). Error bars represent the SEM; *p<0.05, **p<0.01, 
***p<0.001. In all measurements, the background (no cells with reaction 
buffer) has been subtracted. Aconitase activity is expressed in mol/min/mg. All 
values have been adjusted for the protein level in each sample. 
0
1E-09
2E-09
3E-09
4E-09
5E-09
6E-09
7E-09
8E-09
control rot pqA
co
n
it
a
se
 a
ct
iv
it
y
 (
m
o
l/
m
in
/m
g
)
Aconitase activity (n=15) 
raji
jurkat***
** ***
*
  
224 
 
Discussion: Paraquat, a known generator of ROS, caused significant oxidative 
damage to the two cell lines, as demonstrated by the statistically significant 
reduction in the aconitase activity. Similarly, rotenone had a statistically 
significant effect on the aconitase activity in both cell lines, thus suggesting 
that rotenone at this concentration (0.5µM) can also lead to oxidative damage, 
which may be linked to its ability to inhibit complex I and cause mitochondrial 
dysfunction. Interestingly, as already shown with the previous methods, the 
aconitase activity in the Raji cells was more significantly affected than in the 
Jurkat cells. 
 
4.1.6 Conclusion 
In summary, we have modelled mitochondrial dysfunction and oxidative stress 
(by using rotenone and paraquat respectively) in B- and T- lymphocyte cell 
lines and have demonstrated that the four experimental techniques described 
above (see sections 4.1.2 - 4.1.5) were effective in measuring changes to these 
cells upon rotenone and paraquat treatment.  
 
4.2 Healthy volunteers 
4.2.1 Introduction 
The purpose of this section was to demonstrate that the four aforementioned 
experimental techniques (ADP Phosphorylation, TMRM, DHE and aconitase) 
can be used to measure mitochondrial dysfunction and oxidative stress not 
only in a cell line system, but also in human lymphocytes from healthy 
volunteers. Lymphocytes were isolated, after the removal of monocytes, from 
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anticoagulated peripheral blood using Lymphoprep (see section 2.3.2), and 
maintained under unstimulated conditions for subsequent experiments, as 
shown in the red boxes of the flowchart below (Fig 4.8). Approximately 25-
30mls of peripheral blood were collected from each volunteer and the isolated 
PBMC were resuspended in the appropriate medium (see section 2.3.1) to 
create a cell density of approximately 1million PBMC/ml. PBMC were treated 
with 0.5µM rotenone overnight, 100µM paraquat overnight or incubated 
overnight without treatment (Fig 4.8). The Raji cells were chosen in the 
volunteers’ experiments as a reference, since Raji were found in the previous 
section to be more sensitive than Jurkat. 
 
  
Fig 4.8: Schematic representation of the 
PBMC derived from human volunteers.
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4.2.2 ADP Phosphorylation Assay (complexes I, II/III and IV)
Fig 4.9: Graph showing the rate of ATP synthesis by complexes I, II/III and IV in 
the volunteers’ lymphocytes and in the Ra
treatment with 0.5µM rotenone for 24hrs. The ATP synthesis rate is expressed 
in pmol/min/mg lysate. Error bars represent the 
***p<0.001, NS: not significant, c1: complex I, c2/3: complex
complex IV, rot: rotenone. 
Complex I: A statistically significant reduction in the rate of ATP synthesis by 
complex I was noted upon treat
the volunteers’ lymphocytes (from 5321±667 pmol/min/mg to 70±55 
pmol/min/mg) and Raji cells (from 8724±1105 pmol/min/mg to 286±57 
pmol/min/mg).  
Complexes II/III: Upon treatment with 0.5µM rotenone for 24hrs, Raji cells 
demonstrated a statistically significant reduction in the rate of ATP synthesis 
by complexes II/III (from 4698±67
227 
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The effect on the volunteers’ lymphocytes was not significant (from 3921±350 
pmol/min/mg to 3554±348 pmol/min/mg).  
Complex IV: Similarly to complex I, 0.5µM rotenone for 24hrs caused a 
statistically significant reduction in the rate of ATP synthesis by complex IV in 
both the volunteers’ lymphocytes (from 881±143 pmol/min/mg to 78±32 
pmol/min/mg) and Raji cells (from 1701±588 pmol/min/mg to 311±93 
pmol/min/mg). 
Discussion: The ADP phosphorylation assay appears to be a useful method in 
human lymphocytes to measure the mitochondrial dysfunction caused by the 
complex I inhibitor rotenone. In the case of complex I, rotenone was found to 
cause a statistically significant reduction in the rate of ATP synthesis by 
complex I in healthy volunteers’ lymphocytes.  Upon rotenone treatment, the 
rate of ATP synthesis by complex IV in healthy volunteers’ lymphocytes was 
also reduced, suggesting that the inhibitory effect of rotenone on complex I 
could also influence the activity of other complexes. In the case of complexes 
II/III, the effect of rotenone was significant in the Raji cells, but not in the 
volunteers’ lymphocytes, suggesting that human lymphocytes may be less 
sensitive to mitochondrial dysfunction and oxidative stress comparing to a B-
lymphocytic cell line. 
 
4.2.3 Mitochondrial Membrane Potential (steady-state TMRM staining) 
Fig 4.10 presents the results of the mitochondrial membrane potential 
experiment with the use of the red fluorescent dye TMRM. In the absence of 
TMRM staining, the % gated events were almost zero. A statistically significant 
reduction in the TMRM staining was noted in the volunteers’ lymphocytes 
  
(from 65±2% to 39±7%) and in the Raji cells (from 71±2% to 48±4%) upon 
treatment with 0.5µM rotenone for 24hrs. As expected, t
uncoupler (FCCP 10 µM) also caused a statistically significant reduction in 
TMRM staining to 38±4% and 18±6% in the volunteers’ lymphocytes and Raji 
cells, respectively. 
Fig 4.10: Graph representing 
volunteers’ lymphocytes and Raji cells upon treatment with 0.5µM rotenone 
for 24hrs, and upon treatment with FCCP (in red). Error bars represent the 
(n=5); ***p<0.001, NS: not significant.
experiments. 
Discussion: Flow cytometry 
TMRM staining that represents the 
human (healthy volunteers’)
(25nM) was mitochondria
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he addition of 
the change in the % gated events in the human 
 The same gate was used in all 
is a useful method for measuring the steady
mitochondrial membrane potential in 
 lymphocytes. The concentration of TMRM used 
-specific and the uncoupler FCCP acted as an 
 
SEM 
-state 
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effective positive control leading to the depolarisation of the mitochondria and 
causing the TMRM staining to dissipate. Rotenone led to a statistically 
significant reduction in TMRM staining in both human lymphocytes and Raji 
cells.  Similarly to the ADP phosphorylation assay for compexes II/III above 
(section 4.2.2), the mitochondrial membrane potential in the human 
lymphocytes appears more resistant to the rotenone treatment comparing to 
the Raji cells. 
 
4.2.4 Dihydroethidium (DHE) staining 
Human lymphocytes showed a statistically significant increase in the DHE 
staining comparing to control human lymphocytes (100%, not shown on Fig 
4.11) upon treatment with 5µM instant rotenone (125±4%), 5µM rotenone for 
2hrs (114±6%), 0.5µM rotenone for 24 hrs (139±5%) and 100µM paraquat for 
24 hrs (120±9%). Raji cells also showed a statistically significant increase in the 
DHE staining comparing to control Raji (100%, not shown on Fig 4.11)  upon 
treatment with 5µM instant rotenone (205±10%), 5µM rotenone for 2hrs 
(205±3%), 0.5µM rotenone for 24 hrs (404±2%) and 100µM paraquat for 24 hrs 
(189±18%). 
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Fig 4.11: Graph representing the percentage change in the rate of DHE staining 
in the lymphocytes from healthy volunteers and in Raji cells, upon treatment 
with 5µM instant rotenone, 5µM rotenone for 2hrs, 0.5µM rotenone for 24hrs 
and 100µM paraquat for 24hrs (n=7). The volunteers’ (grey bars) and Raji (blue 
bars) results are expressed as the percentage change from control human 
lymphocytes without rotenone (100%, not shown) and control Raji without 
rotenone (100%, not shown), respectively. Error bars represent the SEM. An 
equal number of cells was added into each well of the 96-well plate (50,000 
cells/well); **p<0.01, **p<0.01, ***p<0.001, Rot: rotenone, PQ: paraquat. 
40µM DHE was used in this experiment. 
Discussion: A statistically significant increase in the rate of DHE staining, and 
therefore in the rate of superoxide production, was noted in the volunteers' 
lymphocytes and the Raji cells upon treatment with 5µM instant rotenone, 
5µM rotenone for 2hrs, 0.5µM rotenone for 24 hrs and 100µM paraquat for 
24hrs. In all cases, the human healthy volunteers' lymphocytes showed a 
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smaller increase in the production of superoxide than the Raji cells, suggesting 
that the human lymphocytes may be less sensitive to oxidative stress 
comparing to the B-lymphocytic cell line. The highest increase in the level of 
DHE staining, in both human lymphocytes and Raji cells, was found upon 
treatment with 0.5µM rotenone for 24hrs and this was used for subsequent 
DHE experiments in section 4.3. 
 
4.2.5 Aconitase enzymatic assay 
The baseline aconitase enzymatic activity in the volunteers’ lymphocytes 
(1.64±0.12pmol/min/mg) appears lower comparing to the Raji cells 
(5.84±0.95pmol/min/mg) (Fig 4.12). Upon paraquat treatment, the aconitase 
activity for the volunteers’ lymphocytes and Raji cells was reduced to 
0.83±0.09pmol/min/mg and 2.3±0.4pmol/min/mg, respectively (p<0.001, as 
compared to baseline). 
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Fig 4.12: Graph showing the change in the aconitase enzymatic activity of 
volunteers’ lymphocytes and Raji cells with and without treatment with 100µM 
paraquat over 24hrs (n=5). Error bars represent the SEM; ***p<0.001, pq: 
paraquat. In all measurements, the background (no cells with reaction buffer) 
has been subtracted. Aconitase activity is expressed in mol/min/mg. All values 
have been adjusted for the protein level in each sample, as described in 
section 2.3.7. 
Discussion: The lower baseline aconitase enzymatic activity in volunteers’ 
lymphocytes comparing to the Raji cells may reflect the differences between 
unstimulated human lymphocytes and immortalised lymphocytic cell lines, and 
suggest that the volunteers’ lymphocytes may be under more oxidative stress 
comparing to the Raji cell line.  Upon free-radical induction with paraquat, a 
statistically significant reduction was noted in the volunteers’ lymphocytes, 
suggesting that this assay is useful in our model for detecting changes in the 
oxidative stress levels of human lymphocytes. 
 
4.2.6 Conclusion 
In summary, in this chapter we have demonstrated that the four experimental 
techniques described (ATP, TMRM, DHE and aconitase) can measure 
mitochondrial dysfunction and oxidative stress not only in a cell line system, 
but also in human lymphocytes from healthy volunteers. 
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4.3 Patients with normal tension glaucoma, ocular hypertension and controls 
4.3.1 Introduction 
In this section we present our results on human unstimulated lymphocytes 
isolated from patients with normal tension glaucoma (NTG), ocular 
hypertension (OHT) and controls. A series of different assays were employed, 
as discussed later in more detail, to measure parameters relating to 
mitochondrial function (ATP for complexes I, II/III and IV, TMRM, calcium 
mobilisation, mTOR), oxidative stress (DHE, aconitase, 8OHdG) and antioxidant 
defence (SOD2, vitamins A, B6, B12, C, folate, urate). 
Two cohorts of 30 subjects with ≥8 Humphrey 24-2 visual fields over ≥5 years 
of follow-up were recruited prospectively from Moorfields Eye Hospital:  
a) Normal Tension Glaucoma (NTG) group: rapidly progressing patients with 
Mean Deviation change > -1.0 dB/yr and mean IOP<16;  
b) Ocular Hypertension (OHT) group: non-progressing patients with mean 
IOP>24.  
An equal number of age-similar subjects with normal IOP, healthy discs and no 
family history of glaucoma was also recruited as controls. 
Approximately 50-60mls of peripheral blood were collected from each 
participant and transferred from Moorfields Eye Hospital to the Department of 
Clinical Neurosciences, Royal Free Hospital within 1-2 hours from collection. 
The blood was processed as shown in the flowchart below (Fig 4.13). In 
summary, 8mls of SST blood were spun at 800 x g for 15min to separate the 
serum, which was frozen in 1ml aliquots at -80oC for future analyses. The 
remaining blood was used for the isolation of PBMC as described previously 
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(see section 2.3.2) and maintained under unstimulated conditions in the 
appropriate medium (see section 2.3.1) to create a cell density of 
approximately 1million PBMC/ml.  A first morning mid-stream urine sample 
was also collected from each patient. Five 1ml urine aliquots were prepared 
and both the aliquots and the remaining urine were stored at -80
o
C for future 
analyses, including the measurement of 8OHdG. 
  
Fig 4.13: Schematic representation of the experimental design used for the 
patients’ and controls’ PBMC.
40 million PBMC (in 
RPMI)
3 million PBMC 
aliquoted and       
stored at -80C
7 million PBMC 
treated with 0.5µM 
rotenone overnight
1 million PBMC stored 
in mTOR buffer
4 million PBMC treated 
with 100µM       
paraquat overnight
25 million PBMC 
incubated overnight 
without treatment
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Future analyses (eg TaqMan)
ATP (4 million) 
TMRM (2 million) 
DHE (1 million)
ATP (4 million) 
TMRM (2 million) 
DHE (1 million) 
Aconitase (4 million) 
Calcium assay (1 million)
Remaining lymphocytes aliquoted and 
stored at -80C
mTOR assay
Aconitase assay
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4.3.2 Baseline characteristics 
Demographic and other baseline clinical data 
The mean age of the subjects (control: 67.8, NTG: 73.9, and OHT: 67.8 years) 
was similar between the three groups and only slightly higher in the NTG 
group. Most participants were white, with the exception of 2 controls, 3 NTGs 
and 2 OHTs of Asian ethnic background, and 3 NTGs and 1 OHT of Carribean 
background. Right and left eyes were almost equally represented between the 
three groups. The median rate of VF progression for the whole field over the 
follow-up period, measured with the Moorfields Progressor software (section 
2.2.8), was -1.14dB/year (IQR -1.05 to -1.49) in the NTG group, while the 
median rate only for the VF progressing points was -3.24dB/year. It is clear that 
this NTG group was carefully selected to represent a fast-progressing group, 
while the OHT cohort showed no (or minimal) progression with a median rate 
of -0.11dB/year (IQR 0.03 to -0.23). It should also be noted that all the OHT 
patients had full VFs and that a significant number of VFs was performed in the 
NTG and OHT groups to provide sufficient information for representative 
progression measurements. Importantly, despite the fast disease progression, 
the mean IOP in the NTG group over 6 years of follow-up was only 13.2mmHg. 
In the OHT group, despite no VF progression, the mean IOP over 8.5 years of 
follow-up was 25.0mmHg. The mean CCT was higher in the OHT group 
(579.6µm) and lower in the NTG group (528.8µm), as compared to the controls 
(547.2µm). The mean cup-to-disc ratio in the OHT subjects was very similar to 
the controls, while the NTG group showed advanced cupping with an almost 
double cup-to-disc ratio, as compared to the other two groups. By definition, 
none of the controls had a family history (FH) of glaucoma. Amongst the 16 
NTGs and 19 OHTs with a positive FH of glaucoma, first degree relatives were 
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reported in 15 subjects from each group. Protocol violations were noted in 
participant n23, whose mean GAT IOP during follow-up was 16.3; in n27, who 
was 101 years of age and could not be age-matched; and in o29, whose VF 
progression rate was -0.63dB/year. The records of the latter participant were 
rechecked to confirm that he does not suffer from glaucoma and the relatively 
high progression rate was attributed to a Progressor software error. All 30 
participants from each group were included in the analysis. 
Variable Control (n=30) NTG (n=30) OHT (n=30) 
Mean age (±SD) 67.8 (±8.2) 73.9 (±11.7) 67.8 (±8.9) 
Ethnicity (white) 28 24 27 
Right eyes 18 16 18 
Median (IQR) VF 
progression rate 
(dB/year)  
n/a -1.14 (-1.05 to -1.49) -0.11 (0.03 to -0.23) 
Median number of 
VFs (IQR) 
n/a 9.5 (8.75 to 11) 10.5 (8 to 11) 
Median years of 
follow-up (IQR) 
n/a 6.0 (5.0 to 6.5) 8.5 (7.0 to 10.15)  
Mean GAT IOP 
during follow-up 
(mmHg) (range) 
n/a 13.2 (9.1-16.3) 25.0 (24.0 to 26.6) 
Mean maximum 
reported GAT IOP 
(mmHg) 
n/a 19.8  33.4 
Cup-to-disc ratio 0.40 0.88 0.49 
Family history  0 16 19 
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Table 4.1: Demographic and other baseline clinical data for Control, NTG and 
OHT subjects in the mitochondrial pilot study; n/a: not applicable.  
 
Cardiovascular background and other past medical history  
Symptoms of Raynaud’s, vasospasm and migraines were significantly over-
represented in the NTG cohort. Extreme dippers, defined as subjects whose 
mean night time SBP was more than 20% lower as compared to the mean day 
time ambulatory SBP, were equally distributed between the three groups. The 
mean SBP during the day and at night were higher in the OHT group, as 
compared to the other two groups, while the mean DBP was lower in the NTG 
group. The mean body mass index (BMI), which represents a balance between 
nutrient intake from all sources and energy expenditure, was relatively higher 
in the OHT subjects, as compared to the other two groups. History of systemic 
hypertension and diabetes mellitus was more common in the NTG and OHT 
groups, as compared to the control subjects. Other cardiovascular diseases, 
including cerebrovascular accident and myocardial infarction, were rare in our 
cohort. Cancer was slightly over-represented in the OHT cohort, while 
hypothyroidism was far more common in the NTG group. 
 Control  NTG  OHT  
Raynaud’s or 
vasospasm 
0 6 0 
Migraine 4 8 0 
Extreme dippers 3 3 3 
SBP during day 
(mmHg) (mean±SD) 
133.2±16.6 133.0±13.1 145.5±17.7 
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DBP during day 
(mmHg) (mean±SD) 
79.5±10.4 70.9±9.5 79.2±9.5 
SBP at night  
(mmHg) (mean±SD) 
117.4±17.1 117.7±15.9 127.6±20.6 
DBP at night 
(mmHg) (mean±SD) 
64.1±7.7 59.0±8.1 64.0±9.2 
Systemic 
Hypertension 
7 14 13 
Diabetes mellitus 0 2 5 
Other cardiovascular 
history (CVA, MI) 
2 3 0 
Body Mass Index 
(mean±SD) 
25.4±4.7 25.0±6.5 27.4±5.0 
Cancer 2 4 6 
Hypothyroidism 1 7 2 
Table 4.2: Cardiovascular background and other past medical history in our 
cohort; SBP: systolic blood pressure; DBP: diastolic blood pressure; CVA: 
cerebrovascular accident; MI: myocardial infarction. 
Discussion: Symptoms of Raynaud’s or vasospasm were significantly over-
represented in the NTG cohort. This is interesting, considering evidence from 
the literature that supports an association between vasospasm and glaucoma, 
and an abnormal peripheral reactivity to cold in glaucoma patients (Gasser et 
al 1990), and particularly in NTG (Gasser et al 1991, Drance et al 1988). 
Migraines were also more common in our NTG group, in line with previous 
studies (Phelps et al 1985, Cursiefen et al 2000, Orgul et al 1994a), although 
other studies have not confirmed this association between migraines and NTG 
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(Usui et al 1991, Wang et al 1997). Also, a history of hypothyroidism was more 
often encountered in the NTG cohort, consistent with previous studies 
showing that hypothyroidism can be associated with OAG (Girkin et al 2004, 
Smith et al 1993, Jämsén 1996) and with changes in ocular blood flow in 
glaucoma patients that may be reversible upon treatment of the 
hypothyroidism (Smith et al 1992). Another mechanism for increased OAG risk 
in hypothyroidism, proposed by Becker et al in 1966, was the presence of 
myxoedema of the trabecular meshwork in patients with abnormal thyroid 
function (Becker et al 1966). Similarly to the study by Smith et al, who found 
that 23% of POAG patients suffered from hypothyroidism (Smith et al 1993), 
exactly the same percentage of our NTG subjects (n=7) also had a history of 
thyroid disease. However, other studies have not been able to show a link 
between hypothyroidism and OAG (Karadimas et al 2001, Munoz-Negrete et al 
2000, Motsko et al 2008), with the authors suggesting that the large 
proportion of patients receiving thyroid replacement therapy may have 
negated any OAG-related consequences of hypothyroidism.  
With regards to systemic blood pressure, SBP both during the day and at night 
was found to be relatively increased in the OHT group, in line with previous 
reports that show blood pressure and IOP to be positively associated (Hennis 
et al 2003, Klein et al 2005). However, the DBP was lower in the NTG cohort, in 
line with evidence from the Thessaloniki Eye Study that lower DBP secondary 
to antihypertensive treatment was associated with increased disc cupping and 
decreased rim area (Topouzis et al 2006). Similarly, a lower DBP was linked to a 
higher prevalence of OAG in the Los Angeles Latino Eye Study (Memarzadeh et 
al 2010). 
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The relatively increased BMI in the OHT group may be consistent with the 
recently reported finding in the Rotterdam Study that obesity was associated 
with a higher IOP and a lower risk of developing OAG, although these 
associations were only present in women (Ramdas et al 2011b). In line with the 
Rotterdam Study, various other studies also document a positive association 
between BMI and IOP (Yoshida et al 2003, Klein et al 1992b, Wu et al 1997, 
Mori et al 2000), while the few studies that have directly studied the relation 
between BMI and POAG suggest an inverse association between BMI and 
POAG (Gasser et al 1999, Leske et al 1995). In our study, the mean BMI in the 
NTG was only marginally lower as compared to the control group and, similarly 
to the study by Gasser et al, this difference was not statistically significant. 
Cancer and diabetes mellitus were slightly more frequent in the OHT group, 
although it is unclear to what extent these conditions would have affected 
mitochondrial function in the lymphocytes. Lymphocytes may not be as 
critically involved in the pathophysiology of certain diseases as other tissues, 
and type II diabetes, for example, has been associated with mitochondrial 
dysfunction in insulin-sensitive tissues, including myocytes (Kelley et al 2002), 
hepatocytes (Sivitz et al 2010, Vester et al 1957) and adipocytes (Choo et al 
2006), but not in lymphocytes. It is also important to note the relatively short 
half life of peripheral blood lymphocytes (usually days to month) and their 
relatively high turnover, which would perhaps minimise the accumulating 
impact of chronic diseases on mitochondrial function. Fortunately, no patients 
in our cohort were suffering from active haematological malignancy or 
infection at the time of the blood sampling or had undergone recent 
chemotherapy, factors which, if present, might have impacted more directly on 
the function of the lymphocytes. 
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Systemic medications and lifestyle parameters 
Smokers were only found in the OHT group and above average alcohol 
consumption (>21 units/week for males and >14 units/week for females) was 
slightly more common in the control group. Above average (≥5 cups a day) 
coffee consumption, the primary dietary source of caffeine, was noted in very 
few subjects from each cohort. Antioxidant supplements were equally 
common between the control and NTG groups, while the frequency of 
antioxidant supplements in the OHT group was significantly lower and almost 
half, as compared to the other two groups. Intake of NSAIDs was slightly more 
common in the NTG group, while statins were almost equally represented 
between the NTG and OHT subjects and were less common in the control 
group. Topical prostaglandin analogues and b-blockers were slightly more 
common in the NTG as compared to the OHT group, while none of the controls 
were on topical medications. 
 Control NTG OHT 
Smoking 0 0 3 
Alcohol
1 
6 2 3 
Coffee
2 
3 1 3 
Antioxidant 
supplements 
15 14 7 
NSAIDs 4 8 6 
Statins 5 13 12 
PG analogues
3 
0 20 17 
B-blockers
3 0 11 7 
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Table 4.3: Systemic medications and lifestyle parameters in our cohort; 1 >21 
units/week for males and >14 units/week for females; 
2 
≥5 cups a day; 
3 
topical 
medications; NSAIDs: non steroidal anti-inflammatory drugs; PG: 
prostaglandin. 
Discussion: In terms of the role of systemic medications on mitochondrial 
function, it is important to note the tissue specificity of such medications. 
Statins, for example, have been shown to be beneficial to heart muscle 
mitochondria, while having a damaging effect on mitochondria from skeletal 
muscle and causing rabdomyolysis (Bouitbir et al 2012, Jones et al 2003). 
Similarly, pioglitazone is thought to improve mitochondrial biogenesis in the 
adipose tissue, while having the opposite effect in the pancreas (Bogacka et al 
2005, Lamontagne et al 2009). Another commonly used group of drugs, b-
blockers, improves mitochondrial function in the cardiac muscle, but not in 
skeletal muscle (Dreisbach et al 1993, Hugel et al 1999). This tissue specificity 
of medications on mitochondrial function could reflect the different 
mechanisms of action of drugs and their interaction with other drugs, as well 
as the diverse energy requirements of different tissues and their unique 
receptor profiles, which eventually impacts on intracellular signals and 
mitochondrial function. Also, the fact that NSAIDS were slighty more common 
in the NTG group may not have impacted significantly on mitochondrial 
function in this group, since it was not possible to find convincing evidence 
that NSAIDS affect lymphocytic mitochondria, although NSAIDs are known to 
affect gastrointestinal mucosa mitochondria (Somasundaram et al 2000) and 
liver mitochondria (Browne et al 1999). Moreover, no convincing evidence 
exists to date to suggest that drugs applied topically would have a major 
impact on human circulating lymphocytes. 
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By focusing on evidence for systemic medications that could have a direct 
negative effect on lymphocytic mitochondria, it was discovered that such 
effect has clearly been reported for amiodarone (Yasuda et al 1996), 
tetracyclins, chloramphenicol (Riesbeck et al 1990) and antiretroviral drugs 
(Tolomeo et al 2003). None of our subjects were on any of the above 
medications at the time of the blood collection. Smoking has also been 
described to clearly affect lymphocytic mitochondrial function (Miro et al 1999, 
Cardellach et al 2003), although, in the only 3 OHT patients who smoked, 
mitochondrial function was not significantly reduced. Nevertheless, it remains 
possible that the results of enhanced mitochondrial function in the OHT group 
(see section 4.3.3) have been masked to some extent by the presence of 
smokers in this group.  Interestingly, in a prospective study evaluating the 
effect of cigarette smoking on the risk of POAG, after controlling for potential 
risk factors of POAG, including age, hypertension and African American 
heritage, neither current smokers nor past smokers were at greater risk for 
POAG than those who had never smoked (Kang et al 2003). Similarly, a 
systematic literature review concluded that there is little evidence for a causal 
association between smoking and POAG development, and that there is no 
evidence of a dose-response relationship with smoking or of reversibility of 
effect in the studies where this was assessed (Edwards et al 2008). 
Ethanol is also known to directly affect lymphocytic mitochondria (Kapasi et al 
2003), although the mean rate of ATP synthesis by the different complexes for 
the 6 controls that exceeded the alcohol limit was very similar to the mean 
rate of ATP synthesis for the whole control group. However, it could be argued 
that the presence of more above average alcohol consumers in the control 
group (n=6) as compared to the NTG group (n=2) could have contributed to the 
lack of significant reduction in mitochondrial function in the NTG cohort. In the 
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large prospective Nurses' Health Study and the Health Professionals Follow-up 
Study, alcohol consumption was not found to influence the risk of POAG (Kang 
et al 2007). Similarly, in the recently published results from the Rotterdam 
Study with 3939 eligible participants, smoking and alcohol consumption were 
not associated with POAG (Ramdas et al 2011b). Additional case-control and 
prevalence studies provide mixed results regarding the relation between 
alcohol use and glaucoma, with one showing an inverse relation (Fan et al 
2004), others showing no association (Wilson et al 1987, Klein et al 1993, Leske 
et al 1995) and one actually showing a positive association (Kahn et al 1980). 
Similarly, the link between alcohol and IOP is not clear, with acute ingestion of 
alcohol thought to promptly lower IOP in a dose-dependent manner (Peczon et 
al 1965, Houle et al 1967), while some studies suggest that daily alcohol 
consumption is associated with increased IOP (Leske et al 1996, Yoshida et al 
2003, Lin et al 2005).  
With regards to caffeine consumption, in a large prospective population-based 
sample of health professionals (n=121,172), consumption of ≥5 cups of 
caffeinated coffee, the primary dietary source of caffeine, daily was associated 
with 1.6-fold increased risk of POAG, while tea or caffeinated cola intake were 
not associated (Kang et al 2008). In our cohort only a very small number of 
subjects from each group consumed ≥5 cups of caffeinated coffee a day 
making it difficult to draw any conclusions. In the same study by Kang et al, 
greater caffeine intake was more adversely associated with POAG among those 
reporting a family history of glaucoma, particularly in relation to POAG with 
elevated IOP (Kang et al 2008). A typical cup of coffee is thought to cause a 
1−4mmHg rise in IOP that lasts for at least 90 minutes (Higginbotham et al 
1989, Avisar et al 2002), while in the Blue Mountain Eye Study OAG patients 
who consumed coffee regularly had higher IOP than their counterparts who 
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abstained from coffee consumption (19.6mmHg vs 16.8mmHg; p=0.03) 
(Chandrasekaran et al 2005). The mean number of cups of coffee a day in our 
cohort was 1.8, 1.2 and 1.3 for the control, NTG and OHT groups, respectively, 
and did not differ significantly between groups. 
In this pilot study, instead of excluding subjects on the basis of co-existing 
diseases, medications or lifestyle parameters, we selected patients based on 
VF progression and IOP-related criteria only. This follows a more ‘real life’ 
approach, identifying mitochondrial function and related variables as manifest 
in these patients and then identifying lifestyle factors that may account for any 
differences identified, despite the relatively small sample size and the 
multiplicity of potential variables. Lifestyle parameters were often difficult to 
accurately characterise and measure. Similarly, the contents and strength of 
antioxidant supplements varied significantly amongst subjects, making more 
detailed comparisons difficult. An alternative approach followed in this study 
was to explore the role of antioxidant defences in the three groups of 
participants by directly measuring the levels of multiple antioxidants (vitamins 
A, B6, B12, C, folate, urate) in the peripheral blood.  
 
Ocular features 
 Control  NTG  OHT  
CCT (µm) 547.2±45.9 528.8±36.6 579.6±35.5 
AL (mm) 23.8±1.4 24.3±2.2 23.7±1.3 
ACD (mm) 3.1±0.4 3.5±0.6 3.2±0.5 
SE (Dioptres) -0.6±3.1 -1.9±3.5 0.2±3.0 
Phasing GAT IOP (mmHg)  13.6±2.5 12.6±3.4 22.3±3.0 
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Phasing DCT IOP (mmHg)  16.2±2.7 15.5±3.0 23.9±2.9 
ORA IOPcc (mmHg) 14.4±3.1 15.6±3.8 23.2±3.9 
Supine GAT (mmHg)  13.2±2.7 12.3±3.6 22.1±3.9 
CRF (mmHg) 10.1±1.9 8.2±1.9 12.1±2.3 
CH (mmHg) 10.6±1.8 8.7±1.5 9.7±1.7 
Phasing DCT OPA (mmHg) 2.3±0.8 2.3±1.0 4.2±1.3 
Table 4.4: Summary (mean±SD) of ocular features for the three groups of 
participants; CCT: central corneal thickness; AL: axial length; ACD: anterior 
chamber depth; SE: spherical equivalent; GAT: Goldmann applanation 
tonometry; DCT: dynamic contour tonometry; CRF: corneal resistance factor; 
CH: corneal hysteresis; OPA: ocular pulse amplitude; ORA: ocular response 
analyser; IOPcc: corneal compensated intraocular pressure. 
The central corneal thickness was slightly higher in the OHT group and lower in 
the NTG group, as compared to the controls. The mean CCT in the control 
group was consistent with the mean CCT reported in epidemiological studies 
(Wolfs et al 1997) and meta-analyses (Doughty et al 2000). The mean AL, ACD 
and SE show that the NTG group were a little more myopic than the other two 
groups. Pseudophakia was noted in 3 controls, 15 NTG patients and 2 OHT 
patients.  
As expected, the mean diurnal GAT and DCT IOPs, calculated from the average 
of 5 GAT and 5 DCT (mean of three measurements at each time point) IOP 
measurements taken during daytime phasing (between 9am and 5pm) for each 
participant, was significantly higher in the OHT group, as compared to the NTG 
and controls. The DCT IOP, thought to display better repeatability and 
reproducibility than GAT IOP and ORA IOPcc (Kotecha et al 2010, Wang et al 
2013) and be less influenced by the corneal biomechanics (Kotecha et al 2005, 
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Kotecha et al 2009, Boehm et al 2008), was higher than the GAT IOP in all three 
groups and this difference was smaller in the group with higher IOP and thicker 
CCT (OHT group). Also, the difference between DCT and GAT phasing IOPs was 
highest in our NTG group. Similarly, in a recent study by Ito et al (2012) that did 
not include phasing, the mean DCT IOP was 2.8 mm Hg higher than the GAT 
IOP, with the difference being greater with thinner CCT and in the lower IOP 
group, as compared to the higher IOP group. The standard deviation of the 5 
GAT IOP diurnal phasing measurements in the control, NTG and OHT groups 
was 1.1±0.5, 1.2±0.6 and 1.8±0.7mmHg, respectively. Similarly, a higher 
variability in the 5 DCT diurnal measurements was noted in the OHT group 
(standard deviation 1.8±0.7mmHg), as compared to the control 
(1.0±0.4mmHg) and NTG groups (1.1±0.6mmHg). The variability noted during 
DCT phasing was similar and not significantly better than that noted during 
GAT phasing. The mean GAT diurnal supine IOP was similar to the mean 
phasing diurnal sitting GAT IOP in all three groups.  
Similarly to the DCT IOP, the IOPcc was also higher than the GAT IOP in all 
three groups, in line with previous studies that show GAT to under-read both 
DCT and ORA IOP measurements (Kotecha et al 2010, Sullivan-Mee et al 2012). 
Interestingly, the IOPcc was lower than the DCT IOP in both OHT subjects and 
controls, while in NTG it was marginally higher. This could be explained by the 
fact that the DCT IOP is known to be correlated with CCT (DCT IOP/CCT slope 
0.03 mmHg/µm; 95% CI 0.00-0.05) (Kotecha et al 2009), while the IOPcc is 
thought to be less affected by CCT (Nessim et al 2013) and believed not to 
change significantly following laser refractive surgery, although this has not 
been confirmed in several studies (Pepose et al 2007, Shah et al 2009). A 
higher IOPcc in NTG was also reported recently in a Japanese cohort, with the 
authors suggesting that IOP values may be underestimated with GAT and DCT 
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(Morita et al 2010).  The CRF was lower in the NTG group and higher in the 
OHT group, as compared to the controls. Interestingly, while the CH was 
similar to the CRF in the controls and NTG subjects, in the OHT patients the 
mean CH was lower than the CRF, underlying the distinct corneal properties 
represented by these two parameters. Similarly to our study, lower CRF and CH 
in glaucoma have also been noted in several previous studies for both NTG 
(Nessim et al 2013) and POAG (Abitbol et al 2010, Mangouritsas et al 2009).  
The mean phasing DCT OPA was significantly higher in the OHT cohort, as 
compared to the NTG patients and controls. Increased OPA has been shown to 
correlate with less severe glaucoma (Kynigopoulos et al 2012) and with 
increased CCT (Weizer et al 2007) and GAT and DCT IOP (Kaufmann et al 2006, 
Ishii et al 2012), as in our OHT group. No difference was noted in the OPA 
between the controls and NTG, as reported recently by Lee et al (2012), 
although other studies have reported a reduction in OPA in NTG patients as 
compared to controls (Stalmans et al 2008, Schwenn et al 2002). Based on the 
thinner cornea and lower DCT and GAT IOPs in the NTG group, one might have 
expected a smaller OPA in NTG as compared to the control group. However, 
OPA has also been shown to be negatively correlated with DBP (Detry-Morel et 
al 2007) and the lower DBP in our NTG cohort may have accounted for this lack 
of difference in the OPA between NTG and control. 
 
4.3.3 Measurements relating to mitochondrial function – content 
4.3.3.1 Introduction 
In the box-and-whisker plots presented below, the middle (horizontal) line of 
each box represents the median. The lower and upper horizontal lines of each 
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box represent the lower and upper quartile values, respectively. The difference 
between the lower and upper quartiles is the interquartile range (IQR). Results 
are presented as median (IQR) for each parameter (n=30 from each group); 
*p<0.05, **p<0.01, ***p<0.001, NS: not significant. Outliers are highlighted 
with a circle or asterisk on the box-and-whisker plot. 
 
4.3.3.2 ADP Phosphorylation Assay (complexes I, II/III and IV) 
 
 
Fig 4.14: The rate of ATP synthesis by complex I in the lymphocytes of NTG, 
OHT patients and controls. The ATP synthesis rate is expressed in 
pmol/min/mg lysate.  
** 
*** 
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Complex I: A statistically significant increase in the rate of ATP synthesis by 
complex I was noted in the OHT group [8632 pmol/min/mg, (3788 to 11798)] 
as compared to the NTG [6063 pmol/min/mg, (1810 to 10380)] and controls 
[4646 pmol/min/mg, (3438 to 8148)]. The difference between NTG and 
controls was not significant (p=0.804). 
 
 
Fig 4.15: The rate of ATP synthesis by complexes II/III in the lymphocytes of 
NTG, OHT patients and controls. The ATP synthesis rate is expressed in 
pmol/min/mg lysate.  
Complexes II/III: A statistically significant increase in the rate of ATP synthesis 
by complex I was noted in the OHT group [7709 pmol/min/mg, (4732 to 
11640)] as compared to the NTG [4663 pmol/min/mg, (1896 to 8959)] and 
** 
*** 
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controls [3627 pmol/min/mg, (1961 to 7086)]. The difference between NTG 
and controls was not significant (p=0.509). 
 
 
Fig 4.16: The rate of ATP synthesis by complex IV in the lymphocytes of NTG, 
OHT patients and controls. The ATP synthesis rate is expressed in 
pmol/min/mg lysate.  
Complex IV: A statistically significant increase in the rate of ATP synthesis by 
complex IV was noted in the OHT group [1876 pmol/min/mg, (610 to 3019)] as 
compared to the NTG group [605 pmol/min/mg, (172 to 1772)]. The difference 
between controls [1166 pmol/min/mg, (442 to 2701)] and either NTG or OHT 
was not significant (p=0.102 and 0.382, respectively), although there was a 
trend for the NTG group to show lower levels of ATP, as compared to the 
** 
  
controls. Upon correction of the rate of ATP synthesis for mitochondrial
content, as measured by porin
significantly lower in the NTG group, as compared to both the controls (p=0.03) 
and OHT subjects (p=0.005) (Fig 4.17
II/III, upon porin correction all the significant differences in the rate of ATP 
synthesis noted between the OHT and the other two groups were maintained 
(data not shown), as described previously.
Fig 4.17: The rate of ATP synthesis by complex IV, after correction for
the lymphocytes of NTG, OHT patients and controls. The ATP synthesis rate is 
expressed in pmol/min/mg lysate.
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, the complex IV-driven ATP synthesis was 
). In the case of complex I and complexes 
 
  
* ** 
 
 porin, in 
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Discussion: These results suggest for the first time that, compared with the 
NTG and control groups, lymphocytes from the OHT group may have more 
efficient mitochondria, capable of producing more energy under conditions of 
unrestricted substrate supply, or contain a higher percentage of well 
functioning mitochondria per cell, as demonstrated by the higher levels of ATP 
produced by mitochondrial complexes I, II/III and IV. RGCs are known to be 
particularly vulnerable to OXPHOS impairment, especially in the presence of 
external stressors, such as raised IOP (Kong et al 2011), and the finding of good 
systemic mitochondrial function in OHT subjects may contribute to the 
reduced susceptibility of their RGCs and may be implicated in resistance to 
glaucomatous optic neuropathy and glaucoma progression. Similarly to the 
study by Lee et al (2012), discussed in more detail in section 1.6.1, complex II 
driven ATP synthesis was similar in our NTG cohort and the controls. However, 
unlike the latter study, which showed that POAG lymphoblasts have lower 
rates of complex I driven ATP synthesis, as compared to controls (Lee et al 
2012), the results presented here do not support the presence of a significant 
defect in complex I in NTG. It should be noted though that the complex I defect 
in the study by Lee et al was not sufficient to impact negatively on the ability of 
the POAG lymphoblasts to grow in galactose media, where they were forced to 
rely on mitochondrial ATP production, and that the EBV-transformed 
lymphocytes (lymphoblasts) used by Lee et al. may behave differently from the 
unstimulated fresh lymphocytes employed in our cohort. 
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4.3.3.3 Mitochondrial Membrane Potential (steady-state 
TMRM staining) 
 
 
Fig 4.18: This graph presents the TMRM staining in the lymphocytes of controls 
and NTG and OHT patients. TMRM staining is expressed as the mean red 
fluorescence % change from Raji, which acts as an internal control (100%, not 
shown here). 
The OHT lymphocyte TMRM staining [184% (152 to 215)] was significantly 
higher than that in the NTG [170% (140 to 196)] and control [166% (141 to 
187)] groups. The difference between NTG and controls was not significant 
(p=0.716). 
** * 
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Fig 4.19: The TMRM staining in the lymphocytes of controls and NTG and OHT 
patients, upon rotenone treatment (0.5µM 24hrs). TMRM staining is expressed 
as the mean red fluorescence % change from Raji, which acts as an internal 
control (100%, not shown here). 
 
Upon rotenone treatment, the TMRM staining for the control, NTG and OHT 
groups was significantly reduced to 145% (118 to 161) (p<0.001 comparing to 
baseline), 150% (115 to 169) (p<0.001) and 154% (134 to 173) (p<0.001), 
respectively. Even after rotenone treatment, the OHT group maintained higher 
levels of TMRM staining than the controls, although the difference was not 
significant (p=0.062), and significantly higher TMRM staining than the NTG 
group (p=0.031). 
* 
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Discussion: These findings suggest for the first time that lymphocytes from the 
OHT group demonstrate a higher ΔΨm, as compared to the NTG and control 
groups. This finding is in line with the increased rate of ATP synthesis in the 
OHT group and in support of the idea that OHT patients demonstrate healthy 
and efficient systemic mitochondria, especially since the ΔΨm is a key indicator 
of mitochondrial function, as discussed in section 2.3.5. Interestingly, however, 
excessive increase in the ΔΨm is thought to be associated with slowed 
electron transport, particularly at complex III, prolonged ubiquinol occupancy 
in the complex and increased electron leak thus favouring ROS production 
(Zhang et al 2007), while uncouplers of OXPHOS, such as 2,4-dinitrophenol and 
mitochondrial uncoupling proteins (UCPs), a family of mitochondrial anion 
carriers that induce proton leak across the inner membrane, suppress the ΔΨm 
resulting in reduced ROS formation (Fink et al 2005, Duval et al 2002). 
Nevertheless, in view of the increased ATP production by various 
mitochondrial complexes (I, II/III and IV) in the OHT cohort, the overall 
increased ΔΨm reported in this group, as reflected by the TMRM staining, is 
unlikely to represent the presence of heavily hyperpolarised mitochondria in 
the OHT lymphocytes, and should be attributed to the presence of more 
efficient mitochondria or of a higher percentage of well functioning 
mitochondria per OHT lymphocyte. The increased TMRM staining in OHT could 
also represent an increase in mitochondrial content in this group, without 
necessarily an increase in the ΔΨm per mitochondrion, although this is not 
supported by the lack of any difference in mitochondrial content between the 
three groups, as measured by porin and citrate synthase enzymatic activity 
below (see section 4.3.3.6). 
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4.3.3.4 Calcium mobilisation 
 
Fluo3 (Cytosolic calcium) 
 
Fig 4.20: Graph showing the change in fluo3 fluorescence upon ionomycin 
treatment divided by the baseline fluo3 fluorescence (fluo3 ΔF/Fo) in the 
control, NTG and OHT lymphocytes. 
The median (IQR) fluo3 ΔF/Fo for the control, NTG and OHT groups, was 0.09 
(0.0375 to 0.15), 0.065 (0.03 to 0.125) and 0.06 (0.025 to 0.115), respectively. 
Although the difference between the three groups was not significant, the 
fluo3 ΔF/Fo was lowest in the OHT group. Smoking is known to impact 
negatively on lymphocytic mitochondrial function (section 4.3.2) and, 
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interestingly, in a post-hoc analysis for non-smokers (all study participants 
apart from 3 OHT subjects who were active smokers), the fluo3 ΔF/Fo in OHT 
subjects [0.05 (0.02 to 0.0825)] was significantly lower as compared to the 
controls (Fig 4.21 below), while there was no difference between NTG subjects 
and controls. The low fluo3 ΔF/Fo in the OHT lymphocytes would suggest the 
presence of less free Ca
+2
 in the cytosol after ionomycin treatment, which, in 
view of the aforementioned better ATP synthesis and ΔΨm in OHT, could 
potentially represent a better capacity of the OHT mitochondria to take up free 
Ca+2 from the cytosol. 
 
 
Fig 4.21: Graph showing the fluo3 ∆F/Fo for the control, NTG and OHT 
lymphocytes, in non-smokers. 
* 
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Rhod 2 (Mitochondrial calcium) 
 
Fig 4.22: Graph showing the change in rhod2 fluorescence upon ionomycin 
treatment divided by the baseline rhod2 fluorescence (rhod2 ΔF/Fo) in the 
control, NTG and OHT lymphocytes. 
The median (IQR) rhod2 ΔF/Fo for the control, NTG and OHT groups, was 0.075 
(0.028 to 0.125), 0.04 (0.01 to 0.083) and 0.035 (0.075 to 0.053), respectively. 
A significant difference was noted between the control and the other two 
groups, while, similarly to the fluo3 ΔF/Fo above, the rhod2 ΔF/Fo was lowest 
in the OHT group. Again, in the absence of smokers, the rhod2 ΔF/Fo in OHT 
was further reduced [0.03 (0.00 to 0.04)], as compared to the control [0.075 
(0.028 to 0.125)] and NTG [0.04 (0.01 to 0.083)] groups (Fig 4.23 below).  
** 
** 
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Fig 4.23: Graph showing the rhod2 ΔF/Fo for the control, NTG and OHT 
lymphocytes, in non–smokers. 
The low rhod2 ΔF/Fo in the OHT lymphocytes would suggest the presence of 
less free mitochondrial Ca+2 after ionomycin treatment, which, in view of the 
aforementioned better ATP synthesis and ΔΨm in OHT, could potentially 
represent the better capacity of the OHT mitochondria to buffer free 
mitochondrial Ca
+2
. Buffering capacity could be regarded as an additional 
measure of mitochondrial function, as explained in more detail in the 
discussion below. It is however difficult to explain why the rhod2 ΔF/Fo in NTG 
subjects was lower than in the control group, although ionomycin has been 
accused of inducing variable mitochondrial depolarisation in the acute phase in 
intact cells (Abramov et al 2003), thus causing unexpected changes to Ca
+2
 
** 
** 
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kinetics. Perhaps, therefore, the changes described above (fluo3 ΔF/Fo and 
rhod2 ΔF/Fo) in the Ca
+2 
dynamics in the acute phase after ionomycin 
treatment may not be as representative as the changes during the more 
chronic phase (Δrhod2 chr / Δfluo3 chr), presented below. 
 
Δrhod2 / Δfluo3 (chronic phase) 
 
 
Fig 4.24: Graph showing the rate of increase in the rhod2 fluorescence during 
the chronic phase divided by the rate of increase in the fluo3 fluorescence 
during the same phase (Δrhod2 chr/ Δfluo3 chr) in the control, NTG and OHT 
lymphocytes. 
The median (IQR) Δrhod2 chr/ Δfluo3 chr for the control, NTG and OHT groups, 
was 0.55 (0.41 to 0.79), 0.60 (0.37 to 0.88) and 0.39 (0.24 to 0.59), 
** 
* 
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respectively. A significant difference was noted between the OHT and the 
other two groups, while no difference was found between control and NTG 
(p=0.696). Similarly to the fluo3 ΔF/Fo and rhod2 ΔF/Fo above, the Δrhod2 chr/ 
Δfluo3 chr was lowest in the OHT group. In the absence of smokers, the 
Δrhod2 chr/ Δfluo3 chr in OHT [0.39 (0.28 to 0.58)] was again significantly 
lower, as compared to the control [0.55 (0.41 to 0.79)] and NTG [0.60 (0.37 to 
0.88)] groups (Fig 4.25 below). The low Δrhod2 chr/ Δfluo3 chr in the OHT 
lymphocytes would suggest a relative reduction in free mitochondrial Ca
+2
 and 
relative increase in free cytosolic Ca
+2
 during the chronic phase of calcium 
mobilisation following ionomycin treatment. Again, this could potentially be 
interpreted as reflecting a better capacity of the OHT mitochondria to buffer 
free mitochondrial Ca+2. Alternatively, this could also reflect a better function 
of the mitochondrial calcium uniporter (MCU) in the OHT lymphocytes, as 
explained in more detail in the discussion below.  
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Fig 4.25: Graph showing the Δrhod2 chr/ Δfluo3 chr for the control, NTG and 
OHT lymphocytes, in non–smokers.   
 
Discussion: In summary, these results highlight the enhanced capacity of the 
OHT mitochondria both to take up free Ca
2+
 (fluo3 ΔF/Fo), especially in non-
smokers, and to buffer free Ca
2+
 (rhod2 ΔF/Fo and Δrhod2 chr/ Δfluo3 chr). The 
main transporter involved in the uptake of Ca
2+
 into the mitochondria is the 
MCU, an inner mitochondrial membrane (IMM)-located channel driven by the 
IMM electrochemical gradient (Kirichok et al 2004, De Stefani et al 2011, 
Bragadin et al 1979). Importantly, a biphasic effect of Ca2+ on the MCU has 
been reported: beyond a certain level, cytosolic Ca
2+
 inactivates the uniporter, 
preventing further Ca
2+
 uptake and this process might prevent an excessive 
accumulation of the cation in the mitochondria (Moreau et al 2006). Perhaps in 
* 
* 
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efficiently functioning mitochondria, such as in the OHT group, this 
compensatory mechanism remains intact after the ionomycin insult, thus 
protecting the OHT mitochondria from excessive influx of Ca
2+
, while in less 
healthy mitochondria, such as in the Control and NTG groups, this mechanism 
is less efficient leading to overloading of the mitochondria with Ca
2+
 and 
increasing the Δrhod2 chr/ Δfluo3 chr. This overloading is known to lead to the 
opening of the mitochondrial permeability transition pore (mPTP) and cause 
cell death either by energetic collapse and ATP depletion or by initiating 
mitochondrial swelling (Giorgi et al 2008, Abramov et al 2003). Interestignly, a 
link between normal MCU function and intact mitochondrial metabolic activity 
has been suggested, and our ATP results would support this hypothesis. 
Evidence for this link can be obtained from a recent study from Perocchi et al, 
who demonstrated that silencing MICU1 (mitochondrial calcium uptake 1), a 
key regulator of MCU, abolishes Ca
2+
 entry in intact and permeabilised cells, 
and attenuates the metabolic coupling between cytosolic Ca
2+
 transients and 
activation of mitochondrial matrix dehydrogenases (Perocchi et al 2010).  
Another explanation for finding that free mitochondrial Ca2+ was lower in the 
OHT lymphocytes, as compared to NTG and controls, is the capacity of the 
mitochondria under physiological conditions to buffer mitochondrial Ca
2+
 (Hoth 
et al 1997, Babcock et al 1997). This can be achieved either by interaction of 
mitochondrial Ca
2+ 
with negatively charged intramitochondrial polyphosphates 
(PolyPs), strong chelators of divalent cations known to form complexes with 
Ca2+ and play an important role in cellular metabolism, or by efficient export of 
mitochondrial Ca
2+
 into the cytosol. The results presented here could imply 
that the healthy mitochondria in the OHT group are more capable of buffering 
mitochondrial Ca
2+
, thus reducing the amount of free Ca
2+
 that can be detected 
by rhod2. PolyPs participate in the regulation of gene expression, protect cells 
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from the toxicity of heavy metals by forming complexes with them and 
participate in channel formation through assembly into complexes with 
polyhydroxybutyrate (PHB) and Ca
2+
 (polyP/Ca2+/PHB complex) (Reusch 1989). 
Importantly, the presence of abundant PolyPs in the OHT mitochondria would 
be in line with the better mitochondrial function noted in the OHT group, since 
PolyPs are known to directly bind to mitochondrial proteins and regulate their 
activities, and are required for normal function of the respiratory chain, 
especially Complex IV (Abramov et al 2007). Also, calcium export from the 
mitochondria into the cytosol is achieved via multiple mechanisms, including 
an electroneutral Na
+
/Ca
2+
 exchanger (Crompton et al 1976, Gunter et al 1990) 
and our data could suggest that such mechanisms are more efficient in the 
healthier mitochondria of the OHT group, as compared to those from NTG 
patients and controls. 
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4.3.3.5 Mammalian Target of Rapamycin (mTOR) activity 
 
  
 
Fig 4.26: The mTOR activity, expressed as the ratio between phosphorylated 
(active) mTOR and total mTOR, in the control, NTG and OHT lymphocytes. 
The median (IQR) mTOR activity in the control, NTG and OHT groups, was 
0.307 (0.21 to 0.42), 0.243 (0.18 to 0.36) and 0.308 (0.19 to 0.40), respectively. 
There was a trend for the NTG cohort to have lower mTOR activity, as 
compared to the other two groups, although no statistically significant 
difference was noted between the three groups. Interestingly, activation of the 
mTOR pathway is known to mediate vasospastic phenomena (Zhang et al 
2012) and in a post hoc analysis of a subgroup of patients without history of 
vasospasm/Raynaud’s (all participants apart from 6 NTG subjects), a 
statistically significant reduction in the mTOR activity was noted in the NTG 
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subjects [0.229 (0.15 to 0.33)], as compared to the controls [0.307 (0.21 to 
0.42)] (Fig 4.27 below). When the 3 OHT smokers were removed from the 
analysis, the median (IQR) in the OHT group increased from 0.308 (0.19 to 
0.40) to 0.320 (0.21 to 0.40), further supporting the link between smoking, 
mTOR inhibition and lymphocytic mitochondrial dysfunction.  
 
Fig 4.27: The mTOR activity in the control, NTG and OHT lymphocytes, in 
subjects without history of vasospasm-Raynaud’s. 
Discussion: As discussed in more detail in section 2.3.11, mTOR colocalises with 
the outer mitochondrial membrane (Desai et al 2002) and mTOR suppression 
has been found to result in increased autophagy, reduced mitochondrial 
function (Ramanathan et al 2009) and decreased mitochondrial respiration 
(Schieke et al 2006). Based on this relationship between mTOR activity and 
* 
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mitochondrial function, the reduced mTOR activity in the lymphocytes of the 
NTG patients would suggest for the first time that mTOR dysfunction may be 
implicated in the pathogenesis of NTG and could shed some light to the link 
between mitochondrial dysfunction and glaucoma, at a cellular mechanistic 
level. 
The link between mTOR and vasospasm is a very novel and interesting one. 
mTOR inhibitors have been shown to decrease hypoxia inducible factor 1α 
(HIF1α) levels (Carew et al 2011, Faivre et al 2006), while HIF1a inhibition is 
known to reduce the cerebral vasospasm following subarachnoid haemorrhage 
in rats and attenuate the expression of its downstream target vascular 
endothelial growth factor (VEGF) (Yan et al 2006). VEGF is a potent stimulant of 
angiogenesis and is involved in the pathogenesis of cerebral vasospasm 
(Bhardwaj 2003, Borel et al 2003, McGirt et al 2002). Also, in the recent study 
by Zhang et al (2012), treatment with the mTOR inhibitors rapamycin and 
AZD8055 led to the attenuation of angiographic vasospasm and improvement 
in clinical behavioral scores. The results presented in this thesis support the 
above link between mTOR and vasospasm, possibly mediated via HIF1a and 
VEGF, and highlight for the first time this link in humans with glaucoma. 
 
4.3.3.6 Mitochondrial content 
TOM20 
TOM20 (Translocase of the Outer Membrane 20 or Mitochondrial import 
receptor subunit tom20) is a 20kDa outer mitochondrial membrane protein 
that forms a central component of the receptor complex responsible for the 
recognition and translocation of cytosolically synthesised mitochondrial 
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preproteins. Together with TOM22 it functions as the transit peptide receptor 
at the surface of the mitochondrial outer membrane and is a well known 
measure of mitochondrial content (Goping et al 1995, Likic et al 2005).  
 
Fig 4.28: Graph showing the protein levels of TOM20 in the control, NTG and 
OHT lymphocytes. TOM20 is expressed as a percentage of Raji (100%, not 
shown here), which served as an internal control. 
The median (IQR) TOM20 levels in the control, NTG and OHT groups, were 0.08 
(0.57 to 0.11), 0.08 (0.04 to 0.10) and 0.11 (0.07 to 0.13). Interestingly, the 
levels of TOM20 were significantly higher in the OHT group, as compared to 
the other two groups, while no statistically significant difference was noted 
between the NTG and control (p=0.381) (Fig 4.29). 
* 
* 
  
  
Fig 4.29: Representative western blot bands for TOM20, porin and SOD2
well as for the loading control (b
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caveolae and the plasma membrane, where they are involved in cell volume 
regulation and apoptosis (Bathori et al 1999). 
 
Fig 4.30: Graph showing the protein levels of porin in the control, NTG and OHT 
lymphocytes. Porin is expressed as a percentage of Raji (100%, not shown 
here), which served as an internal control. 
The median (IQR) porin levels in the control, NTG and OHT groups, were 0.29 
(0.24 to 0.32), 0.30 (0.23 to 0.37) and 0.29 (0.24 to 0.34). No statistically 
significant difference was noted in porin levels between the three groups (Fig 
4.29). 
 
Citrate synthase  
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As discussed in section 2.3.9, citrate synthase (CS), unlike TOM20 and porin, is 
localised in the mitochondrial matrix and is commonly used as a quantitative 
marker enzyme for the content of intact mitochondria (Holloszy et al 1970, 
Williams et al 1986). Due to its location in the mitochondria, it is thought to be 
less influenced by mitophagy and processes involved in mitochondrial damage, 
as compared to TOM20 and porin. CS is an integral enzyme in the Krebs cycle, 
where it catalyses the condensation of acetyl coenzyme A and oxaloacetate to 
form citrate (acetyl-CoA + oxaloacetate + H2O → citrate + CoA-SH), and thus its 
activity is considered to be less affected by changes in mitochondrial 
metabolism, including OXPHOS and glycolysis.  
 
Fig 4.31: Graph showing the citrate synthase (CS) activity in the control, NTG 
and OHT lymphocytes. CS enzymatic activity is expressed in µmol/min/mg. 
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The median (IQR) CS activity in the control, NTG and OHT groups, were 0.19 
(0.14 to 0.23), 0.19 (0.15 to 0.23) and 0.19 (0.13 to 0.26). Similarly to porin, no 
statistically significant difference was noted in the CS activity between the 
three groups. 
Discussion: In summary, these results demonstrate no significant change in 
mitochondrial content, as demonstrated by porin levels and CS activity, thus 
suggesting that a functionally efficient mitochondrial electron transport chain 
may be a critical mechanism underlying the increased ATP synthesis and high 
ΔΨm noted in OHT, rather than any net increase in mitochondrial content per 
se. Interestingly, the TOM20 levels in OHT were increased, as compared to the 
other two groups. Since TOM20 is an important and specific component of an 
outer mitochondrial membrane receptor complex, this increase in OHT may 
reflect a selective increase in processes involving the outer mitochondrial 
membrane. Interestingly, increased density of theTOM20 clusters has recently 
been found to be associated with a higher mitochondrial activity and higher 
mitochondrial membrane potential (Wurm et al 2011), thus further supporting 
the finding of increased ATP and ΔΨm in OHT subjects. This correlation was 
demonstrated in cells of different species origin with distinct physiological 
activities (different respiratory rates, doubling times, and cytochrome c 
oxidase activities), as well as in cells grown to different densities. However, 
unlike CS, which is located in the matrix, TOM20 would be expected to be 
more influenced by mitophagy and other outer membrane processes involved 
in mitochondrial damage, as well as by changes in mitochondrial metabolism. 
It is perhaps interesting to note that this lack of correlation between enhanced 
mitochondrial function and increased mitochondrial content noted in our OHT 
cohort has recently been confirmed in the context of diet restriction (DR) 
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(Hempenstall et al 2012). In this study, DR was able to induce PGC-1α, a 
marker of mitochondrial biogenesis, and increase mitochondrial respiration in 
mouse skeletal muscle, but without increasing mitochondrial content, as 
determined by CS activity (Hempenstall et al 2012), although other studies 
have shown an increase in CS activity following DR (Lopez-Lluch et al 2006). 
Interestingly, another study has been unable to demonstrate a change in CS 
activity in DR, while other markers of mitochondrial content and biogenesis 
were significantly increased (Civitarese et al 2007), with the authors suggesting 
that mtDNA level or other non-enzymatic structural markers of mitochondrial 
content (such as cardiolipin) may be better indicators of mitochondrial content 
than enzymatic CS activity. To provide a link with glaucoma, DR mice have 
recently been found to show greater recovery in inner retinal function 
following IOP challenge, as compared to age-matched ad libitum fed controls. 
DR was also associated with reduced oxidative stress levels (HO-1 and HNE) 
following injury and improved mitochondrial OXPHOS enzymatic activity 
(complex IV), as compared with ad libitum controls, with no significant change 
in CS activity (Kong et al 2012). DR is thought to promote mitochondrial 
biogenesis and extend life-span by inducing the expression of eNOS (Nisoli et al 
2005) and the SIRT1 deacetylase (Cohen et al 2004) and it remains to be seen 
whether the same mechanisms that become activated in the mitochondria of 
DR mice operate in the mitochondria of OHT patients or whether DR is a more 
common lifestyle factor in OHT patients.  
 
4.3.4 Measurements relating to oxidative stress and antioxidant 
defence 
4.3.4.1 Dihydroethidium (DHE) staining 
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Fig 4.32: Graph showing the percentage change in the rate of DHE oxidation in 
the lymphocytes from control, NTG and OHT subjects at baseline (before 
treatment with 0.5µM rotenone for 24hrs). The results are expressed as the 
percentage change from Raji (100%, not shown), which served as an internal 
control.  
The median (IQR) level of DHE staining in the control, NTG and OHT 
lymphocytes was 52.4% (42.3 to 77.1), 48.6% (41.3 to 74.6) and 55.4% (38.3 to 
70.0), respectively. No statistically significant difference was noted between 
the three groups, suggesting similar baseline superoxide levels between 
control, NTG and OHT lymphocytes. 
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Fig 4.33: Graph showing the percentage increase in the rate of DHE oxidation in 
the lymphocytes from control, NTG and OHT subjects after treatment with 
0.5µM rotenone for 24hrs. The results are expressed as the percentage 
increase from the level of DHE oxidation before rotenone exposure (100%, not 
shown) in the control, NTG and OHT lymphocytes. 
  
The median (IQR) % increase in DHE staining in the control, NTG and OHT 
lymphocytes after rotenone treatment was 25.6% (16.7 to 57.9), 38.0% (30.6 
to 62.9) and 15.9% (3.8 to 33.0), respectively. Although a statistically significant 
increase was noted upon rotenone treatment in all three groups, as expected 
given the strength and duration of the oxidative stress-inducing insult, this 
increase was significantly less in the OHT group, as compared to the other two 
groups. The percentage increase in the NTG and controls was similar, with the 
*** 
** 
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NTG group showing the highest % increase in superoxide staining after 
exposure to rotenone.  
Discussion: Superoxide anions, as measured by DHE staining, were present at 
similar levels in the lymphocytes from each group of participants. While high 
levels of ROS are considered to be toxic, causing cell damage and cell death, 
moderate amounts of ROS can be beneficial and serve in the function of a 
number of physiological cellular signalling pathways, in the defence against 
infectious agents, and in the induction of mitogenic responses (Valko et al 
2007). Under physiological conditions, and although the mitochondrial 
electron transport chain is a very efficient system, the very nature of the 
alternating one-electron oxidation-reduction reactions it catalyses, predispose 
each electron carrier to side reactions with molecular oxygen to produce 
superoxide. Thus, it is commonly held that mitochondrial generation of 
superoxide represents the major intracellular source of oxygen radicals. With 
estimates of 1–2% of the total daily oxygen consumption going to 
mitochondrial superoxide generation, a 60 kg woman would produce some 
160–320mmol of superoxide each day from mitochondrial respiration alone 
(based on an O2 consumption of 6.4 l/kg/day) and an 80 kg man would 
produce some 215–430mmol of superoxide per day (Cadenas et al 2000). 
When cells were treated with rotenone to generate ROS within the 
mitochondria (Li et al 2003) and expose the lymphocytes to oxidative stress, 
the OHT lymphocytes were more capable of dealing with this insult, as 
compared to the control and NTG lymphocytes, thus further supporting the 
idea of the presence of more functionally efficient mitochondria in OHT. 
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4.3.4.2 Aconitase enzymatic assay 
 
 
Fig 4.34: Graph showing the aconitase enzymatic activity in the control, NTG 
and OHT lymphocytes. In all measurements, the background (no cells with 
reaction buffer) has been subtracted and the aconitase activity is expressed in 
nmol/min/mg.   
The median (IQR) aconitase activity in the control, NTG and OHT lymphocytes 
was 1.85 (1.35 to 3.10), 1.39 (1.03 to 2.01) and 1.78 (1.39 to 2.74), 
respectively. The aconitase activity in the NTG group was significantly lower, as 
compared to the control (p=0.015) and OHT (p=0.027) groups, thus suggesting 
increased systemic oxidative damage in NTG. 
* * 
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Fig 4.35: Graph showing the aconitase enzymatic activity in the control, NTG 
and OHT lymphocytes, after treatment with paraquat (PQ) 100µM for 24hrs. In 
all measurements, the background (no cells with reaction buffer) has been 
subtracted and the aconitase activity is expressed in nmol/min/mg.   
The median (IQR) aconitase activity in the control, NTG and OHT lymphocytes 
after PQ treatment was, as expected, significantly reduced in all cases, as 
compared to the baseline (prior to PQ treatment), to 1.17 (0.92 to 2.42), 1.09 
(0.65 to 1.69) and 1.10 (0.81 to 2.05), respectively. No significant difference 
was noted between the three groups after PQ treatment, suggesting that the 
PQ insult was sufficient to produce ROS and impact negatively on the aconitase 
activity in all cases, thus serving as a positive control in this experiment. 
 
  
282 
 
Discussion: As discussed in section 2.3.7, a reduction in aconitase enzymatic 
activity is a well known measure of cellular oxidative damage (Yan et al 1997), 
as aconitase is sensitive not only to free redicals, such as superoxide and 
hydrogen peroxide, but also  to powerful oxidants, including peroxynitrite 
(Grune et al 1998). It therefore serves as a more generalised marker of 
oxidative damage in cells. Over 95% of all the oxygen we breathe undergoes a 
concerted tetravalent reduction to produce water in a reaction catalysed by 
complex IV in the mitochondrial electron transport chain (ETC) (O2 + 4e
-
 + 4H
+
 
→ 2H2O). Therefore, the cumulative oxidative damage noted in NTG may in 
part be attributed to a reduction in the ETC efficiency, as demonstrated by the 
reduced complex IV-linked ATP synthesis in NTG, thus extending the length of 
time that the electrons remain at complexes I and III, and increasing the 
potential for donation of electrons to oxygen (Kushnareva et al 2002). It is less 
likely that the opposite association is observed, in other words that the 
reduction in complex IV-linked ATP synthesis in NTG is caused by oxidative 
stress, especially since there is evidence to suggest that complex IV is 
remarkably resistant to oxidative inactivation (Zhang et al 1990). The same 
study, using bovine heart submitochondrial particles exposed radiolytically to 
various defined oxygen species, indicated that several different mitochondrial 
complexes (especially complex I and V, and less complex III) are mostly 
susceptible to inactivation by superoxide, but surprisingly rather resistant to 
the effects of other free radicals, such as H2O2. This could perhaps explain to 
some extent why the increased oxidative damage noted in NTG may not have 
impacted significantly on the complex I- and II/III-linked ATP synthesis in this 
group, as compared to the controls. 
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4.3.4.3 Superoxide dismutase 2 (SOD2) 
SOD2 is a mitochondrial matrix protein, which transforms toxic superoxide, a 
byproduct of the mitochondrial ETC, into hydrogen peroxide and diatomic 
oxygen (Melov et al 1999). Thus, and similarly to glutathione peroxidase, SOD2 
is considered one of the main cellular components of antioxidant defence 
(Macmillan-Crow et al 2001), thought to be upregulated as a response to 
oxidative stress. The relatively high rate of superoxide production in the inner 
mitochondrial membrane is in functional relationship to the localisation of 
SOD2 in the mitochondrial matrix (Mn-superoxide dismutase). The steady state 
concentration of superoxide in the mitochondrial matrix [O2
.-
] may be 
calculated, based on the reaction below, considering the following aspects: a) 
the rate of superoxide production by the respiratory chain d[O2
.-
]/dt; b) 
assuming that the main reaction of superoxide utilisation is the Mn-superoxide 
dismutase-catalysed disproportionation (k) and; c) the concentration of SOD2 
in the mitochondrial matrix [SOD]. 
    
Thus, for the [superoxide] to remain the same, as shown between the three 
groups in our cohort, any increase in [SOD] would need to be accompanied by 
an equivalent increase in the rate of superoxide production by the respiratory 
chain d[superoxide]/dt. 
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Fig 4.36: Graph showing the level of SOD2 in the control, NTG and OHT 
lymphocytes. SOD2 is expressed as a percentage of Raji (100%, not shown) that 
acted as an internal control. 
 
The median (IQR) SOD2 level for the control, NTG and OHT lymphocytes, was 
0.69 (0.57 to 0.75), 0.67 (0.63 to 0.83) and 0.69 (0.61 to 0.82), respectively. No 
difference was noted between the three groups (Fig 4.29), however when the 
level of SOD2 was corrected for mitochondrial content the SOD2 level in NTG 
[3.53 (3.03 to 4.57)] was significantly higher than that in OHT [3.28 (2.72 to 
3.99] (p=0.046) (Fig 4.36 below). This result would suggest an increase in the 
antioxidant defences in NTG, potentially to compensate for the increased 
oxidative damage noted in this group of patients, as measured by the reduced 
aconitase activity.   
  
 
Fig 4.37: Graph showing the 
lymphocytes, after correction for mitochondrial content.
 
Discussion: Together these data suggest that 
damage, as measured by aconitase, is increased in NTG. 
superoxide levels were not significantly increased in NTG, t
superoxide production is likely to be 
the protective masking effect of the relatively increased SOD2. 
of SOD2 in OHT, with similar
that the overall rate of superoxide pr
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thus further supporting the idea of increased ETC efficiency in OHT. This 
efficiency is also highlighted by the fact that in OHT the mitochondria showed 
enhanced ETC function with increased energy production by the different 
mitochondrial complexes, higher ΔΨm and enhanced calcium buffering 
capacity, but without generating significantly more superoxide, as shown by 
the baseline DHE staining. Furthermore, under conditions of stress, the OHT 
lymphocytes showed superior antioxidant capacity to the NTG lymphocytes, as 
demonstrated by the smaller increase in DHE staining upon rotenone 
treatment, thus suggesting reduced susceptibility of the OHT cells to oxidative 
damage under these conditions.  
Similarly to the present results of increased SOD2 in NTG, Ferreira et al (2004) 
have shown that the activity of two enzymes involved in antioxidant defence 
(SOD and glutathione peroxidase) in the aqueous humour of POAG patients 
was nearly 1.6 times greater, as compared to a control cataract group. 
Similarly, increased expression of the SOD2 gene has been observed in the 
aqueous humour of POAG patients (Ghanem et al 2010) and in the ciliary 
processes and iris tissue of subjects with pseudoexfoliation glaucoma (Zenkel 
et al 2007). However, in the study by Wolf et al (2009) no association was 
found between NTG and SOD2 sequence variants. 
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4.3.4.4 Urinary 8-hydroxydeoxyguanosine (8OHdG) 
 
Fig 4.38: Graph showing the level of urinary 8OHdG in the control, NTG and 
OHT subjects. 8OHdG is corrected for the level of creatinine in the urine and 
expressed in ng/g creatinine.  
The median (IQR) 8OHdG level in the urine of control, NTG and OHT subjects 
was 0.09 (0.06 to 0.24), 0.11 (0.075 to 0.20) and 0.14 (0.078 to 0.19), 
respectively. No statistically significant difference was noted between the 
three groups, in line with the finding of similar baseline systemic levels of 
superoxide in the lymphocytes amongst the three groups, as demonstrated by 
the DHE staining.   
However, it is perhaps relevant to note that cancer and DM, conditions known 
to increase urinary 8OHdG (Wu et al 2004, Valavanidis et al 2009), were 
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relatively more common in the OHT group. In a post hoc analysis of a subgroup 
of subjects (28 controls, 24 NTGs and 22 OHTs) with no history of DM or active 
cancer, there was again no significant difference between the controls [0.09 
(0.065 to 0.25)], NTG [0.11 (0.087 to 0.21)] and OHT subjects [0.14 (0.08 to 
0.17)] (Fig 4.38 below), thus further supporting the above conclusion. 
 
Fig 4.39: Graph showing the level of urinary 8OHdG in a subgroup of control, 
NTG and OHT subjects, with no history of DM or active cancer. 8OHdG is 
corrected for the level of creatinine in the urine and expressed in ng/g 
creatinine.  
 
Discussion: The generation of superoxide and hydrogen peroxide by the 
respiratory chain, in close proximity to the active redox pools of Cu and Fe in 
  
289 
 
the mitochondrial membranes, provides the requisite conditions leading to 
hydroxyl radical (HO•) formation and, hence, the rather specific addition of 
HO• onto the desoxyguanosine base of DNA to yield 8OHdG (Giulivi et al 
1995).  
    
The lack of any difference in the levels of superoxide at baseline between the 
three groups, as demonstrated by the DHE staining, may therefore explain the 
lack of any statistically significant difference in urinary 8-OHdG. Also, while ROS 
generation is thought to be qualitatively related to the amount of 8OHdG 
detected in the mtDNA (Cadenas et al 2000), the rates of ROS production are 
not supposed to be strictly correlated with 8-OHdG formation for various 
reasons: First, the actual sites of HO• formation in mitochondria are not 
known; second, the highly reactive HO• is able to diffuse several molecular 
diameters from its site of formation before it reacts; and third, formation of 
8OHdG could result from site-specific damage, entailing cleavage by redox 
active metals (Cu, Fe) bound to the mtDNA. Thus, the stereo- and region-
selectivity of HO• formation in the vicinity of the DNA determines the chemical 
structure of the products formed (Giulivi et al 1995). 
Interestingly, urinary 8OHdG was reported to be reduced in 43 NTG patients as 
compared to 40 healthy controls, indicating, according to the authors, a 
compensatory response to increased systemic oxidative stress in glaucoma 
(Yuki et al 2010), while the presence of oxidative stress in several other 
diseases has been clearly linked with elevated, rather than reduced, urinary 
8OHdG (Wu et al 2004, Kasai et al 1997). Another unexpected finding in the 
same study by Yuki et al was that the serum total antioxidant status (TAS) was 
significantly higher in NTG, as compared to controls, unlike previous studies 
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that have demonstrated reduced antioxidant capacity in glaucoma patients 
(Ferreira et al 2004, Sorkhabi et al 2011). To explain the lack of difference in 
urinary 8OHdG in our cohort, one would need to consider that oxidative stress 
may manifest differently in different tissues and at different disease stages, 
and that perhaps the Japanese NTG cohort in the study by Yuki et al (2010) is 
inherently different from our NTG cohort with fast VF progression. Unlike our 
cohort, the Japanese population in the study by Yuki et al was specially 
selected, with the authors excluding active or ex smokers, patients on vitamins 
or other forms of antioxidants and those with DM or any other systemic 
disease, except hypertension. Nevertheless, active cancer and DM were not 
associated with elevated urinary 8OHdG in our cohort. 
In the study by Sorkhabi et al, where mainly the aqueous, and less so the 
serum, levels of 8OHdG were increased in glaucoma patients as compared to 
age-similar cataract patients, the authors proposed that in glaucoma the 
oxidative burden to the anterior chamber may be overwhelming, 
compromising the trabecular meshwork cells and their functions, and 
suggested that localised oxidative damage may play a more important role in 
the pathogenesis of glaucoma than systemic oxidative stress. This, as well as 
the intra-individual variability of the measurement (Pilger et al 2001) and the 
fact that measuring oxidative damage in a peripheral tissue, such as urine, may 
not be as sensitive or relevant to the pathogenesis of a disease like glaucoma, 
could perhaps explain the absence of any differences in the levels of 8OHdG 
between the three groups in our cohort. Also, 8OHdG is a specific marker of 
DNA oxidation and therefore the presence of oxidative damage in other 
macromolecules cannot be excluded, while the sensitivity of our measurement 
could have been influenced by the fact that DNA purification was not required 
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in our protocol, unlike previous studies that measured 8OHdG levels from 
purified trabecular meshwork DNA (Izzotti et al 2003). 
 
4.3.4.5 Urate 
 
 
Fig 4.40: Graph showing the levels of urate in the serum of control, NTG and 
OHT subjects. Urate is expressed in µmol/lt (normal reference range 266-474 
µmol/lt). 
The median (IQR) urate levels in the control, NTG and OHT groups, were 305 
µmol/lt (235 to 345) or 5.13mg/dl, 277 µmol/lt (217 to 343) or 4.66mg/dl and 
359 µmol/lt (258 to 395) or 6.04mg/dl, respectively. The urate levels in the 
NTG group were significantly lower as compared to the OHT group (p=0.012), 
* * 
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while the urate levels in the OHT group were significantly higher to the 
controls (p=0.045), thus further supporting the idea of increased antioxidant 
capacity in OHT and relatively reduced antioxidant capacity in NTG. 
 
Discussion: Whether or not urate functions physiologically as an antioxidant 
remains controversial (Glantzounis et al 2005), although there is some 
evidence in the literature to suggest that urate can act as an antioxidant in 
vitro (Becker 1993) and in humans (Ames et al 1981). Urate is the end product 
of purine metabolism in humans and serves as a primary antioxidant in the 
human blood, as it is known to remove singlet oxygen and radicals as 
effectively as vitamin C (Wayner et al 1987). Furthermore, a highly significant 
positive correlation between mammalian maximum life span and the 
concentration of serum urate has been reported (Cutler 1984). Urate has been 
shown to contribute up to two-thirds of the antioxidant capacity of human 
blood (Maxwell et al 1997) and intravenous infusion of urate has been found 
to increase the plasma total antioxidative status of healthy volunteers (Waring 
et al 2001). Thus, the observed association between OHT and higher urate 
levels may provide an alternative explanation for the enhanced capacity to 
deal with exogenous oxidative stress in this group, as demonstrated by DHE 
staining. At this stage it is not clear whether this association is merely an 
epiphenomenon or whether a causal relationship exists between higher urate 
levels and increased mitochondrial function, and this hypothesis will be tested 
in the UKGTS. 
Also, there was a trend for urate levels to be lower in our NTG group, in line 
with multiple previous studies that have linked reduced antioxidant capacity 
with human glaucoma (Zanon-Moreno et al 2008, Gherghel et al 2005, Ren et 
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al 2006). However, unlike our study, Elisaf et al showed in 2001 that 
abnormalities of urate metabolism, such as hyperuricaemia and defective renal 
tubular transport of urate, were more common in 49 POAG patients with a 
known history of diabetes mellitus, as compared to 72 age and sex- matched 
controls (Elisaf et al 2001). The coexisting carbohydrate metabolism 
disturbances noted in the glaucoma group could not explain the urate 
metabolism abnormalities observed and the authors concluded that urate 
metabolism could independently play a role in glaucoma pathogenesis. 
Similarly, the study by Yuki et al (2010b) showed increased serum urate in NTG 
(P = 0.01; NTG 5.8 +/- 1.5 mg/dl vs control 4.9 +/- 1.4 mg/dl), although the 
same authors showed that serum levels of another antioxidant, vitamin C, 
were significantly lower in their NTG cohort, as compared to healthy controls. 
Aqueous urate levels have also been found to be higher at the time of surgery 
in eyes with unsuccessful outcomes after trabeculectomy, as compared to 
those with successful outcomes, and elevated aqueous urate has been 
proposed as a risk factor for trabeculectomy failure (Jampel et al 1998) by 
having a direct deleterious effect on trabecular tissues, retinal cells and wound 
healing.  
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4.3.4.10 Vitamins A and C  
 
Fig 4.41: Graph showing the levels of vitamin A in the serum of control, NTG 
and OHT subjects. Vitamin A is expressed in µmol/lt (normal reference range 
1.54-3.84 µmol/lt). 
The median (IQR) vitamin A levels in the control, NTG and OHT groups, were 
2.61 µmol/lt (2.28 to 3.03) or 74.8μg/dl, 2.15 µmol/lt (1.83 to 2.76) or 
61.6μg/dl, and 2.91 µmol/lt (2.32 to 3.31) or 83.4μg/dl, respectively. There was 
a trend for the vitamin A levels in the NTG group to be lower as compared to 
the OHT (p=0.054) and control (p=0.077) groups, thus further supporting the 
idea of relatively reduced antioxidant capacity in NTG. 
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Fig 4.42: Graph showing the levels of vitamin C in the serum of control, NTG 
and OHT subjects. Vitamin C is expressed in µmol/lt (normal reference range 
>11.4µmol/lt). 
The median (IQR) vitamin C levels in the control, NTG and OHT groups, were 
48.1 µmol/lt (24.5 to 66.4) or 8.47µg/ml, 30.4 µmol/lt (10.4 to 50.4) or 
5.35µg/ml and 27.6 µmol/lt (11.4 to 45.0) or 4.86µg/ml, respectively. The 
vitamin C levels in both the OHT (p=0.001) and NTG (p=0.002) groups were 
significantly lower, as compared to the control. 
 
Discussion: Vitamin A (retinol) is an important antioxidant (Palace et al 1999) 
and an essential nutrient in maintaining ocular health. This vitamin plays a key 
role in the development of vision and the prevention of eye diseases (Luo et al 
** 
** 
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2006). Our study is the first to find a trend for reduced vitamin A levels in NTG 
patients, as compared to OHT and controls, thus further supporting the 
evidence that links reduced antioxidant capacity with glaucoma. In the study 
by Yuki et al, no statistically significant difference was seen in vitamin A (P = 
0.41; normal-tension glaucoma; 82.1±26.7 µg/dl control; 77.1±30.1 µg/dl) 
between NTG and control groups (Yuki et al 2010b). Similarly, in the study by 
Zanon-Moreno et al (2011), although the plasma vitamin A concentrations 
tended to be lower in 150 POAG patients than in 150 controls, this difference 
was not statistically significant (519.3±47.1 ng/ml in POAG cases vs 527.7±58.9 
ng/ml in controls; p=0.174) (Zanon-Moreno et al 2011).  
With regards to vitamin C, the results presented here show significantly lower 
vitamin C levels in NTG, as compared to controls, thus further supporting the 
evidence that links reduced antioxidant capacity with glaucoma. Similarly, Yuki 
et al (2010b) reported lower vitamin C levels in their NTG cohort (P = 0.04; NTG 
4.6±4.0 µg/ml vs control 6.3±3.9 µg/ml). Interestingly, the lower systemic 
vitamin C was associated with a mild IOP elevation that did not exceed 21 
mmHg in these Japanese NTG patients (Yuki et al 2010b), with the authors 
speculating that reduction of vitamin C levels may cause IOP elevation and 
glaucomatous optic neuropathy, even in NTG patients. Moreover, in a recent 
study by Zanon-Moreno et al, POAG patients were found to have lower plasma 
vitamin C concentrations than control subjects (9.9±1.7 µg/ml vs 11.7±1.8 
µg/ml, p<0.001) and the rs1279683 SNP in SLC23A2 (a gene encoding the Na⁺-
dependent L-ascorbic acid transporter 2) was significantly associated with 
lower vitamin C concentration and a higher risk of POAG (Zanon-Moreno et al 
2011). An additional link between vitamin C and glaucoma has been proposed 
by Coleman et al (2008) in a relatively recent epidemiological study involving 
1,155 women in the United States, who reported that a higher intake of kale, 
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known to be rich in vitamin C, was associated with a decreased risk of POAG 
(Coleman et al 2008). However, Kang et al did not find any significant 
associations between POAG and antioxidant consumption in the Nurses' 
Health Study (n = 76,200) and the Health Professionals Follow-up Study (n = 
40,284), where participants were followed biennially from 1980 and 1986, 
respectively, to 1996 (Kang et al 2003). 
The finding of lower serum vitamin C in OHT in this study appears to be 
conflicting to the elevated serum levels of another antioxidant, urate, found in 
the same group. Similarly conflicting results for vitamin C and urate were 
presented by Yuki et al (2010b) for NTG. It is, however, interesting to note that 
very few OHT subjects were on antioxidant supplements in our cohort, as 
compared to the other two groups, and this may have accounted for the 
relative reduction in vitamin C levels in the OHT group. Also, the 
aforementioned link between IOP elevation and reduced vitamin C levels 
reported by Yuki et al in 2010 for NTG, has been reinforced by studies 
reporting considerable reductions in IOP in glaucoma patients after 
administration of vitamin C (Fishbein et al 1972, Virno et al 1966). Vitamin C 
may reduce IOP by the depolymerisation of the trabecular meshwork`s 
hyaluronic acid component (Linner 1969) and it remains to be seen whether 
the significantly reduced vitamin C levels in OHT may have contributed to some 
extent to the significantly elevated IOP in this group. An alternative 
explanation for the high urate and low vitamin C in OHT could be based on in 
vitro studies indicating that interactions between urate and vitamin C can 
change the viscosity of some glycosaminoglycans (Liu et al 1984). More 
specifically, vitamin C reduces the viscosity of hyaluronic acid and increases 
outflow facility, while urate, used at concentrations within the range observed 
in the human aqueous, was found to inhibit the oxidative degradation of 
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rooster comb and umbilical cord hyaluronic acid by ascorbate in vitro, thus 
potentially reducing outflow facility and increasing IOP. Since the trabecular 
meshwork contains glycosaminoglycans as a portion of the extracellular 
matrix, it is tempting to suggest that increase in urate levels may have 
important implications in the trabecular meshwork physiology, decrease the 
outflow facility of aqueous humour and cause eventual IOP elevation in the 
OHT cohort. 
 
4.3.4.7 Vitamin B6 
 
Fig 4.43: Graph showing the levels of vitamin B6 in the plasma of control, NTG 
and OHT subjects. Vitamin B6 is expressed in µg/lt (normal reference range 
8.7-27.2 µg/lt). 
* 
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The median (IQR) vitamin B6 levels in the control, NTG and OHT groups, were 
26.1µg/lt (22.3 to 41.5), 26.2µg/lt (21.4 to 33.2) and 24.2µg/lt (21.5 to 27.9), 
respectively. The vitamin B6 plasma levels in OHT were lower as compared to 
the control group with the difference achieving marginal statistical significance 
(0.049). No difference was noted between the OHT and NTG groups (p=0.294) 
or between the NTG and control groups (p=0.761).  
Discussion: In the case of Vitamin B6, no significant difference was noted 
between NTG and controls, unlike the study by Turgut et al where elevated 
serum B6 levels were noted in POAG (30.22±12.15μg/l) and NTG patients 
(30.50±11.29μg/l), as compared to controls (20.09±5.54μg/l) (Turgut et al 
2010). It is interesting to note that the levels of vitamin B6 in our control group 
(median 26.1µg/lt) appear higher than those reported in the latter study, 
possibly due to the fact that 15 out of the 30 controls were on antioxidant 
supplements. Importantly, and unlike our study, the values presented by 
Turgut et al represent a more ‘pure’ population, since the authors included a 
whole list of patient exclusions ranging from any systemic disease (eg 
cardiomyopathy, diabetes mellitus, systemic hypertension, renal or hepatic 
dysfunction, gastrointestinal malabsorption, psychiatric illness) to any systemic 
medication or food supplement (Turgut et al 2010).  
The levels of vitamin B6 have not been reported before in OHT. Similarly to 
vitamin C, the reduced vitamin B6 levels in OHT, as compared to controls, are 
likely to reflect the relatively small number of OHT patients that were on 
antioxidants, as compared to the other two groups. Also, the effect of 
antioxidant supplements on the vitamin B6 results is highlighted by the 
relatively high percentage of controls and NTG patients that exceed the 
physiological range of B6 (>27.2 µg/lt) and the higher IQR in these two groups, 
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as compared to the OHT group. The effect of antioxidant supplements on the 
vitamin C results is more difficult to detect, since there is no upper 
physiological limit for this vitamin.  
 
4.3.4.8 Vitamins B12 and folate 
Vitamin B12 
 
Fig 4.44: Graph showing the levels of vitamin B12 in the serum of control, NTG 
and OHT subjects. Vitamin B12 is expressed in pg/ml (normal reference range 
191-663pg/ml). 
The median (IQR) vitamin B12 levels in the control, NTG and OHT groups, were 
401 pg/ml (289 to 471), 416 pg/ml (299 to 726) and 374pg/ml (282 to 470), 
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respectively. No difference was noted in the vitamin B12 levels between the 
three groups.  
 
Serum folate 
 
Fig 4.45: Graph showing the levels of serum folate in control, NTG and OHT 
subjects. Serum folate is expressed in µg/lt (normal reference range 4.6-
18.7µg/lt). 
The median (IQR) vitamin C levels in the control, NTG and OHT groups, were 
11.1 µg/lt (8.8 to 15.5), 9.3 µg/lt (7.8 to 13.7) and 9.0 µg/lt (6.0 to 13.3), 
respectively. Similarly to B12, no difference was noted in the serum folate 
levels between the three groups. 
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RBC folate 
 
Fig 4.46: Graph showing the levels of red blood cell folate in control, NTG and 
OHT subjects. RBC folate is expressed in nmol/lt (normal reference range 158-
1099 nmol/lt). 
RBC folate was also measured, since it is thought to reflect long-term folate 
status, as compared to serum folate, which may be more influenced by recent 
dietary intake (Piyathilake et al 2007). The median (IQR) RBC folate levels in the 
control, NTG and OHT groups, were 671 nmol/lt (538 to 1048), 678 nmol/lt 
(467 to 1003) and 585 nmol/lt (478 to 1081), respectively. Similarly to B12 and 
serum folate, no difference was noted in the RBC folate levels between the 
three groups. 
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Discussion: Serum and RBC folate levels were similar between the three groups 
in our cohort, in line with the findings by Turgut et al that there was no 
difference in serum folate levels among control (9.00±6.39ng/ml), NTG 
(9.71±3.86ng/ml),  PXG  (10.82±4.92ng/ml) and POAG (11.59±9.40ng/ml) 
subjects (Turgut et al 2010). Also, the reported lack of statistically significant 
difference in B12 levels between the three groups in our cohort, is supported 
by the study by Turgut et al, who showed no difference in serum B12 levels 
among control subjects and NTG, PXG and POAG groups (Turgut et al 2010).  
 
4.3.4.9 Homocysteine 
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Fig 4.47: Graph showing the levels of plasma homocysteine in control, NTG and 
OHT subjects. Plasma homocysteine is expressed in µmol/lt (normal reference 
range <15µmol/lt). 
The median (IQR) homocysteine levels in the control, NTG and OHT groups, 
were 13.5 µmol/lt (11.8 to 17.7), 13.7 µmol/lt (10.1 to 19.1) and 14.5 µmol/lt 
(10.6 to 17.5), respectively. Similarly to B12 and serum and RBC folate, no 
difference was noted in the homocysteine levels between the three groups. 
 
Discussion: In view of the vascular theories in the aetiology of glaucoma (see 
sections 1.3.6 and 1.5.7), increased attention has been directed at studying the 
total plasma level of the amino acid homocysteine (tHcy), which has been 
identified as a possible risk factor for arteriosclerosis (McCully 1969) and 
symptomatic peripheral vascular (Clarke et al 1991), cerebrovascular (Perry et 
al 1995) and coronary heart disease (Nygard et al 1997). 
Hyperhomocysteinaemia has also been demonstrated to be a risk factor for 
retinal vascular disease, including central retinal vein and artery occlusion 
(Biousse et al 1997, Cahill et al 2000), as well as for non-arteritic ischemic optic 
neuropathy (Pianka et al 2000). A link has also been proposed between 
elevated tHcy (generally defined as tHcy ≥15μmol/l) and oxidative stress 
(Mujumdar et al 2001). In 2002, Bleich et al found for the first time a 
significantly higher mean tHcy level in 18 POAG patients (12.52μmol/l) 
compared with 19 control subjects (8.40μmol/l), while other studies have also 
shown increased Hcy levels in the tear fluid (Roedl et al 2008) and plasma 
(Roedl et al 2008, Clement et al 2009) of patients with OAG. A higher 
prevalence of the C677T single nucleotide polymorphism in the 5,10-
methylentetrahydrofolate reductase (MTHFR) gene has also been noted in 
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POAG, leading to moderate hyperhomocysteinaemia (Junemann et al 2005). In 
addition, it has been suggested that elevated Hcy could impact on the 
microvascular circulation of the optic nerve head in glaucoma through its 
ability to cause endothelial injury (Stamler et al 1993), smooth muscle 
proliferation (Tsai et al 1994), platelet activation and thrombogenesis (Rodgers 
et al 1986), while Moore et al have demonstrated that homocysteine induces 
apoptotic cell death in mouse RGcs by NMDA receptor overstimulation and 
caspase-3 activation (Moore et al 2001).  
However, the evidence on the role of homocysteine in glaucoma is conflicting 
and several studies (Wang et al 2004, Altintas et al 2005, Turgut et al 2010), 
including ours, have not shown any difference in tHcy levels between POAG, 
NTG and controls. In the study by Wang et al, for example, no difference was 
found in the mean tHcy level in 55 POAG patients (14.90μmol/l) as compared 
to 39 controls (14.30μmol/l). It is possible that the multifactorial nature of 
glaucoma in the different populations examined in different studies could 
mask the contribution of hyperhomocysteinaemia and account for the 
conflicting results. Another factor could be the different characteristics of the 
included populations, such as age, severity of glaucoma, nutritional status, 
presence of associated illnesses, use of medications and lifestyle determinants, 
including smoking, coffee consumption, alcoholism, and physical activity 
(Clarke et al 2001). Also, different methodologies used to assess plasma tHcy 
levels may explain at least in part the different results, since it has been 
suggested that measurements of tHcy with Enzyme Immunoassay (EIA) (such 
as in the study by Bleich et al above) have a higher inaccuracy and imprecision 
compared with High Performance Liquid Chromatography (HPLC) (Nexo et al 
2000), which was used by Wang et al above. Also, data from the Centers for 
Disease Control and Prevention on 14 laboratories performing tHcy assays on 
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reference materials have indicated a high variation between laboratories, and 
for one reference material with a mean concentration of 11.1μmol/l, the 
reported values ranged from 8.3 to 14μmol/l (CDCP 1999). Finally, it is perhaps 
relevant to note that conflicting evidence also largely exists among the clinical 
studies evaluating tHcy as a risk factor for cardiovascular disease (Ford et al 
2002), suggesting possibly that the role of elevate tHcy is not as clear and 
convincing as originally thought.  
Interestingly, vitamins B6, B12 and folate are considered cofactors for the 
catabolism of homocysteine, and deficiencies in these vitamins have been 
associated with hyperhomocysteinaemia in PXG (Roedl et al 2007). For 
example, excess tHcy is converted to methionin by vitamin B12 and when 
vitamin B12 is deficient this can result in higher levels of Hcy. In our cohort, the 
levels of B6, B12 and folate in the NTG group were very similar to the other 
two groups, and these findings would certainly be in line with the lack of 
differences in the plasma tHcy levels between the three groups. If anything, 
the levels of B6 were slightly lower in the OHT group, potentially as a result of 
the high frequency of food supplementation in the other two groups, which 
may have masked the relative decrease in tHcy in the OHT cohort. 
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4.3.5 Perfusion pressure 
Systolic perfusion pressure (day) 
 
Fig 4.48: Graph showing the systolic perfusion pressure (SPP) during the day 
for the control, NTG and OHT subjects. The SPP was expressed in mmHg and 
calculated as follows: mean SBP during the day – mean GAT IOP. 
The median (IQR) SPP for the control, NTG and OHT groups was 118mmHg 
(108 to 130), 121mmHg (110 to 127) and 123mmHg (106 to 136), respectively. 
No difference was noted in the SPP (day) between the three groups.  
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Diastolic perfusion pressure (day) 
 
Fig 4.49: Graph showing the diastolic perfusion pressure (DPP) during the day 
for the control, NTG and OHT subjects. The DPP was expressed in mmHg and 
calculated as follows: mean DBP during the day – mean GAT IOP. 
The median (IQR) DPP for the control, NTG and OHT groups was 68mmHg (57 
to 73), 56mmHg (53 to 64) and 55mmHg (50 to 66), respectively. Interestingly, 
a statistically significant reduction was noted in the DPP of the NTG (p=0.11) 
and OHT (p=0.001) subjects, as compared to the control group. 
 
 
 
** 
* 
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Mean ocular perfusion pressure (day) 
 
Fig 4.50: Graph showing the mean ocular perfusion pressure (MOPP) during 
the day for the control, NTG and OHT subjects. The MOPP (day) was expressed 
in mmHg and calculated as follows: 2/3 Mean arterial pressure (MAP) day – 
GAT IOP, where MAP day =2/3DBP (day) + 1/3SBP (day). 
The median (IQR) MOPP (day) for the control, NTG and OHT groups was 
53mmHg (47 to 56), 49mmHg (44 to 54) and 45mmHg (38 to 53), respectively. 
Similarly to DPP, a statistically significant reduction was noted in the MOPP 
(day) of the OHT subjects, as compared to the control group (p=0.026). Also, 
the MOPP (day) of the OHT patients was significantly lower, as compared to 
that of the NTG subjects (p=0.021). No difference was noted between the 
control and NTG groups (p=0.13). 
* 
* 
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SPP (night) 
 
Fig 4.51: Graph showing the SPP at night for the control, NTG and OHT 
subjects. The SPP (night) was expressed in mmHg and calculated as follows: 
mean SBP at night – supine IOP. 
The median (IQR) SPP ‘at night’ for the control, NTG and OHT groups was 
106mmHg (97 to 115), 104mmHg (94 to 114) and 102mmHg (89 to 120), 
respectively. Similarly to the SPP (day), no difference was noted in the SPP 
(night) between the three groups. 
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DPP (night) 
 
Fig 4.52: Graph showing the diastolic perfusion pressure (DPP) at night for the 
control, NTG and OHT subjects. The DPP (night) was expressed in mmHg and 
calculated as follows: mean DBP at night – supine IOP. 
The median (IQR) DPP (night) for the control, NTG and OHT groups was 
52mmHg (45 to 57), 50mmHg (41 to 54) and 43mmHg (34 to 47), respectively. 
Similarly to the MOPP (day), a statistically significant reduction was noted in 
the DPP (night) of the OHT subjects, as compared to the control (p=0.001) and 
NTG (p=0.006) groups. Unlike the DPP (day), the DPP (night) in the NTG cohort 
was not significantly lower as compared to the controls, probably reflecting the 
only slight reduction in DBP (night) in the NTG group, as compared to the 
significant reduction in DBP (day) noted in the same group. 
** 
** 
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Mean ocular perfusion pressure (night) 
 
 
Fig 4.53: Graph showing the mean ocular perfusion pressure (MOPP) at night 
for the control, NTG and OHT subjects. The MOPP (night) was expressed in 
mmHg and calculated as follows: 2/3 Mean arterial pressure (MAP) night – 
supine IOP, where MAP night =2/3DBP (night) + 1/3SBP (night). 
The median (IQR) MOPP (night) for the control, NTG and OHT groups was 
42mmHg (37 to 47), 40mmHg (35 to 44) and 34mmHg (26 to 39), respectively. 
Similarly to the DPP (day and night) and the MOPP (day), a statistically 
significant reduction was noted in the MOPP (night) of the OHT subjects, as 
compared to the control group (p=0.009). Also, similarly to the MOPP (day) 
and DPP (night), the MOPP (night) of the OHT patients was significantly lower, 
** 
** 
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as compared to that of the NTG subjects (p=0.001). No difference was noted 
between the control and NTG groups (p=0.79). 
Discussion: Based on Fig 4.48, it appears that the equally low DPP (day) in the 
NTG and OHT groups, as compared to the controls, reflects the relatively low 
DBP (day) in the case of the NTG patients and the relatively high mean GAT IOP 
(day) in the case of the OHT subjects. Similarly to our study, several studies, 
such as the LALES (Memarzadeh et al 2010), Barbados Eye Study (Leske et al 
2008), EMGT (Leske et al 2007) and Egna-Neumarkt (Banomi et al 2000), have 
shown a link between low PPs and glaucoma, in line with the vascular 
hypothesis for the development of glaucomatous optic neuropathy. It is, 
however, interesting to note that in the LALES the association between low PPs 
and higher prevalence of OAG was not present in persons with low SBP and 
low DBP (Memarzadeh et al 2010), thus reflecting the influence of IOP on PP. 
This is evident in our NTG group by the low DBP (day), which might better 
reflect the potential vascular risks in this group than the PPs. An important 
strength of the analysis presented here is the use of 24-hr ABP monitoring, 
unlike many of the aforementioned epidemiological studies, such as the LALES 
and BES, which only performed 2 BP readings during the day. The pattern 
followed for the MOPP (day and night) is more similar to the DPP (day and 
night) than the SPP (day and night) pattern, as explained by the relatively 
higher contribution of DBP, as compared to SBP, to the calculation of MAP.  
As discussed previously (see sections 1.3.6 and 1.5.7), vascular dysregulation 
has been associated with OAG (Flammer et al 2007, Grieshaber et al 2007). 
Apart from the role of chronically low perfusion in OAG, as supported in the 
present study by the reduced DPP (day) in NTG, vascular dysregulation could 
also manifest as unstable perfusion with either wide fluctuations or nocturnal 
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dips in perfusion pressure. In the present study, the median (IQR) % drop in the 
SPP from day to night for the control, NTG and OHT subjects was 13.4% (5.4 to 
17.9), 14.2% (7.4 to 17.6) and 16.9% (8.1 to 19.6), respectively. No difference 
was noted in the % drop in the SPP between the three groups. However, the % 
drop in the DPP from day to night for the control, NTG and OHT subjects was 
21.6% (11.5 to 28.4), 19.9% (13.2 to 26.1) and 29.0% (17.6 to 32.9), 
respectively, with the % drop in the DPP of the OHT subjects being significantly 
higher than the NTG patients (p=0.001) and showing a trend to be higher than 
the controls (p=0.097). Also, the % drop in the MOPP from day to night for the 
control, NTG and OHT subjects was 19.9% (8.6 to 26.3), 17.9% (8.6 to 23.1) and 
26.6% (14.1 to 32.4), respectively. Similarly to the DPP, the % drop in the 
MOPP of the OHT subjects was significantly higher than the NTG patients 
(p=0.004) and showed a trend to be higher than the controls (p=0.076). In 
summary, in OHT, rather unexpectedly, the % drop in DPP and MOPP from day 
to night was more pronounced, despite starting from an already low DPP and 
MOPP during the day. Since mean GAT IOP during the day was overall similar 
to the supine IOP, the reported % drop in PPs is more likely to reflect changes 
in the SBP, DBP and MAP from day to night in these patients.  
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Chapter 5: General discussion and future work 
In this thesis, the methodology, baseline characteristics and results from the 
UKGTS, the first randomised, double-masked, placebo-controlled, multicentre 
treatment trial for OAG, are presented. As discussed in more detail in Chapter 
3, the UKGTS confirms the importance of IOP in the pathogenesis of glaucoma 
and that IOPcc appears to predict progression behaviour better than the 
conventional measure (and the one used in all previous trials) of GAT. The 
survival analysis showed a statistically significant difference in the time from 
baseline to the event of confirmed VF progression in the medical treatment 
(latanoprost) group, as compared to placebo, over 24 months. Median IOP 
during follow-up, as measured by GAT, DCT, IOPcc and IOPg, was significantly, 
but weakly, correlated with VF progression. The IOPcc appeared the best 
predictor of progression across all the UKGTS sites, either because IOPcc 
provided a more accurate or consistent measure of IOP or because it may have 
better reflected ocular susceptibility to IOP, to the extent that susceptibility is 
influenced by the material properties of the eye and reflected in the corneal 
biomechanics. Also, IOPcc appeared to be less dependent on the operator, as 
shown by the relatively consistent relationship between IOP and progression 
rate across sites.  
Interestingly, DCT IOP, despite being known to be the most accurate and 
precise IOP measurement, proved the best model to predict progression only 
at some UKGTS sites, when sites were considered individually, suggesting 
possible differences in calibration and/or operation across sites. Also, while the 
addition of CCT slightly improved the GAT IOP prediction model, CCT on its 
own was not a significant predictor of progression in the UKGTS. CH was 
superior to CCT in improving the GAT model prediction, suggesting that CH 
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better reflects the GAT IOP measurement error than CCT (see section 3.5.2). In 
summary, the UKGTS is the first randomised, double-masked, placebo-
controlled, multicentre treatment trial for OAG, and the analysis presented 
here from this unique cohort provides a novel insight into the role of IOP, as a 
risk factor for progression. Future work will explore the association between 
additional covariates (CRF and AL) and both IOP and glaucoma progression. 
Also, the role of the diurnal IOP variation and of the DCT ocular pulse 
amplitude in glaucoma progression will be investigated.  
In Chapter 4, the purpose of the mitochondrial pilot study was, for the first 
time, to explore the role, and measure the potential contribution, of systemic 
mitochondrial dysfunction- and oxidative stress- related risk factors as 
background susceptibility factors for glaucoma. A major strength of the 
mitochondrial exploratory study was its prospective and unique design, where 
patients at the extremes of IOP susceptibility (with progressing NTG and stable 
OHT) were compared to age-similar controls. NTG patients were carefully 
selected to have at least 5 years of follow-up demonstrating fast VF 
progression and a mean IOP<16mmHg. Similarly, OHT patients were required 
to have a mean IOP>24mmHg over at least 5 years of follow-up without VF 
progression. We carefully considered the possibility of including POAG patients 
in our analysis, although it was felt that, within a pilot study, focusing on 
patients with aggressive disease and normal IOP would be more likely to reveal 
and highlight the potential ‘mitochondrial’ or ‘oxidative stress’ component of 
the disease. Moreover, the clinical phenotyping of the participants was 
performed by one investigator (GL) and was detailed enough to include, 
amongst other things, phasing with GAT and DCT, analysis of corneal 
biomechanics with ORA, 24-hr BP monitoring and ocular biometry.  
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Studies on human samples, although in many ways closer to and more 
representative of human disease than studies on animals or cell cultures, tend 
to be associated with the variability that often characterises human beings. 
Being aware of this limitation, and to ensure the validity of our results, 
multiple experimental techniques were employed to evaluate mitochondrial 
function (ATP, TMRM, Calcium, mTOR), oxidative stress (DHE, aconitase, 
8OHdG) and antioxidant reserve/defence (vitamins A, B6, B12, C, folate, urate, 
SOD2). Each of these techniques targeted a distinct and carefully selected 
component of cellular/mitochondrial function and, although this exploratory 
study was largely descriptive and has not exhaustively probed mechanisms, it 
has provided unique insight into potential mechanisms.  
The utility of using lymphocyte-derived cells (lymphoblasts) to investigate 
systemic mitochondrial dysfunction in optic neuropathies has been 
demonstrated previously in studies that determined OXPHOS defects in LHON 
(Brown et al 2000, Brown et al 2001), ADOA (Van Bergen et al 2011) and POAG 
(Lee et al 2012). In this study, and in accordance to previous studies from our 
group (Schapira et al 1992) and other groups (Yoshino et al 1992, Barroso et al 
1993, Shinde et al 2006) in Parkinson’s disease, we chose to use fresh 
unstimulated peripheral blood cells. More specifically, and for the first time in 
the field of ophthalmology, we chose to use fresh unstimulated lymphocytes, 
as a more ‘pure’ human model that would minimise any potential effect of 
viral transformation on the measurements of mitochondrial function. 
Glaucomatous optic neuropathy is increasingly considered a 
neurodegenerative disease, while recently the generalised neurodegenerative 
background of glaucoma was described by Rance et al, who reported 
vulnerability to widespread neurodegenerative disease in POAG patients, 
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including a temporal processing defect in the auditory pathways (Rance et al 
2012). Interestingly, very few of our NTG patients had any co-existing 
neurological diseases, such as Parkinson’s disease (n=1) or dementia (n=1). The 
lack of systemic phenotypic changes (eg neurological) in the NTG group, as one 
might anticipate in line with the reduced mitochondrial function reported for 
complex IV, may be explained by the relatively small contribution of complex 
IV, as compared to mitochondrial complexes I and II/III, to the total 
mitochondrial ATP production and by the diverse metabolic requirements of 
different tissues. To further illustrate the complexity of correlating phenotype 
with genotype and mitochondrial function, some patients with LHON do not 
appear to have primary LHON mutations (Lamminen et al 1997) or, in certain 
cases, any mtDNA changes at all (Fauser et al 2002). 
LHON mutations have been described in patients with NTG (Opial et al 2001); 
however we did not screen for such mutations in our cohort. The VF loss found 
in our NTG group was atypical for hereditary optic neuropathies, and the vast 
majority of our patients were unusually old for LHON and other hereditary 
optic neuropathies. LHON is typically associated with subacute injury of the 
majority of optic nerve fibers (Howell et al 2003), often in a young adult male 
with a maternal family history of visual loss, and is a very different optic 
neuropathy from NTG, which causes the gradual loss of optic nerve fibres over 
a period of years in an older individual.  
Glaucoma is clearly a multifactorial disease and it was therefore expected that 
mitochondrial dysfunction and oxidative stress might not be the dominant risk 
factors in all our NTG patients. In some patients other factors (such as vascular) 
may predominate and this could explain the lack of differences between the 
NTG and control groups, particularly in the ATP (Complex I and Complexes 
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II/III), TMRM, DHE and calcium measurements. The impact of co-existing 
systemic diseases could also not be ignored, as discussed in more detail in the 
results section, especially in the context of the mTOR and 8OHdG 
measurements.  
The potential impact of topical medications on our measurements of oxidative 
stress and mitochondrial dysfunction was also considered, although no 
convincing evidence exists to date to suggest that drugs applied topically 
would have a major impact on human circulating lymphocytes. Moreover, it 
has been suggested that the two main types of glaucoma drops used 
nowadays, prostaglandin analogues and b-blockers, which were slightly more 
common in the NTG as compared to the OHT group, may have a protective, 
rather than damaging, effect. More specifically, in a relatively recent study by 
Izzotti at el, timolol was found to protect human endothelial cells in culture 
from oxidative stress and it was hypothesised that this antioxidant activity was 
involved in the therapeutic effect of this drug in glaucoma (Izzotti et al 2008). 
Moreover, prostaglandin E(2) has been shown to protect human lung 
fibroblasts from cigarette smoke extract-induced apoptosis (Sugiura et al 
2007). Similar protective effects and improvement in the TAS in the aqueous of 
glaucoma patients have also been reported with topical dorzolamide (Zanon-
Moreno et al 2009). 
With regards to oxidative stress, the data presented here suggest that at 
baseline the overall oxidative damage, as measured by aconitase, is increased 
in NTG. Also, although the baseline superoxide levels were not significantly 
increased in NTG, the overall rate of superoxide production is likely to be 
relatively higher in NTG, probably due to the protective masking effect of the 
relatively higher SOD2. Importantly, the higher consumption of antioxidants in 
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the NTG cohort (14 out of 30), as compared to the OHT patients (7 out of 30) 
may have masked the lower antioxidant reserves noted in the NTG group and 
could explain the only marginally reduced levels of urate and vitamin A in this 
group. Also, the differences in antioxidant use between groups could explain 
the relatively reduced levels of vitamins C and B6 in the OHT group, where 
comparatively little antioxidant consumption was reported. 
In OHT, the lower levels of SOD2 noted in this group with similar baseline 
superoxide levels to NTG, would suggest that the overall rate of superoxide 
production in OHT is lower than in NTG, thus further supporting the idea of 
increased ETC efficiency in OHT. This efficiency is also highlighted by the fact 
that in OHT the mitochondria showed enhanced ETC function with increased 
energy production by complexes I and II/III, higher ΔΨm and enhanced calcium 
buffering capacity, but without generating significantly more superoxide, as 
shown by the baseline DHE staining. Furthermore, under conditions of stress, 
the OHT lymphocytes showed superior antioxidant capacity to the NTG 
lymphocytes, as demonstrated by the smaller increase in DHE staining upon 
rotenone treatment, thus suggesting reduced susceptibility of the OHT cells to 
oxidative damage under these conditions.  
In the study by Ferreira et al (2004), the level of water-soluble antioxidants 
(glutathione, vitamin C, tyrosine) was lower in the aqueous humour of POAG 
patients as compared to a control cataract group, while the activity of two 
enzymes involved in antioxidant defence (SOD and glutathione peroxidase) in 
the aqueous was nearly 1.6 times greater (Ferreira et al 2004). Such 
contradictory observations might be explained by the existence of 
compensatory mechanisms related to redox metabolism in glaucoma. It is also 
interesting to note that our results of increased SOD2 expression and lower 
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vitamin C in the NTG cohort would be in line with the results by Ferreira et al 
and would be supported by the above explanation.  
A study is currently under way to better understand why patients with OHT 
have more efficient mitochondria by measuring for the first time the transcript 
levels of various genes that influence mitochondrial function/structure in the 
lymphocytes of OHT and NTG patients, and control subjects. Lymphocyte 
pellets from the 90 participants in the mitochondrial pilot study have been 
stored at -80
o
C to assist with this genetic project and with other future 
analyses.  Understanding the complex genetic influences that may lead to 
resistance to glaucoma damage and glaucoma progression in our OHT cohort is 
of paramount importance, in order to elucidate potentially important 
pathophysiological pathways amenable to therapeutic intervention. Apart 
from the stored lymphocyte pellets, stored serum and urine aliquots from the 
pilot mitochondrial study participants will be valuable for studies such as 
immunoproteomics (Grus et al 2008). 
In the future, and in order to explore these mechanisms in more detail, a 
different model may be developed to characterise the mitochondria with the 
use of fibroblasts from NTG patients. Transforming fibroblasts into induced 
pluripotent stem cells (iPS) and from there to neurons or retinal ganglion cells 
(Chen et al 2010) would provide a model of human glaucoma, in which 
additional mechanistic pathways could be evaluated, potentially leading to 
new therapeutic approaches.  
Furthermore, the unique UKGTS cohort, which includes OAG patients with 
detailed phenotyping and known rates of progression, would be ideally suited 
for an observational study looking at the relationship between systemic 
mitochondrial function, as measured in this thesis, and rate of progression. 
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This study would aim to explore whether the findings from the mitochondrial 
pilot study (with patients at the extreme of IOP susceptibility) operate as 
susceptibility factors in a wider unselected population of patients with 
glaucoma by associating mitochondrial function with progression rates. The 
identification of mitochondrial biomarkers associated most strongly with 
glaucoma progression, perhaps in certain subgroups of patients, may be used 
in glaucoma risk stratification, enabling closer monitoring and more intensive 
treatment of susceptible patients and, therefore, help prevent glaucoma 
blindness.  
From a translational perspective, and should enhanced mitochondrial function 
be confirmed as protective for glaucoma development and progression, clinical 
trials aiming at improving systemic mitochondrial function might prove 
beneficial for delaying VF loss, especially in carefully selected subgroups of 
patients. Idebenone, as an example, has recently been shown to be safe and 
well tolerated, and also beneficial to LHON patients with discordant visual 
acuities, in other words to patients at the early stages of the disease (Klopstock 
et al 2011).  
In summary, the mitochondrial pilot study suggests for the first time that OHT 
patients may have more efficient mitochondria at a systemic level, when 
compared to age-similar NTG subjects and non-glaucomatous controls. Overall, 
OHT lymphocytes produced higher levels of ATP (as demonstrated separately 
for Complex I and Complexes II/III), had higher mitochondrial membrane 
potential, enhanced capacity to deal with exogenous oxidative stress insults, 
higher serum levels of urate (a potent antioxidant), and were more capable of 
taking up and buffering cytosolic calcium, as compared to NTG and control 
lymphocytes. Lymphocytes from NTG patients, when compared to the OHT 
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and control groups, showed lower ATP synthesis from Complex IV, lower 
aconitase activity, lower serum levels of vitamin C, and enhanced antioxidant 
defence (SOD2), while there was a trend for the levels of another antioxidant 
(vitamin A) to be lower in the serum of NTG patients. No difference was noted 
in urinary 8OHdG levels between control, NTG and OHT subjects, in line with 
the presence of similar baseline superoxide levels in the lymphocytes of 
participants from each of the three groups. Also, the activity of mTOR, in a 
subgroup of patients with no history of vasospasm, was significantly lower in 
the NTG lymphocytes, as compared to the controls. In conclusion, this study 
implicates the role of a) systemic oxidative damage and complex IV-linked 
mitochondrial defects in the pathogenesis of NTG and b) healthy systemic 
mitochondria in resistance to glaucomatous optic neuropathy development 
and progression, particularly in the context of OHT.  
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